#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Effects of familial risk and stimulant drug use on the anticipation of monetary reward: an fMRI study
#Text=The association between stimulant drug use and aberrant reward processing is well-documented in the literature, but the nature of these abnormalities remains elusive.
1-1	0-7	Effects	_
1-2	8-10	of	_
1-3	11-19	familial	_
1-4	20-24	risk	_
1-5	25-28	and	_
1-6	29-38	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[1]
1-7	39-43	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[1]
1-8	44-47	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[1]
1-9	48-50	on	_
1-10	51-54	the	_
1-11	55-67	anticipation	_
1-12	68-70	of	_
1-13	71-79	monetary	_
1-14	80-86	reward	_
1-15	86-87	:	_
1-16	88-90	an	_
1-17	91-95	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]
1-18	96-101	study	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]
1-19	102-105	The	_
1-20	106-117	association	_
1-21	118-125	between	_
1-22	126-135	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[3]
1-23	136-140	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[3]
1-24	141-144	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[3]
1-25	145-148	and	_
1-26	149-157	aberrant	_
1-27	158-164	reward	_
1-28	165-175	processing	_
1-29	176-178	is	_
1-30	179-194	well-documented	_
1-31	195-197	in	_
1-32	198-201	the	_
1-33	202-212	literature	_
1-34	212-213	,	_
1-35	214-217	but	_
1-36	218-221	the	_
1-37	222-228	nature	_
1-38	229-231	of	_
1-39	232-237	these	_
1-40	238-251	abnormalities	_
1-41	252-259	remains	_
1-42	260-267	elusive	_
1-43	267-268	.	_

#Text=The present study aims to disentangle the separate and interacting effects of stimulant drug use and pre-existing familial risk on abnormal reward processing associated with stimulant drug addiction.
2-1	269-272	The	_
2-2	273-280	present	_
2-3	281-286	study	_
2-4	287-291	aims	_
2-5	292-294	to	_
2-6	295-306	disentangle	_
2-7	307-310	the	_
2-8	311-319	separate	_
2-9	320-323	and	_
2-10	324-335	interacting	_
2-11	336-343	effects	_
2-12	344-346	of	_
2-13	347-356	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[4]
2-14	357-361	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[4]
2-15	362-365	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[4]
2-16	366-369	and	_
2-17	370-382	pre-existing	_
2-18	383-391	familial	_
2-19	392-396	risk	_
2-20	397-399	on	_
2-21	400-408	abnormal	_
2-22	409-415	reward	_
2-23	416-426	processing	_
2-24	427-437	associated	_
2-25	438-442	with	_
2-26	443-452	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[5]
2-27	453-457	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[5]
2-28	458-467	addiction	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[5]
2-29	467-468	.	_

#Text=We used the Monetary Incentive Delay task, a well-validated measure of reward processing, during fMRI scanning in four distinct groups: individuals with familial risk who were either stimulant drug-dependent (N = 41) or had never used stimulant drugs (N = 46); and individuals without familial risk who were either using stimulant drugs (N = 25) or not (N = 48).
3-1	469-471	We	_
3-2	472-476	used	_
3-3	477-480	the	_
3-4	481-489	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]
3-5	490-499	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]
3-6	500-505	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]
3-7	506-510	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]
3-8	510-511	,	_
3-9	512-513	a	_
3-10	514-528	well-validated	_
3-11	529-536	measure	_
3-12	537-539	of	_
3-13	540-546	reward	_
3-14	547-557	processing	_
3-15	557-558	,	_
3-16	559-565	during	_
3-17	566-570	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-18	571-579	scanning	_
3-19	580-582	in	_
3-20	583-587	four	_
3-21	588-596	distinct	_
3-22	597-603	groups	_
3-23	603-604	:	_
3-24	605-616	individuals	*[7]
3-25	617-621	with	*[7]
3-26	622-630	familial	*[7]
3-27	631-635	risk	*[7]
3-28	636-639	who	_
3-29	640-644	were	_
3-30	645-651	either	_
3-31	652-661	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[8]
3-32	662-676	drug-dependent	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[8]
3-33	677-678	(	_
3-34	678-679	N	_
3-35	680-681	=	_
3-36	682-684	41	_
3-37	684-685	)	_
3-38	686-688	or	_
3-39	689-692	had	_
3-40	693-698	never	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
3-41	699-703	used	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
3-42	704-713	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
3-43	714-719	drugs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
3-44	720-721	(	_
3-45	721-722	N	_
3-46	723-724	=	_
3-47	725-727	46	_
3-48	727-728	)	_
3-49	728-729	;	_
3-50	730-733	and	_
3-51	734-745	individuals	_
3-52	746-753	without	_
3-53	754-762	familial	_
3-54	763-767	risk	_
3-55	768-771	who	_
3-56	772-776	were	_
3-57	777-783	either	_
3-58	784-789	using	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[10]
3-59	790-799	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[10]
3-60	800-805	drugs	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[10]
3-61	806-807	(	_
3-62	807-808	N	_
3-63	809-810	=	_
3-64	811-813	25	_
3-65	813-814	)	_
3-66	815-817	or	_
3-67	818-821	not	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-68	822-823	(	_
3-69	823-824	N	_
3-70	825-826	=	_
3-71	827-829	48	_
3-72	829-830	)	_
3-73	830-831	.	_

#Text=We first examined task-related whole-brain activation followed by a psychophysiological interaction analysis to further explore brain functional connectivity.
4-1	832-834	We	_
4-2	835-840	first	_
4-3	841-849	examined	_
4-4	850-862	task-related	_
4-5	863-874	whole-brain	_
4-6	875-885	activation	_
4-7	886-894	followed	_
4-8	895-897	by	_
4-9	898-899	a	_
4-10	900-919	psychophysiological	_
4-11	920-931	interaction	_
4-12	932-940	analysis	_
4-13	941-943	to	_
4-14	944-951	further	_
4-15	952-959	explore	_
4-16	960-965	brain	_
4-17	966-976	functional	_
4-18	977-989	connectivity	_
4-19	989-990	.	_

#Text=For analyses, we used a univariate model with two fixed factors (familial risk and stimulant drug use).
5-1	991-994	For	_
5-2	995-1003	analyses	_
5-3	1003-1004	,	_
5-4	1005-1007	we	_
5-5	1008-1012	used	_
5-6	1013-1014	a	_
5-7	1015-1025	univariate	_
5-8	1026-1031	model	_
5-9	1032-1036	with	_
5-10	1037-1040	two	_
5-11	1041-1046	fixed	_
5-12	1047-1054	factors	_
5-13	1055-1056	(	_
5-14	1056-1064	familial	_
5-15	1065-1069	risk	_
5-16	1070-1073	and	_
5-17	1074-1083	stimulant	_
5-18	1084-1088	drug	_
5-19	1089-1092	use	_
5-20	1092-1093	)	_
5-21	1093-1094	.	_

#Text=Our results showed increased task-related activation in the putamen and motor cortex of stimulant-using participants.
6-1	1095-1098	Our	_
6-2	1099-1106	results	_
6-3	1107-1113	showed	_
6-4	1114-1123	increased	_
6-5	1124-1136	task-related	_
6-6	1137-1147	activation	_
6-7	1148-1150	in	_
6-8	1151-1154	the	_
6-9	1155-1162	putamen	_
6-10	1163-1166	and	_
6-11	1167-1172	motor	_
6-12	1173-1179	cortex	_
6-13	1180-1182	of	_
6-14	1183-1198	stimulant-using	_
6-15	1199-1211	participants	_
6-16	1211-1212	.	_

#Text=We also found altered task-related functional connectivity between the putamen and frontal regions in participants with a familial risk (irrespective of whether they were using stimulant drugs or not).
7-1	1213-1215	We	_
7-2	1216-1220	also	_
7-3	1221-1226	found	_
7-4	1227-1234	altered	_
7-5	1235-1247	task-related	_
7-6	1248-1258	functional	_
7-7	1259-1271	connectivity	_
7-8	1272-1279	between	_
7-9	1280-1283	the	_
7-10	1284-1291	putamen	_
7-11	1292-1295	and	_
7-12	1296-1303	frontal	_
7-13	1304-1311	regions	_
7-14	1312-1314	in	_
7-15	1315-1327	participants	_
7-16	1328-1332	with	_
7-17	1333-1334	a	_
7-18	1335-1343	familial	_
7-19	1344-1348	risk	_
7-20	1349-1350	(	_
7-21	1350-1362	irrespective	_
7-22	1363-1365	of	_
7-23	1366-1373	whether	_
7-24	1374-1378	they	_
7-25	1379-1383	were	_
7-26	1384-1389	using	_
7-27	1390-1399	stimulant	_
7-28	1400-1405	drugs	_
7-29	1406-1408	or	_
7-30	1409-1412	not	_
7-31	1412-1413	)	_
7-32	1413-1414	.	_

#Text=Additionally, we identified an interaction between stimulant drug use and familial risk in task-related functional connectivity between the putamen and motor-related cortical regions in potentially at-risk individuals.
8-1	1415-1427	Additionally	_
8-2	1427-1428	,	_
8-3	1429-1431	we	_
8-4	1432-1442	identified	_
8-5	1443-1445	an	_
8-6	1446-1457	interaction	_
8-7	1458-1465	between	_
8-8	1466-1475	stimulant	_
8-9	1476-1480	drug	_
8-10	1481-1484	use	_
8-11	1485-1488	and	_
8-12	1489-1497	familial	_
8-13	1498-1502	risk	_
8-14	1503-1505	in	_
8-15	1506-1518	task-related	_
8-16	1519-1529	functional	_
8-17	1530-1542	connectivity	_
8-18	1543-1550	between	_
8-19	1551-1554	the	_
8-20	1555-1562	putamen	_
8-21	1563-1566	and	_
8-22	1567-1580	motor-related	_
8-23	1581-1589	cortical	_
8-24	1590-1597	regions	_
8-25	1598-1600	in	_
8-26	1601-1612	potentially	_
8-27	1613-1620	at-risk	_
8-28	1621-1632	individuals	_
8-29	1632-1633	.	_

#Text=Our findings suggest that abnormal task-related activation in motor brain systems is associated with regular stimulant drug use, whereas abnormal task-related functional connectivity in frontostriatal brain systems, in individuals with familial risk, may indicate pre-existing neural vulnerability for developing addiction.
9-1	1634-1637	Our	_
9-2	1638-1646	findings	_
9-3	1647-1654	suggest	_
9-4	1655-1659	that	_
9-5	1660-1668	abnormal	_
9-6	1669-1681	task-related	_
9-7	1682-1692	activation	_
9-8	1693-1695	in	_
9-9	1696-1701	motor	_
9-10	1702-1707	brain	_
9-11	1708-1715	systems	_
9-12	1716-1718	is	_
9-13	1719-1729	associated	_
9-14	1730-1734	with	_
9-15	1735-1742	regular	_
9-16	1743-1752	stimulant	_
9-17	1753-1757	drug	_
9-18	1758-1761	use	_
9-19	1761-1762	,	_
9-20	1763-1770	whereas	_
9-21	1771-1779	abnormal	_
9-22	1780-1792	task-related	_
9-23	1793-1803	functional	_
9-24	1804-1816	connectivity	_
9-25	1817-1819	in	_
9-26	1820-1834	frontostriatal	_
9-27	1835-1840	brain	_
9-28	1841-1848	systems	_
9-29	1848-1849	,	_
9-30	1850-1852	in	_
9-31	1853-1864	individuals	_
9-32	1865-1869	with	_
9-33	1870-1878	familial	_
9-34	1879-1883	risk	_
9-35	1883-1884	,	_
9-36	1885-1888	may	_
9-37	1889-1897	indicate	_
9-38	1898-1910	pre-existing	_
9-39	1911-1917	neural	_
9-40	1918-1931	vulnerability	_
9-41	1932-1935	for	_
9-42	1936-1946	developing	_
9-43	1947-1956	addiction	_
9-44	1956-1957	.	_

#Text=Introduction
#Text=A change in our understanding of drug addiction as a brain disorder was influenced by the notion that drug addiction was not a deficit of character, but rather the result of aberrant brain function caused by excessive drug use.
10-1	1958-1970	Introduction	_
10-2	1971-1972	A	_
10-3	1973-1979	change	_
10-4	1980-1982	in	_
10-5	1983-1986	our	_
10-6	1987-2000	understanding	_
10-7	2001-2003	of	_
10-8	2004-2008	drug	_
10-9	2009-2018	addiction	_
10-10	2019-2021	as	_
10-11	2022-2023	a	_
10-12	2024-2029	brain	_
10-13	2030-2038	disorder	_
10-14	2039-2042	was	_
10-15	2043-2053	influenced	_
10-16	2054-2056	by	_
10-17	2057-2060	the	_
10-18	2061-2067	notion	_
10-19	2068-2072	that	_
10-20	2073-2077	drug	_
10-21	2078-2087	addiction	_
10-22	2088-2091	was	_
10-23	2092-2095	not	_
10-24	2096-2097	a	_
10-25	2098-2105	deficit	_
10-26	2106-2108	of	_
10-27	2109-2118	character	_
10-28	2118-2119	,	_
10-29	2120-2123	but	_
10-30	2124-2130	rather	_
10-31	2131-2134	the	_
10-32	2135-2141	result	_
10-33	2142-2144	of	_
10-34	2145-2153	aberrant	_
10-35	2154-2159	brain	_
10-36	2160-2168	function	_
10-37	2169-2175	caused	_
10-38	2176-2178	by	_
10-39	2179-2188	excessive	_
10-40	2189-2193	drug	_
10-41	2194-2197	use	_
10-42	2197-2198	.	_

#Text=A prominent hypothesis has been that drugs of abuse alter reward processing through disruption of the mesolimbic dopamine reward system – a theory that has since been supported by both animal models and human research.
11-1	2199-2200	A	_
11-2	2201-2210	prominent	_
11-3	2211-2221	hypothesis	_
11-4	2222-2225	has	_
11-5	2226-2230	been	_
11-6	2231-2235	that	_
11-7	2236-2241	drugs	_
11-8	2242-2244	of	_
11-9	2245-2250	abuse	_
11-10	2251-2256	alter	_
11-11	2257-2263	reward	_
11-12	2264-2274	processing	_
11-13	2275-2282	through	_
11-14	2283-2293	disruption	_
11-15	2294-2296	of	_
11-16	2297-2300	the	_
11-17	2301-2311	mesolimbic	_
11-18	2312-2320	dopamine	_
11-19	2321-2327	reward	_
11-20	2328-2334	system	_
11-21	2335-2336	–	_
11-22	2337-2338	a	_
11-23	2339-2345	theory	_
11-24	2346-2350	that	_
11-25	2351-2354	has	_
11-26	2355-2360	since	_
11-27	2361-2365	been	_
11-28	2366-2375	supported	_
11-29	2376-2378	by	_
11-30	2379-2383	both	_
11-31	2384-2390	animal	_
11-32	2391-2397	models	_
11-33	2398-2401	and	_
11-34	2402-2407	human	_
11-35	2408-2416	research	_
11-36	2416-2417	.	_

#Text=The brain reward system assimilates both top-down and bottom-up inputs from cortical and subcortical brain circuitry, including prefrontal and motor cortical systems, to support the integrated evaluation of environmental stimuli.
12-1	2418-2421	The	_
12-2	2422-2427	brain	_
12-3	2428-2434	reward	_
12-4	2435-2441	system	_
12-5	2442-2453	assimilates	_
12-6	2454-2458	both	_
12-7	2459-2467	top-down	_
12-8	2468-2471	and	_
12-9	2472-2481	bottom-up	_
12-10	2482-2488	inputs	_
12-11	2489-2493	from	_
12-12	2494-2502	cortical	_
12-13	2503-2506	and	_
12-14	2507-2518	subcortical	_
12-15	2519-2524	brain	_
12-16	2525-2534	circuitry	_
12-17	2534-2535	,	_
12-18	2536-2545	including	_
12-19	2546-2556	prefrontal	_
12-20	2557-2560	and	_
12-21	2561-2566	motor	_
12-22	2567-2575	cortical	_
12-23	2576-2583	systems	_
12-24	2583-2584	,	_
12-25	2585-2587	to	_
12-26	2588-2595	support	_
12-27	2596-2599	the	_
12-28	2600-2610	integrated	_
12-29	2611-2621	evaluation	_
12-30	2622-2624	of	_
12-31	2625-2638	environmental	_
12-32	2639-2646	stimuli	_
12-33	2646-2647	.	_

#Text=Dysregulation of the mesolimbic dopamine reward system has been associated with both acute and chronic use of stimulant drugs, leading to changes in how drug users perceive and process reward.
13-1	2648-2661	Dysregulation	_
13-2	2662-2664	of	_
13-3	2665-2668	the	_
13-4	2669-2679	mesolimbic	_
13-5	2680-2688	dopamine	_
13-6	2689-2695	reward	_
13-7	2696-2702	system	_
13-8	2703-2706	has	_
13-9	2707-2711	been	_
13-10	2712-2722	associated	_
13-11	2723-2727	with	_
13-12	2728-2732	both	_
13-13	2733-2738	acute	_
13-14	2739-2742	and	_
13-15	2743-2750	chronic	_
13-16	2751-2754	use	_
13-17	2755-2757	of	_
13-18	2758-2767	stimulant	_
13-19	2768-2773	drugs	_
13-20	2773-2774	,	_
13-21	2775-2782	leading	_
13-22	2783-2785	to	_
13-23	2786-2793	changes	_
13-24	2794-2796	in	_
13-25	2797-2800	how	_
13-26	2801-2805	drug	_
13-27	2806-2811	users	_
13-28	2812-2820	perceive	_
13-29	2821-2824	and	_
13-30	2825-2832	process	_
13-31	2833-2839	reward	_
13-32	2839-2840	.	_

#Text=These changes hypothetically facilitate the development and maintenance of addiction.
14-1	2841-2846	These	_
14-2	2847-2854	changes	_
14-3	2855-2869	hypothetically	_
14-4	2870-2880	facilitate	_
14-5	2881-2884	the	_
14-6	2885-2896	development	_
14-7	2897-2900	and	_
14-8	2901-2912	maintenance	_
14-9	2913-2915	of	_
14-10	2916-2925	addiction	_
14-11	2925-2926	.	_

#Text=However, the notion that drug use is the sole cause of aberrant reward processing in addicted individuals is disputable.
15-1	2927-2934	However	_
15-2	2934-2935	,	_
15-3	2936-2939	the	_
15-4	2940-2946	notion	_
15-5	2947-2951	that	_
15-6	2952-2956	drug	_
15-7	2957-2960	use	_
15-8	2961-2963	is	_
15-9	2964-2967	the	_
15-10	2968-2972	sole	_
15-11	2973-2978	cause	_
15-12	2979-2981	of	_
15-13	2982-2990	aberrant	_
15-14	2991-2997	reward	_
15-15	2998-3008	processing	_
15-16	3009-3011	in	_
15-17	3012-3020	addicted	_
15-18	3021-3032	individuals	_
15-19	3033-3035	is	_
15-20	3036-3046	disputable	_
15-21	3046-3047	.	_

#Text=Evidence indicates that stimulant drug users with a family history of substance abuse are eight times more likely to develop an addiction than those without a family history.
16-1	3048-3056	Evidence	_
16-2	3057-3066	indicates	_
16-3	3067-3071	that	_
16-4	3072-3081	stimulant	_
16-5	3082-3086	drug	_
16-6	3087-3092	users	_
16-7	3093-3097	with	_
16-8	3098-3099	a	_
16-9	3100-3106	family	_
16-10	3107-3114	history	_
16-11	3115-3117	of	_
16-12	3118-3127	substance	_
16-13	3128-3133	abuse	_
16-14	3134-3137	are	_
16-15	3138-3143	eight	_
16-16	3144-3149	times	_
16-17	3150-3154	more	_
16-18	3155-3161	likely	_
16-19	3162-3164	to	_
16-20	3165-3172	develop	_
16-21	3173-3175	an	_
16-22	3176-3185	addiction	_
16-23	3186-3190	than	_
16-24	3191-3196	those	_
16-25	3197-3204	without	_
16-26	3205-3206	a	_
16-27	3207-3213	family	_
16-28	3214-3221	history	_
16-29	3221-3222	.	_

#Text=Familial transmission of substance use disorders suggests pre-existing genetic, sociological, economic, and other environmental risk factors that are often shared between biological first-degree relatives (i.e., familial risk-factors).
17-1	3223-3231	Familial	_
17-2	3232-3244	transmission	_
17-3	3245-3247	of	_
17-4	3248-3257	substance	_
17-5	3258-3261	use	_
17-6	3262-3271	disorders	_
17-7	3272-3280	suggests	_
17-8	3281-3293	pre-existing	_
17-9	3294-3301	genetic	_
17-10	3301-3302	,	_
17-11	3303-3315	sociological	_
17-12	3315-3316	,	_
17-13	3317-3325	economic	_
17-14	3325-3326	,	_
17-15	3327-3330	and	_
17-16	3331-3336	other	_
17-17	3337-3350	environmental	_
17-18	3351-3355	risk	_
17-19	3356-3363	factors	_
17-20	3364-3368	that	_
17-21	3369-3372	are	_
17-22	3373-3378	often	_
17-23	3379-3385	shared	_
17-24	3386-3393	between	_
17-25	3394-3404	biological	_
17-26	3405-3417	first-degree	_
17-27	3418-3427	relatives	_
17-28	3428-3429	(	_
17-29	3429-3432	i.e	_
17-30	3432-3433	.	_
17-31	3433-3434	,	_
17-32	3435-3443	familial	_
17-33	3444-3456	risk-factors	_
17-34	3456-3457	)	_
17-35	3457-3458	.	_

#Text=Accordingly, healthy first-degree relatives of individuals affected by addiction report a number of abnormalities in terms of personality traits and brain structure, aberrant striatal dopamine neurotransmission, and altered striatal function during reward processing.
18-1	3459-3470	Accordingly	_
18-2	3470-3471	,	_
18-3	3472-3479	healthy	_
18-4	3480-3492	first-degree	_
18-5	3493-3502	relatives	_
18-6	3503-3505	of	_
18-7	3506-3517	individuals	_
18-8	3518-3526	affected	_
18-9	3527-3529	by	_
18-10	3530-3539	addiction	_
18-11	3540-3546	report	_
18-12	3547-3548	a	_
18-13	3549-3555	number	_
18-14	3556-3558	of	_
18-15	3559-3572	abnormalities	_
18-16	3573-3575	in	_
18-17	3576-3581	terms	_
18-18	3582-3584	of	_
18-19	3585-3596	personality	_
18-20	3597-3603	traits	_
18-21	3604-3607	and	_
18-22	3608-3613	brain	_
18-23	3614-3623	structure	_
18-24	3623-3624	,	_
18-25	3625-3633	aberrant	_
18-26	3634-3642	striatal	_
18-27	3643-3651	dopamine	_
18-28	3652-3669	neurotransmission	_
18-29	3669-3670	,	_
18-30	3671-3674	and	_
18-31	3675-3682	altered	_
18-32	3683-3691	striatal	_
18-33	3692-3700	function	_
18-34	3701-3707	during	_
18-35	3708-3714	reward	_
18-36	3715-3725	processing	_
18-37	3725-3726	.	_

#Text=Thus, pre-existing familial vulnerability renders the individual vulnerable to developing addiction should they start taking drugs.
19-1	3727-3731	Thus	_
19-2	3731-3732	,	_
19-3	3733-3745	pre-existing	_
19-4	3746-3754	familial	_
19-5	3755-3768	vulnerability	_
19-6	3769-3776	renders	_
19-7	3777-3780	the	_
19-8	3781-3791	individual	_
19-9	3792-3802	vulnerable	_
19-10	3803-3805	to	_
19-11	3806-3816	developing	_
19-12	3817-3826	addiction	_
19-13	3827-3833	should	_
19-14	3834-3838	they	_
19-15	3839-3844	start	_
19-16	3845-3851	taking	_
19-17	3852-3857	drugs	_
19-18	3857-3858	.	_

#Text=Likewise, stimulant drugs also exert effects that contribute to aberrant reward processing and problematic drug use.
20-1	3859-3867	Likewise	_
20-2	3867-3868	,	_
20-3	3869-3878	stimulant	_
20-4	3879-3884	drugs	_
20-5	3885-3889	also	_
20-6	3890-3895	exert	_
20-7	3896-3903	effects	_
20-8	3904-3908	that	_
20-9	3909-3919	contribute	_
20-10	3920-3922	to	_
20-11	3923-3931	aberrant	_
20-12	3932-3938	reward	_
20-13	3939-3949	processing	_
20-14	3950-3953	and	_
20-15	3954-3965	problematic	_
20-16	3966-3970	drug	_
20-17	3971-3974	use	_
20-18	3974-3975	.	_

#Text=The potential contribution of both familial and drug use-related risk factors makes it difficult to determine the cause of aberrant reward processing associated with stimulant drug use.
21-1	3976-3979	The	_
21-2	3980-3989	potential	_
21-3	3990-4002	contribution	_
21-4	4003-4005	of	_
21-5	4006-4010	both	_
21-6	4011-4019	familial	_
21-7	4020-4023	and	_
21-8	4024-4028	drug	_
21-9	4029-4040	use-related	_
21-10	4041-4045	risk	_
21-11	4046-4053	factors	_
21-12	4054-4059	makes	_
21-13	4060-4062	it	_
21-14	4063-4072	difficult	_
21-15	4073-4075	to	_
21-16	4076-4085	determine	_
21-17	4086-4089	the	_
21-18	4090-4095	cause	_
21-19	4096-4098	of	_
21-20	4099-4107	aberrant	_
21-21	4108-4114	reward	_
21-22	4115-4125	processing	_
21-23	4126-4136	associated	_
21-24	4137-4141	with	_
21-25	4142-4151	stimulant	_
21-26	4152-4156	drug	_
21-27	4157-4160	use	_
21-28	4160-4161	.	_

#Text=Here, we investigated the effects of stimulant drug use and familial risk within a single statistical model to determine their possible separate and interacting effects on reward processing.
22-1	4162-4166	Here	_
22-2	4166-4167	,	_
22-3	4168-4170	we	_
22-4	4171-4183	investigated	_
22-5	4184-4187	the	_
22-6	4188-4195	effects	_
22-7	4196-4198	of	_
22-8	4199-4208	stimulant	_
22-9	4209-4213	drug	_
22-10	4214-4217	use	_
22-11	4218-4221	and	_
22-12	4222-4230	familial	_
22-13	4231-4235	risk	_
22-14	4236-4242	within	_
22-15	4243-4244	a	_
22-16	4245-4251	single	_
22-17	4252-4263	statistical	_
22-18	4264-4269	model	_
22-19	4270-4272	to	_
22-20	4273-4282	determine	_
22-21	4283-4288	their	_
22-22	4289-4297	possible	_
22-23	4298-4306	separate	_
22-24	4307-4310	and	_
22-25	4311-4322	interacting	_
22-26	4323-4330	effects	_
22-27	4331-4333	on	_
22-28	4334-4340	reward	_
22-29	4341-4351	processing	_
22-30	4351-4352	.	_

#Text=To identify the effects of familial risk we examined candidate endophenotypes based on neural network activation patterns.
23-1	4353-4355	To	_
23-2	4356-4364	identify	_
23-3	4365-4368	the	_
23-4	4369-4376	effects	_
23-5	4377-4379	of	_
23-6	4380-4388	familial	_
23-7	4389-4393	risk	_
23-8	4394-4396	we	_
23-9	4397-4405	examined	_
23-10	4406-4415	candidate	_
23-11	4416-4430	endophenotypes	_
23-12	4431-4436	based	_
23-13	4437-4439	on	_
23-14	4440-4446	neural	_
23-15	4447-4454	network	_
23-16	4455-4465	activation	_
23-17	4466-4474	patterns	_
23-18	4474-4475	.	_

#Text=Endophenotypes are stable, heritable, and quantifiable traits observed in both clinically affected individuals and their unaffected first-degree relatives.
24-1	4476-4490	Endophenotypes	_
24-2	4491-4494	are	_
24-3	4495-4501	stable	_
24-4	4501-4502	,	_
24-5	4503-4512	heritable	_
24-6	4512-4513	,	_
24-7	4514-4517	and	_
24-8	4518-4530	quantifiable	_
24-9	4531-4537	traits	_
24-10	4538-4546	observed	_
24-11	4547-4549	in	_
24-12	4550-4554	both	_
24-13	4555-4565	clinically	_
24-14	4566-4574	affected	_
24-15	4575-4586	individuals	_
24-16	4587-4590	and	_
24-17	4591-4596	their	_
24-18	4597-4607	unaffected	_
24-19	4608-4620	first-degree	_
24-20	4621-4630	relatives	_
24-21	4630-4631	.	_

#Text=Hypothetically, endophenotypic abnormalities, arising from genetic, sociological, economic, and other environmental risk-factors common between biological first-degree relatives (i.e., familial risk-factors), both subserve and predate the development of stimulant drug addiction.
25-1	4632-4646	Hypothetically	_
25-2	4646-4647	,	_
25-3	4648-4662	endophenotypic	_
25-4	4663-4676	abnormalities	_
25-5	4676-4677	,	_
25-6	4678-4685	arising	_
25-7	4686-4690	from	_
25-8	4691-4698	genetic	_
25-9	4698-4699	,	_
25-10	4700-4712	sociological	_
25-11	4712-4713	,	_
25-12	4714-4722	economic	_
25-13	4722-4723	,	_
25-14	4724-4727	and	_
25-15	4728-4733	other	_
25-16	4734-4747	environmental	_
25-17	4748-4760	risk-factors	_
25-18	4761-4767	common	_
25-19	4768-4775	between	_
25-20	4776-4786	biological	_
25-21	4787-4799	first-degree	_
25-22	4800-4809	relatives	_
25-23	4810-4811	(	_
25-24	4811-4814	i.e	_
25-25	4814-4815	.	_
25-26	4815-4816	,	_
25-27	4817-4825	familial	_
25-28	4826-4838	risk-factors	_
25-29	4838-4839	)	_
25-30	4839-4840	,	_
25-31	4841-4845	both	_
25-32	4846-4854	subserve	_
25-33	4855-4858	and	_
25-34	4859-4866	predate	_
25-35	4867-4870	the	_
25-36	4871-4882	development	_
25-37	4883-4885	of	_
25-38	4886-4895	stimulant	_
25-39	4896-4900	drug	_
25-40	4901-4910	addiction	_
25-41	4910-4911	.	_

#Text=To identify endophenotypes in the current study, we included fully-related siblings who not only share approximately 50% of their genes, but also childhood sociological, economic, and other familial risk-factors, which may influence the development of addiction.
26-1	4912-4914	To	_
26-2	4915-4923	identify	_
26-3	4924-4938	endophenotypes	_
26-4	4939-4941	in	_
26-5	4942-4945	the	_
26-6	4946-4953	current	_
26-7	4954-4959	study	_
26-8	4959-4960	,	_
26-9	4961-4963	we	_
26-10	4964-4972	included	_
26-11	4973-4986	fully-related	_
26-12	4987-4995	siblings	_
26-13	4996-4999	who	_
26-14	5000-5003	not	_
26-15	5004-5008	only	_
26-16	5009-5014	share	_
26-17	5015-5028	approximately	_
26-18	5029-5032	50%	_
26-19	5033-5035	of	_
26-20	5036-5041	their	_
26-21	5042-5047	genes	_
26-22	5047-5048	,	_
26-23	5049-5052	but	_
26-24	5053-5057	also	_
26-25	5058-5067	childhood	_
26-26	5068-5080	sociological	_
26-27	5080-5081	,	_
26-28	5082-5090	economic	_
26-29	5090-5091	,	_
26-30	5092-5095	and	_
26-31	5096-5101	other	_
26-32	5102-5110	familial	_
26-33	5111-5123	risk-factors	_
26-34	5123-5124	,	_
26-35	5125-5130	which	_
26-36	5131-5134	may	_
26-37	5135-5144	influence	_
26-38	5145-5148	the	_
26-39	5149-5160	development	_
26-40	5161-5163	of	_
26-41	5164-5173	addiction	_
26-42	5173-5174	.	_

#Text=These individuals are of particular interest not only because of their increased familial risk of developing addiction but also because of their success in avoiding the initiation of stimulant drug use despite the increased risk, potentially indicating compensatory or resiliency mechanisms.
27-1	5175-5180	These	_
27-2	5181-5192	individuals	_
27-3	5193-5196	are	_
27-4	5197-5199	of	_
27-5	5200-5210	particular	_
27-6	5211-5219	interest	_
27-7	5220-5223	not	_
27-8	5224-5228	only	_
27-9	5229-5236	because	_
27-10	5237-5239	of	_
27-11	5240-5245	their	_
27-12	5246-5255	increased	_
27-13	5256-5264	familial	_
27-14	5265-5269	risk	_
27-15	5270-5272	of	_
27-16	5273-5283	developing	_
27-17	5284-5293	addiction	_
27-18	5294-5297	but	_
27-19	5298-5302	also	_
27-20	5303-5310	because	_
27-21	5311-5313	of	_
27-22	5314-5319	their	_
27-23	5320-5327	success	_
27-24	5328-5330	in	_
27-25	5331-5339	avoiding	_
27-26	5340-5343	the	_
27-27	5344-5354	initiation	_
27-28	5355-5357	of	_
27-29	5358-5367	stimulant	_
27-30	5368-5372	drug	_
27-31	5373-5376	use	_
27-32	5377-5384	despite	_
27-33	5385-5388	the	_
27-34	5389-5398	increased	_
27-35	5399-5403	risk	_
27-36	5403-5404	,	_
27-37	5405-5416	potentially	_
27-38	5417-5427	indicating	_
27-39	5428-5440	compensatory	_
27-40	5441-5443	or	_
27-41	5444-5454	resiliency	_
27-42	5455-5465	mechanisms	_
27-43	5465-5466	.	_

#Text=This endophenotype approach has been used previously in addicted populations, although not in relation to reward processing.
28-1	5467-5471	This	_
28-2	5472-5485	endophenotype	_
28-3	5486-5494	approach	_
28-4	5495-5498	has	_
28-5	5499-5503	been	_
28-6	5504-5508	used	_
28-7	5509-5519	previously	_
28-8	5520-5522	in	_
28-9	5523-5531	addicted	_
28-10	5532-5543	populations	_
28-11	5543-5544	,	_
28-12	5545-5553	although	_
28-13	5554-5557	not	_
28-14	5558-5560	in	_
28-15	5561-5569	relation	_
28-16	5570-5572	to	_
28-17	5573-5579	reward	_
28-18	5580-5590	processing	_
28-19	5590-5591	.	_

#Text=To identify effects of stimulant drug use as well as the familial risk of addiction within the same model, we included non-dependent stimulant drug users and non-drug users, both without familial risk, in addition to the sibling pairs with familial risk.
29-1	5592-5594	To	_
29-2	5595-5603	identify	_
29-3	5604-5611	effects	_
29-4	5612-5614	of	_
29-5	5615-5624	stimulant	_
29-6	5625-5629	drug	_
29-7	5630-5633	use	_
29-8	5634-5636	as	_
29-9	5637-5641	well	_
29-10	5642-5644	as	_
29-11	5645-5648	the	_
29-12	5649-5657	familial	_
29-13	5658-5662	risk	_
29-14	5663-5665	of	_
29-15	5666-5675	addiction	_
29-16	5676-5682	within	_
29-17	5683-5686	the	_
29-18	5687-5691	same	_
29-19	5692-5697	model	_
29-20	5697-5698	,	_
29-21	5699-5701	we	_
29-22	5702-5710	included	_
29-23	5711-5724	non-dependent	_
29-24	5725-5734	stimulant	_
29-25	5735-5739	drug	_
29-26	5740-5745	users	_
29-27	5746-5749	and	_
29-28	5750-5758	non-drug	_
29-29	5759-5764	users	_
29-30	5764-5765	,	_
29-31	5766-5770	both	_
29-32	5771-5778	without	_
29-33	5779-5787	familial	_
29-34	5788-5792	risk	_
29-35	5792-5793	,	_
29-36	5794-5796	in	_
29-37	5797-5805	addition	_
29-38	5806-5808	to	_
29-39	5809-5812	the	_
29-40	5813-5820	sibling	_
29-41	5821-5826	pairs	_
29-42	5827-5831	with	_
29-43	5832-5840	familial	_
29-44	5841-5845	risk	_
29-45	5845-5846	.	_

#Text=Together, the four distinct groups each possessed a unique combination of familial and stimulant drug-related risk-factors, allowing the disentanglement of the distinct and interacting effects of both stimulant drug use and familial risk.
30-1	5847-5855	Together	_
30-2	5855-5856	,	_
30-3	5857-5860	the	_
30-4	5861-5865	four	_
30-5	5866-5874	distinct	_
30-6	5875-5881	groups	_
30-7	5882-5886	each	_
30-8	5887-5896	possessed	_
30-9	5897-5898	a	_
30-10	5899-5905	unique	_
30-11	5906-5917	combination	_
30-12	5918-5920	of	_
30-13	5921-5929	familial	_
30-14	5930-5933	and	_
30-15	5934-5943	stimulant	_
30-16	5944-5956	drug-related	_
30-17	5957-5969	risk-factors	_
30-18	5969-5970	,	_
30-19	5971-5979	allowing	_
30-20	5980-5983	the	_
30-21	5984-5999	disentanglement	_
30-22	6000-6002	of	_
30-23	6003-6006	the	_
30-24	6007-6015	distinct	_
30-25	6016-6019	and	_
30-26	6020-6031	interacting	_
30-27	6032-6039	effects	_
30-28	6040-6042	of	_
30-29	6043-6047	both	_
30-30	6048-6057	stimulant	_
30-31	6058-6062	drug	_
30-32	6063-6066	use	_
30-33	6067-6070	and	_
30-34	6071-6079	familial	_
30-35	6080-6084	risk	_
30-36	6084-6085	.	_

#Text=By investigating interacting effects, we may gain insight into possible compensation or resiliency in at-risk individuals, such as those with familial risk who successfully avoided stimulant drug use, and those who use stimulant drugs but successfully avoid the development of addiction.
31-1	6086-6088	By	_
31-2	6089-6102	investigating	_
31-3	6103-6114	interacting	_
31-4	6115-6122	effects	_
31-5	6122-6123	,	_
31-6	6124-6126	we	_
31-7	6127-6130	may	_
31-8	6131-6135	gain	_
31-9	6136-6143	insight	_
31-10	6144-6148	into	_
31-11	6149-6157	possible	_
31-12	6158-6170	compensation	_
31-13	6171-6173	or	_
31-14	6174-6184	resiliency	_
31-15	6185-6187	in	_
31-16	6188-6195	at-risk	_
31-17	6196-6207	individuals	_
31-18	6207-6208	,	_
31-19	6209-6213	such	_
31-20	6214-6216	as	_
31-21	6217-6222	those	_
31-22	6223-6227	with	_
31-23	6228-6236	familial	_
31-24	6237-6241	risk	_
31-25	6242-6245	who	_
31-26	6246-6258	successfully	_
31-27	6259-6266	avoided	_
31-28	6267-6276	stimulant	_
31-29	6277-6281	drug	_
31-30	6282-6285	use	_
31-31	6285-6286	,	_
31-32	6287-6290	and	_
31-33	6291-6296	those	_
31-34	6297-6300	who	_
31-35	6301-6304	use	_
31-36	6305-6314	stimulant	_
31-37	6315-6320	drugs	_
31-38	6321-6324	but	_
31-39	6325-6337	successfully	_
31-40	6338-6343	avoid	_
31-41	6344-6347	the	_
31-42	6348-6359	development	_
31-43	6360-6362	of	_
31-44	6363-6372	addiction	_
31-45	6372-6373	.	_

#Text=Although the risk associated with the development of addiction may not be drug-specific, we deliberately focused on stimulant drugs given their critical dependence on the mesocorticolimbic dopamine system and the hypothesized association between the drug-induced release of dopamine and the drug’s addictive liability.
32-1	6374-6382	Although	_
32-2	6383-6386	the	_
32-3	6387-6391	risk	_
32-4	6392-6402	associated	_
32-5	6403-6407	with	_
32-6	6408-6411	the	_
32-7	6412-6423	development	_
32-8	6424-6426	of	_
32-9	6427-6436	addiction	_
32-10	6437-6440	may	_
32-11	6441-6444	not	_
32-12	6445-6447	be	_
32-13	6448-6461	drug-specific	_
32-14	6461-6462	,	_
32-15	6463-6465	we	_
32-16	6466-6478	deliberately	_
32-17	6479-6486	focused	_
32-18	6487-6489	on	_
32-19	6490-6499	stimulant	_
32-20	6500-6505	drugs	_
32-21	6506-6511	given	_
32-22	6512-6517	their	_
32-23	6518-6526	critical	_
32-24	6527-6537	dependence	_
32-25	6538-6540	on	_
32-26	6541-6544	the	_
32-27	6545-6562	mesocorticolimbic	_
32-28	6563-6571	dopamine	_
32-29	6572-6578	system	_
32-30	6579-6582	and	_
32-31	6583-6586	the	_
32-32	6587-6599	hypothesized	_
32-33	6600-6611	association	_
32-34	6612-6619	between	_
32-35	6620-6623	the	_
32-36	6624-6636	drug-induced	_
32-37	6637-6644	release	_
32-38	6645-6647	of	_
32-39	6648-6656	dopamine	_
32-40	6657-6660	and	_
32-41	6661-6664	the	_
32-42	6665-6669	drug	_
32-43	6669-6670	’	_
32-44	6670-6671	s	_
32-45	6672-6681	addictive	_
32-46	6682-6691	liability	_
32-47	6691-6692	.	_

#Text=The abuse liability of stimulant drugs and the relative high heritability, which has been estimated to be 0.72, suggest that individual variations in behaviorally relevant neural networks may mediate the individual’s susceptibility to drug addiction.
33-1	6693-6696	The	_
33-2	6697-6702	abuse	_
33-3	6703-6712	liability	_
33-4	6713-6715	of	_
33-5	6716-6725	stimulant	_
33-6	6726-6731	drugs	_
33-7	6732-6735	and	_
33-8	6736-6739	the	_
33-9	6740-6748	relative	_
33-10	6749-6753	high	_
33-11	6754-6766	heritability	_
33-12	6766-6767	,	_
33-13	6768-6773	which	_
33-14	6774-6777	has	_
33-15	6778-6782	been	_
33-16	6783-6792	estimated	_
33-17	6793-6795	to	_
33-18	6796-6798	be	_
33-19	6799-6803	0.72	_
33-20	6803-6804	,	_
33-21	6805-6812	suggest	_
33-22	6813-6817	that	_
33-23	6818-6828	individual	_
33-24	6829-6839	variations	_
33-25	6840-6842	in	_
33-26	6843-6855	behaviorally	_
33-27	6856-6864	relevant	_
33-28	6865-6871	neural	_
33-29	6872-6880	networks	_
33-30	6881-6884	may	_
33-31	6885-6892	mediate	_
33-32	6893-6896	the	_
33-33	6897-6907	individual	_
33-34	6907-6908	’	_
33-35	6908-6909	s	_
33-36	6910-6924	susceptibility	_
33-37	6925-6927	to	_
33-38	6928-6932	drug	_
33-39	6933-6942	addiction	_
33-40	6942-6943	.	_

#Text=We examined neural responses to reward using the monetary incentive delay (MID) task—a well-validated paradigm for examining anticipatory brain responses to reward.
34-1	6944-6946	We	_
34-2	6947-6955	examined	_
34-3	6956-6962	neural	_
34-4	6963-6972	responses	_
34-5	6973-6975	to	_
34-6	6976-6982	reward	_
34-7	6983-6988	using	_
34-8	6989-6992	the	_
34-9	6993-7001	monetary	_
34-10	7002-7011	incentive	_
34-11	7012-7017	delay	_
34-12	7018-7019	(	_
34-13	7019-7022	MID	_
34-14	7022-7023	)	_
34-15	7024-7030	task—a	_
34-16	7031-7045	well-validated	_
34-17	7046-7054	paradigm	_
34-18	7055-7058	for	_
34-19	7059-7068	examining	_
34-20	7069-7081	anticipatory	_
34-21	7082-7087	brain	_
34-22	7088-7097	responses	_
34-23	7098-7100	to	_
34-24	7101-7107	reward	_
34-25	7107-7108	.	_

#Text=The MID-task has been associated with abnormal activation in frontostriatal circuits in drug users and those at-risk for addiction; however, these results have been inconsistent and often focus on regions of interest rather than the whole brain.
35-1	7109-7112	The	_
35-2	7113-7121	MID-task	_
35-3	7122-7125	has	_
35-4	7126-7130	been	_
35-5	7131-7141	associated	_
35-6	7142-7146	with	_
35-7	7147-7155	abnormal	_
35-8	7156-7166	activation	_
35-9	7167-7169	in	_
35-10	7170-7184	frontostriatal	_
35-11	7185-7193	circuits	_
35-12	7194-7196	in	_
35-13	7197-7201	drug	_
35-14	7202-7207	users	_
35-15	7208-7211	and	_
35-16	7212-7217	those	_
35-17	7218-7225	at-risk	_
35-18	7226-7229	for	_
35-19	7230-7239	addiction	_
35-20	7239-7240	;	_
35-21	7241-7248	however	_
35-22	7248-7249	,	_
35-23	7250-7255	these	_
35-24	7256-7263	results	_
35-25	7264-7268	have	_
35-26	7269-7273	been	_
35-27	7274-7286	inconsistent	_
35-28	7287-7290	and	_
35-29	7291-7296	often	_
35-30	7297-7302	focus	_
35-31	7303-7305	on	_
35-32	7306-7313	regions	_
35-33	7314-7316	of	_
35-34	7317-7325	interest	_
35-35	7326-7332	rather	_
35-36	7333-7337	than	_
35-37	7338-7341	the	_
35-38	7342-7347	whole	_
35-39	7348-7353	brain	_
35-40	7353-7354	.	_

#Text=More importantly, prior studies have not addressed the critical question of causality.
36-1	7355-7359	More	_
36-2	7360-7371	importantly	_
36-3	7371-7372	,	_
36-4	7373-7378	prior	_
36-5	7379-7386	studies	_
36-6	7387-7391	have	_
36-7	7392-7395	not	_
36-8	7396-7405	addressed	_
36-9	7406-7409	the	_
36-10	7410-7418	critical	_
36-11	7419-7427	question	_
36-12	7428-7430	of	_
36-13	7431-7440	causality	_
36-14	7440-7441	.	_

#Text=To address this question in stimulant drug addiction, we hypothesized that if aberrant reward processing is a consequence of stimulant drug use, then participants with a personal history of stimulant drug use will show altered task-related striatal function during reward processing.
37-1	7442-7444	To	_
37-2	7445-7452	address	_
37-3	7453-7457	this	_
37-4	7458-7466	question	_
37-5	7467-7469	in	_
37-6	7470-7479	stimulant	_
37-7	7480-7484	drug	_
37-8	7485-7494	addiction	_
37-9	7494-7495	,	_
37-10	7496-7498	we	_
37-11	7499-7511	hypothesized	_
37-12	7512-7516	that	_
37-13	7517-7519	if	_
37-14	7520-7528	aberrant	_
37-15	7529-7535	reward	_
37-16	7536-7546	processing	_
37-17	7547-7549	is	_
37-18	7550-7551	a	_
37-19	7552-7563	consequence	_
37-20	7564-7566	of	_
37-21	7567-7576	stimulant	_
37-22	7577-7581	drug	_
37-23	7582-7585	use	_
37-24	7585-7586	,	_
37-25	7587-7591	then	_
37-26	7592-7604	participants	_
37-27	7605-7609	with	_
37-28	7610-7611	a	_
37-29	7612-7620	personal	_
37-30	7621-7628	history	_
37-31	7629-7631	of	_
37-32	7632-7641	stimulant	_
37-33	7642-7646	drug	_
37-34	7647-7650	use	_
37-35	7651-7655	will	_
37-36	7656-7660	show	_
37-37	7661-7668	altered	_
37-38	7669-7681	task-related	_
37-39	7682-7690	striatal	_
37-40	7691-7699	function	_
37-41	7700-7706	during	_
37-42	7707-7713	reward	_
37-43	7714-7724	processing	_
37-44	7724-7725	.	_

#Text=Alternatively, if aberrant reward processing is a pre-existing vulnerability resulting from familial risk, then fully-related sibling pairs will share a similar pattern of abnormal task-related striatal function during reward processing distinct from that of unrelated control participants.
38-1	7726-7739	Alternatively	_
38-2	7739-7740	,	_
38-3	7741-7743	if	_
38-4	7744-7752	aberrant	_
38-5	7753-7759	reward	_
38-6	7760-7770	processing	_
38-7	7771-7773	is	_
38-8	7774-7775	a	_
38-9	7776-7788	pre-existing	_
38-10	7789-7802	vulnerability	_
38-11	7803-7812	resulting	_
38-12	7813-7817	from	_
38-13	7818-7826	familial	_
38-14	7827-7831	risk	_
38-15	7831-7832	,	_
38-16	7833-7837	then	_
38-17	7838-7851	fully-related	_
38-18	7852-7859	sibling	_
38-19	7860-7865	pairs	_
38-20	7866-7870	will	_
38-21	7871-7876	share	_
38-22	7877-7878	a	_
38-23	7879-7886	similar	_
38-24	7887-7894	pattern	_
38-25	7895-7897	of	_
38-26	7898-7906	abnormal	_
38-27	7907-7919	task-related	_
38-28	7920-7928	striatal	_
38-29	7929-7937	function	_
38-30	7938-7944	during	_
38-31	7945-7951	reward	_
38-32	7952-7962	processing	_
38-33	7963-7971	distinct	_
38-34	7972-7976	from	_
38-35	7977-7981	that	_
38-36	7982-7984	of	_
38-37	7985-7994	unrelated	_
38-38	7995-8002	control	_
38-39	8003-8015	participants	_
38-40	8015-8016	.	_

#Text=Materials and methods
#Text=Study sample
#Text=Demographics, personality, clinical and MID-task performance data for all participants
#Text=\tF–S− No familial risk; No stimulant use (N = 48)\tF−S+ No familial risk; Stimulant use (N = 25)\tF+S− Familial risk; No stimulant use (N = 46)\tF+S+ Familial risk; Stimulant use (N = 41)\t \tMean\t(±SD)\tMean\t(±SD)\tMean\t(±SD)\tMean\t(±SD)\t \tDemographics\t \tAge (years)\t32.5\t( ± 8.8)\t28.6\t(±6.6)\t32.3\t(±8.4)\t34.6\t(±7.4)\t \tGender (% male)\t63%\t52%\t48%\t90%\t \tDisposable income (£/month)\t660\t (±940)\t714\t(±1154)\t403\t(±411)\t399\t(±672)\t \tTrait Impulsivity (BIS-11 total score)\t59.3\t(±7.6)\t63.2\t(±10.4)\t67.2\t(±10.4)\t77.0\t(±9.4)\t \tAlcohol consumption (AUDIT total score)\t3.2\t(±2.3)\t5.8\t(±1.5)\t3.9\t(±4.6)\t11.7\t(±11.9)\t \tDrug-taking experiences (DAST-20 total score)\t0.0\t(±0.0)\t2.4\t(±1.0)\t0.5\t(±1.1)\tNot completed\t\t \tCompulsive use of stimulants (OCDUS total score)\t-\t-\t1.2\t(±1.7)\t-\t-\t23.6\t(±9.3)\t \tNicotine Use (current/past)\t12.5%\t43.8%\t68%\t16%\t54%\t37%\t92.7%\t4.9%\t \tCannabis Use (current/Past)\t0%\t20.8%\t36%\t60%\t8.7%\t65.2%\t65.9%\t34.1%\t \tTask performance\t \tMoney gained (£)\t8.65\t(±1.2)\t8.46\t(±1.2)\t8.48\t(±1.2)\t8.49\t(±1.5)\t \tSuccessful responses to neutral trials (number)\t12.4\t(±2.1)\t12.1\t(±1.8)\t12.1\t(±2.4)\t10.2\t(±3.1)\t \tSuccessful responses t rewarding trials (number)\t27.9\t(±3.4)\t28.6\t(±2.9)\t27.8\t(±3.6)\t27.9\t(±4.9)\t \tResponse time for successful neutral trials (ms)\t210.6\t(±23.7)\t206.7\t(±22.4)\t211.5\t(±23.1)\t220.6\t(±40.1)\t \tResponse time for successful rewarding trials (ms)\t204.5\t(±19.0)\t200.8\t(±19.7)\t208.3\t(±21.2)\t207.0\t(±25.8)\t \t
#Text=Data are displayed by individual group status.
39-1	8017-8026	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]
39-2	8027-8030	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]
39-3	8031-8038	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]
39-4	8039-8044	Study	_
39-5	8045-8051	sample	_
39-6	8052-8064	Demographics	_
39-7	8064-8065	,	_
39-8	8066-8077	personality	http://maven.renci.org/NeuroBridge/neurobridge#PersonalityRatingScale
39-9	8077-8078	,	_
39-10	8079-8087	clinical	_
39-11	8088-8091	and	_
39-12	8092-8100	MID-task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
39-13	8101-8112	performance	_
39-14	8113-8117	data	_
39-15	8118-8121	for	_
39-16	8122-8125	all	_
39-17	8126-8138	participants	_
39-18	8140-8143	F–S	_
39-19	8143-8144	−	_
39-20	8145-8147	No	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-21	8148-8156	familial	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-22	8157-8161	risk	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-23	8161-8162	;	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-24	8163-8165	No	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-25	8166-8175	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-26	8176-8179	use	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
39-27	8180-8181	(	_
39-28	8181-8182	N	_
39-29	8183-8184	=	_
39-30	8185-8187	48	_
39-31	8187-8188	)	_
39-32	8189-8190	F	_
39-33	8190-8191	−	_
39-34	8191-8192	S	_
39-35	8192-8193	+	_
39-36	8194-8196	No	_
39-37	8197-8205	familial	_
39-38	8206-8210	risk	_
39-39	8210-8211	;	_
39-40	8212-8221	Stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[13]
39-41	8222-8225	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[13]
39-42	8226-8227	(	_
39-43	8227-8228	N	_
39-44	8229-8230	=	_
39-45	8231-8233	25	_
39-46	8233-8234	)	_
39-47	8235-8236	F	_
39-48	8236-8237	+	_
39-49	8237-8238	S	_
39-50	8238-8239	−	_
39-51	8240-8248	Familial	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[14]
39-52	8249-8253	risk	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[14]
39-53	8253-8254	;	_
39-54	8255-8257	No	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]
39-55	8258-8267	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]
39-56	8268-8271	use	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[15]
39-57	8272-8273	(	_
39-58	8273-8274	N	_
39-59	8275-8276	=	_
39-60	8277-8279	46	_
39-61	8279-8280	)	_
39-62	8281-8282	F	_
39-63	8282-8283	+	_
39-64	8283-8284	S	_
39-65	8284-8285	+	_
39-66	8286-8294	Familial	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[16]
39-67	8295-8299	risk	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus[16]
39-68	8299-8300	;	_
39-69	8301-8310	Stimulant	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[17]
39-70	8311-8314	use	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[17]
39-71	8315-8316	(	_
39-72	8316-8317	N	_
39-73	8318-8319	=	_
39-74	8320-8322	41	_
39-75	8322-8323	)	_
39-76	8326-8330	Mean	_
39-77	8331-8332	(	_
39-78	8332-8333	±	_
39-79	8333-8335	SD	_
39-80	8335-8336	)	_
39-81	8337-8341	Mean	_
39-82	8342-8343	(	_
39-83	8343-8344	±	_
39-84	8344-8346	SD	_
39-85	8346-8347	)	_
39-86	8348-8352	Mean	_
39-87	8353-8354	(	_
39-88	8354-8355	±	_
39-89	8355-8357	SD	_
39-90	8357-8358	)	_
39-91	8359-8363	Mean	_
39-92	8364-8365	(	_
39-93	8365-8366	±	_
39-94	8366-8368	SD	_
39-95	8368-8369	)	_
39-96	8372-8384	Demographics	_
39-97	8387-8390	Age	_
39-98	8391-8392	(	_
39-99	8392-8397	years	_
39-100	8397-8398	)	_
39-101	8399-8403	32.5	_
39-102	8404-8405	(	_
39-103	8406-8407	±	_
39-104	8408-8411	8.8	_
39-105	8411-8412	)	_
39-106	8413-8417	28.6	_
39-107	8418-8419	(	_
39-108	8419-8420	±	_
39-109	8420-8423	6.6	_
39-110	8423-8424	)	_
39-111	8425-8429	32.3	_
39-112	8430-8431	(	_
39-113	8431-8432	±	_
39-114	8432-8435	8.4	_
39-115	8435-8436	)	_
39-116	8437-8441	34.6	_
39-117	8442-8443	(	_
39-118	8443-8444	±	_
39-119	8444-8447	7.4	_
39-120	8447-8448	)	_
39-121	8451-8457	Gender	_
39-122	8458-8459	(	_
39-123	8459-8460	%	_
39-124	8461-8465	male	_
39-125	8465-8466	)	_
39-126	8467-8470	63%	_
39-127	8471-8474	52%	_
39-128	8475-8478	48%	_
39-129	8479-8482	90%	_
39-130	8485-8495	Disposable	_
39-131	8496-8502	income	_
39-132	8503-8504	(	_
39-133	8504-8505	£	_
39-134	8505-8506	/	_
39-135	8506-8511	month	_
39-136	8511-8512	)	_
39-137	8513-8516	660	_
39-138	8518-8519	(	_
39-139	8519-8520	±	_
39-140	8520-8523	940	_
39-141	8523-8524	)	_
39-142	8525-8528	714	_
39-143	8529-8530	(	_
39-144	8530-8531	±	_
39-145	8531-8535	1154	_
39-146	8535-8536	)	_
39-147	8537-8540	403	_
39-148	8541-8542	(	_
39-149	8542-8543	±	_
39-150	8543-8546	411	_
39-151	8546-8547	)	_
39-152	8548-8551	399	_
39-153	8552-8553	(	_
39-154	8553-8554	±	_
39-155	8554-8557	672	_
39-156	8557-8558	)	_
39-157	8561-8566	Trait	_
39-158	8567-8578	Impulsivity	_
39-159	8579-8580	(	_
39-160	8580-8583	BIS	_
39-161	8583-8584	-	_
39-162	8584-8586	11	_
39-163	8587-8592	total	_
39-164	8593-8598	score	_
39-165	8598-8599	)	_
39-166	8600-8604	59.3	_
39-167	8605-8606	(	_
39-168	8606-8607	±	_
39-169	8607-8610	7.6	_
39-170	8610-8611	)	_
39-171	8612-8616	63.2	_
39-172	8617-8618	(	_
39-173	8618-8619	±	_
39-174	8619-8623	10.4	_
39-175	8623-8624	)	_
39-176	8625-8629	67.2	_
39-177	8630-8631	(	_
39-178	8631-8632	±	_
39-179	8632-8636	10.4	_
39-180	8636-8637	)	_
39-181	8638-8642	77.0	_
39-182	8643-8644	(	_
39-183	8644-8645	±	_
39-184	8645-8648	9.4	_
39-185	8648-8649	)	_
39-186	8652-8659	Alcohol	_
39-187	8660-8671	consumption	_
39-188	8672-8673	(	_
39-189	8673-8678	AUDIT	_
39-190	8679-8684	total	_
39-191	8685-8690	score	_
39-192	8690-8691	)	_
39-193	8692-8695	3.2	_
39-194	8696-8697	(	_
39-195	8697-8698	±	_
39-196	8698-8701	2.3	_
39-197	8701-8702	)	_
39-198	8703-8706	5.8	_
39-199	8707-8708	(	_
39-200	8708-8709	±	_
39-201	8709-8712	1.5	_
39-202	8712-8713	)	_
39-203	8714-8717	3.9	_
39-204	8718-8719	(	_
39-205	8719-8720	±	_
39-206	8720-8723	4.6	_
39-207	8723-8724	)	_
39-208	8725-8729	11.7	_
39-209	8730-8731	(	_
39-210	8731-8732	±	_
39-211	8732-8736	11.9	_
39-212	8736-8737	)	_
39-213	8740-8751	Drug-taking	_
39-214	8752-8763	experiences	_
39-215	8764-8765	(	_
39-216	8765-8769	DAST	_
39-217	8769-8770	-	_
39-218	8770-8772	20	_
39-219	8773-8778	total	_
39-220	8779-8784	score	_
39-221	8784-8785	)	_
39-222	8786-8789	0.0	_
39-223	8790-8791	(	_
39-224	8791-8792	±	_
39-225	8792-8795	0.0	_
39-226	8795-8796	)	_
39-227	8797-8800	2.4	_
39-228	8801-8802	(	_
39-229	8802-8803	±	_
39-230	8803-8806	1.0	_
39-231	8806-8807	)	_
39-232	8808-8811	0.5	_
39-233	8812-8813	(	_
39-234	8813-8814	±	_
39-235	8814-8817	1.1	_
39-236	8817-8818	)	_
39-237	8819-8822	Not	_
39-238	8823-8832	completed	_
39-239	8836-8846	Compulsive	_
39-240	8847-8850	use	_
39-241	8851-8853	of	_
39-242	8854-8864	stimulants	_
39-243	8865-8866	(	_
39-244	8866-8871	OCDUS	_
39-245	8872-8877	total	_
39-246	8878-8883	score	_
39-247	8883-8884	)	_
39-248	8885-8886	-	_
39-249	8887-8888	-	_
39-250	8889-8892	1.2	_
39-251	8893-8894	(	_
39-252	8894-8895	±	_
39-253	8895-8898	1.7	_
39-254	8898-8899	)	_
39-255	8900-8901	-	_
39-256	8902-8903	-	_
39-257	8904-8908	23.6	_
39-258	8909-8910	(	_
39-259	8910-8911	±	_
39-260	8911-8914	9.3	_
39-261	8914-8915	)	_
39-262	8918-8926	Nicotine	_
39-263	8927-8930	Use	_
39-264	8931-8932	(	_
39-265	8932-8939	current	_
39-266	8939-8940	/	_
39-267	8940-8944	past	_
39-268	8944-8945	)	_
39-269	8946-8951	12.5%	_
39-270	8952-8957	43.8%	_
39-271	8958-8961	68%	_
39-272	8962-8965	16%	_
39-273	8966-8969	54%	_
39-274	8970-8973	37%	_
39-275	8974-8979	92.7%	_
39-276	8980-8984	4.9%	_
39-277	8987-8995	Cannabis	_
39-278	8996-8999	Use	_
39-279	9000-9001	(	_
39-280	9001-9008	current	_
39-281	9008-9009	/	_
39-282	9009-9013	Past	_
39-283	9013-9014	)	_
39-284	9015-9017	0%	_
39-285	9018-9023	20.8%	_
39-286	9024-9027	36%	_
39-287	9028-9031	60%	_
39-288	9032-9036	8.7%	_
39-289	9037-9042	65.2%	_
39-290	9043-9048	65.9%	_
39-291	9049-9054	34.1%	_
39-292	9057-9061	Task	_
39-293	9062-9073	performance	_
39-294	9076-9081	Money	_
39-295	9082-9088	gained	_
39-296	9089-9090	(	_
39-297	9090-9091	£	_
39-298	9091-9092	)	_
39-299	9093-9097	8.65	_
39-300	9098-9099	(	_
39-301	9099-9100	±	_
39-302	9100-9103	1.2	_
39-303	9103-9104	)	_
39-304	9105-9109	8.46	_
39-305	9110-9111	(	_
39-306	9111-9112	±	_
39-307	9112-9115	1.2	_
39-308	9115-9116	)	_
39-309	9117-9121	8.48	_
39-310	9122-9123	(	_
39-311	9123-9124	±	_
39-312	9124-9127	1.2	_
39-313	9127-9128	)	_
39-314	9129-9133	8.49	_
39-315	9134-9135	(	_
39-316	9135-9136	±	_
39-317	9136-9139	1.5	_
39-318	9139-9140	)	_
39-319	9143-9153	Successful	_
39-320	9154-9163	responses	_
39-321	9164-9166	to	_
39-322	9167-9174	neutral	_
39-323	9175-9181	trials	_
39-324	9182-9183	(	_
39-325	9183-9189	number	_
39-326	9189-9190	)	_
39-327	9191-9195	12.4	_
39-328	9196-9197	(	_
39-329	9197-9198	±	_
39-330	9198-9201	2.1	_
39-331	9201-9202	)	_
39-332	9203-9207	12.1	_
39-333	9208-9209	(	_
39-334	9209-9210	±	_
39-335	9210-9213	1.8	_
39-336	9213-9214	)	_
39-337	9215-9219	12.1	_
39-338	9220-9221	(	_
39-339	9221-9222	±	_
39-340	9222-9225	2.4	_
39-341	9225-9226	)	_
39-342	9227-9231	10.2	_
39-343	9232-9233	(	_
39-344	9233-9234	±	_
39-345	9234-9237	3.1	_
39-346	9237-9238	)	_
39-347	9241-9251	Successful	_
39-348	9252-9261	responses	_
39-349	9262-9263	t	_
39-350	9264-9273	rewarding	_
39-351	9274-9280	trials	_
39-352	9281-9282	(	_
39-353	9282-9288	number	_
39-354	9288-9289	)	_
39-355	9290-9294	27.9	_
39-356	9295-9296	(	_
39-357	9296-9297	±	_
39-358	9297-9300	3.4	_
39-359	9300-9301	)	_
39-360	9302-9306	28.6	_
39-361	9307-9308	(	_
39-362	9308-9309	±	_
39-363	9309-9312	2.9	_
39-364	9312-9313	)	_
39-365	9314-9318	27.8	_
39-366	9319-9320	(	_
39-367	9320-9321	±	_
39-368	9321-9324	3.6	_
39-369	9324-9325	)	_
39-370	9326-9330	27.9	_
39-371	9331-9332	(	_
39-372	9332-9333	±	_
39-373	9333-9336	4.9	_
39-374	9336-9337	)	_
39-375	9340-9348	Response	_
39-376	9349-9353	time	_
39-377	9354-9357	for	_
39-378	9358-9368	successful	_
39-379	9369-9376	neutral	_
39-380	9377-9383	trials	_
39-381	9384-9385	(	_
39-382	9385-9387	ms	_
39-383	9387-9388	)	_
39-384	9389-9394	210.6	_
39-385	9395-9396	(	_
39-386	9396-9397	±	_
39-387	9397-9401	23.7	_
39-388	9401-9402	)	_
39-389	9403-9408	206.7	_
39-390	9409-9410	(	_
39-391	9410-9411	±	_
39-392	9411-9415	22.4	_
39-393	9415-9416	)	_
39-394	9417-9422	211.5	_
39-395	9423-9424	(	_
39-396	9424-9425	±	_
39-397	9425-9429	23.1	_
39-398	9429-9430	)	_
39-399	9431-9436	220.6	_
39-400	9437-9438	(	_
39-401	9438-9439	±	_
39-402	9439-9443	40.1	_
39-403	9443-9444	)	_
39-404	9447-9455	Response	_
39-405	9456-9460	time	_
39-406	9461-9464	for	_
39-407	9465-9475	successful	_
39-408	9476-9485	rewarding	_
39-409	9486-9492	trials	_
39-410	9493-9494	(	_
39-411	9494-9496	ms	_
39-412	9496-9497	)	_
39-413	9498-9503	204.5	_
39-414	9504-9505	(	_
39-415	9505-9506	±	_
39-416	9506-9510	19.0	_
39-417	9510-9511	)	_
39-418	9512-9517	200.8	_
39-419	9518-9519	(	_
39-420	9519-9520	±	_
39-421	9520-9524	19.7	_
39-422	9524-9525	)	_
39-423	9526-9531	208.3	_
39-424	9532-9533	(	_
39-425	9533-9534	±	_
39-426	9534-9538	21.2	_
39-427	9538-9539	)	_
39-428	9540-9545	207.0	_
39-429	9546-9547	(	_
39-430	9547-9548	±	_
39-431	9548-9552	25.8	_
39-432	9552-9553	)	_
39-433	9557-9561	Data	_
39-434	9562-9565	are	_
39-435	9566-9575	displayed	_
39-436	9576-9578	by	_
39-437	9579-9589	individual	_
39-438	9590-9595	group	_
39-439	9596-9602	status	_
39-440	9602-9603	.	_

#Text=Standard deviation (SD) shown in parentheses.
40-1	9604-9612	Standard	_
40-2	9613-9622	deviation	_
40-3	9623-9624	(	_
40-4	9624-9626	SD	_
40-5	9626-9627	)	_
40-6	9628-9633	shown	_
40-7	9634-9636	in	_
40-8	9637-9648	parentheses	_
40-9	9648-9649	.	_

#Text=[Notes: AUDIT score > 8 indicate harmful drinking.
41-1	9650-9651	[	_
41-2	9651-9656	Notes	_
41-3	9656-9657	:	_
41-4	9658-9663	AUDIT	_
41-5	9664-9669	score	_
41-6	9670-9671	>	_
41-7	9672-9673	8	_
41-8	9674-9682	indicate	_
41-9	9683-9690	harmful	_
41-10	9691-9699	drinking	_
41-11	9699-9700	.	_

#Text=DAST-20 < 5 indicate recreational use of drugs in general (not specific to stimulant drugs).
42-1	9701-9705	DAST	_
42-2	9705-9706	-	_
42-3	9706-9708	20	_
42-4	9709-9710	<	_
42-5	9711-9712	5	_
42-6	9713-9721	indicate	_
42-7	9722-9734	recreational	_
42-8	9735-9738	use	_
42-9	9739-9741	of	_
42-10	9742-9747	drugs	_
42-11	9748-9750	in	_
42-12	9751-9758	general	_
42-13	9759-9760	(	_
42-14	9760-9763	not	_
42-15	9764-9772	specific	_
42-16	9773-9775	to	_
42-17	9776-9785	stimulant	_
42-18	9786-9791	drugs	_
42-19	9791-9792	)	_
42-20	9792-9793	.	_

#Text=The DAST-20 test was not administered in dependent stimulant users as it is not sensitive to clinical populations
#Text=A total of 165 participants were recruited for this study from local treatment centers, by media advertisements, or by word-of-mouth within the community.
43-1	9794-9797	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-2	9798-9802	DAST	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-3	9802-9803	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-4	9803-9805	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-5	9806-9810	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-6	9811-9814	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-7	9815-9818	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-8	9819-9831	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-9	9832-9834	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-10	9835-9844	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-11	9845-9854	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-12	9855-9860	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-13	9861-9863	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-14	9864-9866	it	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-15	9867-9869	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-16	9870-9873	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-17	9874-9883	sensitive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-18	9884-9886	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-19	9887-9895	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-20	9896-9907	populations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-21	9908-9909	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-22	9910-9915	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-23	9916-9918	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-24	9919-9922	165	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-25	9923-9935	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-26	9936-9940	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-27	9941-9950	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-28	9951-9954	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-29	9955-9959	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-30	9960-9965	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-31	9966-9970	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-32	9971-9976	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-33	9977-9986	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-34	9987-9994	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-35	9994-9995	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-36	9996-9998	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-37	9999-10004	media	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-38	10005-10019	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-39	10019-10020	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-40	10021-10023	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-41	10024-10026	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-42	10027-10040	word-of-mouth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-43	10041-10047	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-44	10048-10051	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-45	10052-10061	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
43-46	10061-10062	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]

#Text=All participants were between the age of 18–55 years and fluent in written and spoken English.
44-1	10063-10066	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-2	10067-10079	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-3	10080-10084	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-4	10085-10092	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-5	10093-10096	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-6	10097-10100	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-7	10101-10103	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-8	10104-10106	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-9	10106-10107	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-10	10107-10109	55	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-11	10110-10115	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-12	10116-10119	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-13	10120-10126	fluent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-14	10127-10129	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-15	10130-10137	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-16	10138-10141	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-17	10142-10148	spoken	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-18	10149-10156	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
44-19	10156-10157	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Participants also underwent semi-structured interviews to ascertain personal and family history of drug/alcohol addiction, physical health (including signs of acute intoxication and withdrawal), and mental health as assessed with the Structured Clinical Interview for DSM-IV-TR Axis I Disorders.
45-1	10158-10170	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-2	10171-10175	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-3	10176-10185	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-4	10186-10201	semi-structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-5	10202-10212	interviews	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-6	10213-10215	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-7	10216-10225	ascertain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-8	10226-10234	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-9	10235-10238	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-10	10239-10245	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-11	10246-10253	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-12	10254-10256	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-13	10257-10261	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-14	10261-10262	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-15	10262-10269	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-16	10270-10279	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-17	10279-10280	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-18	10281-10289	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-19	10290-10296	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-20	10297-10298	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-21	10298-10307	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-22	10308-10313	signs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-23	10314-10316	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-24	10317-10322	acute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-25	10323-10335	intoxication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-26	10336-10339	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-27	10340-10350	withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-28	10350-10351	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-29	10351-10352	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-30	10353-10356	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-31	10357-10363	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-32	10364-10370	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-33	10371-10373	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-34	10374-10382	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-35	10383-10387	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-36	10388-10391	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
45-37	10392-10402	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-38	10403-10411	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-39	10412-10421	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-40	10422-10425	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-41	10426-10435	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-42	10436-10440	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-43	10441-10442	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-44	10443-10452	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[20]
45-45	10452-10453	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Participants were split into four groups based on their individual familial risk (F) and stimulant drug-related risk (S).
46-1	10454-10466	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-2	10467-10471	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-3	10472-10477	split	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-4	10478-10482	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-5	10483-10487	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-6	10488-10494	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-7	10495-10500	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-8	10501-10503	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-9	10504-10509	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-10	10510-10520	individual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-11	10521-10529	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-12	10530-10534	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-13	10535-10536	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-14	10536-10537	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-15	10537-10538	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-16	10539-10542	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-17	10543-10552	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-18	10553-10565	drug-related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-19	10566-10570	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-20	10571-10572	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-21	10572-10573	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-22	10573-10574	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
46-23	10574-10575	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]

#Text=Stimulant-dependent individuals (F+S+) and their unaffected siblings (F+S−) composed the groups with familial risk.
47-1	10576-10595	Stimulant-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[22]
47-2	10596-10607	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-3	10608-10609	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-4	10609-10610	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-5	10610-10611	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-6	10611-10612	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-7	10612-10613	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-8	10613-10614	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-9	10615-10618	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-10	10619-10624	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-11	10625-10635	unaffected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-12	10636-10644	siblings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-13	10645-10646	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-14	10646-10647	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-15	10647-10648	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-16	10648-10649	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-17	10649-10650	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-18	10650-10651	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-19	10652-10660	composed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-20	10661-10664	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-21	10665-10671	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-22	10672-10676	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-23	10677-10685	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-24	10686-10690	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
47-25	10690-10691	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]

#Text=Non-dependent stimulant drug users without a family history of addiction (F−S+) and individuals without either family or personal history of drug addiction (F−S−) composed the control groups without familial risk (see Table 1).
48-1	10692-10705	Non-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-2	10706-10715	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-3	10716-10720	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-4	10721-10726	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-5	10727-10734	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-6	10735-10736	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-7	10737-10743	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-8	10744-10751	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-9	10752-10754	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-10	10755-10764	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-11	10765-10766	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-12	10766-10767	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-13	10767-10768	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-14	10768-10769	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-15	10769-10770	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-16	10770-10771	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-17	10772-10775	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-18	10776-10787	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-19	10788-10795	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-20	10796-10802	either	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-21	10803-10809	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-22	10810-10812	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-23	10813-10821	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-24	10822-10829	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-25	10830-10832	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-26	10833-10837	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[24]
48-27	10838-10847	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]|http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[24]
48-28	10848-10849	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-29	10849-10850	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-30	10850-10851	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-31	10851-10852	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-32	10852-10853	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-33	10853-10854	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-34	10855-10863	composed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-35	10864-10867	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-36	10868-10875	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-37	10876-10882	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-38	10883-10890	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-39	10891-10899	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-40	10900-10904	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-41	10905-10906	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-42	10906-10909	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-43	10910-10915	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-44	10916-10917	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-45	10917-10918	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
48-46	10918-10919	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]

#Text=All F+S+ participants were required to satisfy the DSM-IV-TR criteria for stimulant drug dependence (cocaine: 92.7%; amphetamines: 7.3%) and share both biological parents with an F+S− sibling who was also able to participate in the study.
49-1	10920-10923	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-2	10924-10925	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-3	10925-10926	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-4	10926-10927	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-5	10927-10928	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-6	10929-10941	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-7	10942-10946	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-8	10947-10955	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-9	10956-10958	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-10	10959-10966	satisfy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-11	10967-10970	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-12	10971-10980	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-13	10981-10989	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-14	10990-10993	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-15	10994-11003	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[26]
49-16	11004-11008	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[26]
49-17	11009-11019	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[26]
49-18	11020-11021	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-19	11021-11028	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[27]
49-20	11028-11029	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-21	11030-11035	92.7%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-22	11035-11036	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-23	11037-11049	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-24	11049-11050	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-25	11051-11055	7.3%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-26	11055-11056	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-27	11057-11060	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-28	11061-11066	share	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-29	11067-11071	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-30	11072-11082	biological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-31	11083-11090	parents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-32	11091-11095	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-33	11096-11098	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-34	11099-11100	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-35	11100-11101	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-36	11101-11102	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-37	11102-11103	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-38	11104-11111	sibling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-39	11112-11115	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-40	11116-11119	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-41	11120-11124	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-42	11125-11129	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-43	11130-11132	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-44	11133-11144	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-45	11145-11147	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-46	11148-11151	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-47	11152-11157	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
49-48	11157-11158	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Additionally, F−S+ control participants were required to have engaged in regular stimulant drug use for at least two years but had never developed addiction to drugs or alcohol and had never been prescribed stimulant drugs for medical reasons.
50-1	11159-11171	Additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-2	11171-11172	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-3	11173-11174	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-4	11174-11175	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-5	11175-11176	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-6	11176-11177	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-7	11178-11185	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]
50-8	11186-11198	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[28]
50-9	11199-11203	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-10	11204-11212	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-11	11213-11215	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-12	11216-11220	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-13	11221-11228	engaged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-14	11229-11231	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-15	11232-11239	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-16	11240-11249	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-17	11250-11254	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-18	11255-11258	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-19	11259-11262	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-20	11263-11265	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-21	11266-11271	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-22	11272-11275	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-23	11276-11281	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-24	11282-11285	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-25	11286-11289	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-26	11290-11295	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-27	11296-11305	developed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-28	11306-11315	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-29	11316-11318	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-30	11319-11324	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-31	11325-11327	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-32	11328-11335	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-33	11336-11339	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-34	11340-11343	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-35	11344-11349	never	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-36	11350-11354	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-37	11355-11365	prescribed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-38	11366-11375	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-39	11376-11381	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-40	11382-11385	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-41	11386-11393	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-42	11394-11401	reasons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
50-43	11401-11402	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=We intentionally recruited non-dependent stimulant drug-using controls because their lack of dependence reduced their likelihood of possessing those familial risk factors and associated neural vulnerabilities that render individuals susceptible to addiction.
51-1	11403-11405	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-2	11406-11419	intentionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-3	11420-11429	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-4	11430-11443	non-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-5	11444-11453	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-6	11454-11464	drug-using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-7	11465-11473	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-8	11474-11481	because	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-9	11482-11487	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-10	11488-11492	lack	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-11	11493-11495	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-12	11496-11506	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-13	11507-11514	reduced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-14	11515-11520	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-15	11521-11531	likelihood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-16	11532-11534	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-17	11535-11545	possessing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-18	11546-11551	those	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-19	11552-11560	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-20	11561-11565	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-21	11566-11573	factors	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-22	11574-11577	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-23	11578-11588	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-24	11589-11595	neural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-25	11596-11611	vulnerabilities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-26	11612-11616	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-27	11617-11623	render	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-28	11624-11635	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-29	11636-11647	susceptible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-30	11648-11650	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-31	11651-11660	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
51-32	11660-11661	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The sample size was determined by power analysis, establishing a group size of N = 42 for 95% power to identify the effects of familiarity.
52-1	11662-11665	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-2	11666-11672	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-3	11673-11677	size	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-4	11678-11681	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-5	11682-11692	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-6	11693-11695	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-7	11696-11701	power	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-8	11702-11710	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-9	11710-11711	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-10	11712-11724	establishing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-11	11725-11726	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-12	11727-11732	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-13	11733-11737	size	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-14	11738-11740	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-15	11741-11742	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-16	11743-11744	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-17	11745-11747	42	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-18	11748-11751	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-19	11752-11755	95%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-20	11756-11761	power	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-21	11762-11764	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-22	11765-11773	identify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-23	11774-11777	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-24	11778-11785	effects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-25	11786-11788	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-26	11789-11800	familiarity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
52-27	11800-11801	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Semi-structured interviews determined that control participants had no first-degree relative affected by addiction.
53-1	11802-11817	Semi-structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-2	11818-11828	interviews	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-3	11829-11839	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-4	11840-11844	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-5	11845-11852	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-6	11853-11865	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-7	11866-11869	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-8	11870-11872	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-9	11873-11885	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-10	11886-11894	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-11	11895-11903	affected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-12	11904-11906	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-13	11907-11916	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
53-14	11916-11917	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=For all groups, exclusionary criteria included a lifetime history of a psychotic, neurological, or neurodevelopment disorder, or traumatic head injury.
54-1	11918-11921	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-2	11922-11925	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-3	11926-11932	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-4	11932-11933	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-5	11934-11946	exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-6	11947-11955	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-7	11956-11964	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-8	11965-11966	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-9	11967-11975	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-10	11976-11983	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-11	11984-11986	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-12	11987-11988	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-13	11989-11998	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-14	11998-11999	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-15	12000-12012	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-16	12012-12013	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-17	12014-12016	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-18	12017-12033	neurodevelopment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-19	12034-12042	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-20	12042-12043	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-21	12044-12046	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-22	12047-12056	traumatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-23	12057-12061	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-24	12062-12068	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
54-25	12068-12069	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Exclusion criteria for unaffected siblings and unrelated controls also included any personal history of substance addiction (except nicotine).
55-1	12070-12079	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-2	12080-12088	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-3	12089-12092	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-4	12093-12103	unaffected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-5	12104-12112	siblings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-6	12113-12116	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-7	12117-12126	unrelated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-8	12127-12135	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-9	12136-12140	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-10	12141-12149	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-11	12150-12153	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-12	12154-12162	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-13	12163-12170	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-14	12171-12173	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-15	12174-12183	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-16	12184-12193	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-17	12194-12195	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-18	12195-12201	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-19	12202-12210	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-20	12210-12211	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
55-21	12211-12212	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=Concurrent drug and alcohol consumption for these three groups were low (as reflected by the Alcohol Use Disorders Identification Test [AUDIT] and Drug Abuse Screening Test [DAST-20] scores, see Table 1).
56-1	12213-12223	Concurrent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-2	12224-12228	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-3	12229-12232	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-4	12233-12240	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-5	12241-12252	consumption	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-6	12253-12256	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-7	12257-12262	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-8	12263-12268	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-9	12269-12275	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-10	12276-12280	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-11	12281-12284	low	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-12	12285-12286	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-13	12286-12288	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-14	12289-12298	reflected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-15	12299-12301	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-16	12302-12305	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-17	12306-12313	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-18	12314-12317	Use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-19	12318-12327	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-20	12328-12342	Identification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-21	12343-12347	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-22	12348-12349	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-23	12349-12354	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[30]
56-24	12354-12355	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-25	12356-12359	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-26	12360-12364	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-27	12365-12370	Abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-28	12371-12380	Screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-29	12381-12385	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-30	12386-12387	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-31	12387-12391	DAST	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-32	12391-12392	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-33	12392-12394	20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-34	12394-12395	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-35	12396-12402	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#Sedative-hypnotic-anxiolyticUseDisorderScale[31]
56-36	12402-12403	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-37	12404-12407	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-38	12408-12413	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-39	12414-12415	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-40	12415-12416	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
56-41	12416-12417	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Experience with tobacco and nicotine have been reported in all groups (see Table 1).
57-1	12418-12428	Experience	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-2	12429-12433	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-3	12434-12441	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-4	12442-12445	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-5	12446-12454	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-6	12455-12459	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-7	12460-12464	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-8	12465-12473	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-9	12474-12476	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-10	12477-12480	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-11	12481-12487	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-12	12488-12489	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-13	12489-12492	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-14	12493-12498	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-15	12499-12500	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-16	12500-12501	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
57-17	12501-12502	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Group differences in reported nicotine (χ2 = 67.04, p < 0.001) and cannabis use (χ2 = 104.36, p < 0.001) between stimulant drug users and non-users were controlled for in a separate post-hoc analysis.
58-1	12503-12508	Group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-2	12509-12520	differences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-3	12521-12523	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-4	12524-12532	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-5	12533-12541	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-6	12542-12543	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-7	12543-12545	χ2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-8	12546-12547	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-9	12548-12553	67.04	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-10	12553-12554	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-11	12555-12556	p	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-12	12557-12558	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-13	12559-12564	0.001	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-14	12564-12565	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-15	12566-12569	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-16	12570-12578	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-17	12579-12582	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-18	12583-12584	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-19	12584-12586	χ2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-20	12587-12588	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-21	12589-12595	104.36	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-22	12595-12596	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-23	12597-12598	p	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-24	12599-12600	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-25	12601-12606	0.001	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-26	12606-12607	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-27	12608-12615	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-28	12616-12625	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[32]
58-29	12626-12630	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[32]
58-30	12631-12636	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]|http://maven.renci.org/NeuroBridge/neurobridge#StimulantDependence[32]
58-31	12637-12640	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-32	12641-12650	non-users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-33	12651-12655	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-34	12656-12666	controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-35	12667-12670	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-36	12671-12673	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-37	12674-12675	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-38	12676-12684	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-39	12685-12693	post-hoc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-40	12694-12702	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
58-41	12702-12703	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Critically, although drug-taking experiences are common in people with familial risk, F+S− participants in the present study did not report stimulant drug use.
59-1	12704-12714	Critically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-2	12714-12715	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-3	12716-12724	although	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-4	12725-12736	drug-taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-5	12737-12748	experiences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-6	12749-12752	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-7	12753-12759	common	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-8	12760-12762	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-9	12763-12769	people	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-10	12770-12774	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-11	12775-12783	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-12	12784-12788	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-13	12788-12789	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-14	12790-12791	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-15	12791-12792	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-16	12792-12793	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-17	12793-12794	−	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-18	12795-12807	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-19	12808-12810	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-20	12811-12814	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-21	12815-12822	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-22	12823-12828	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-23	12829-12832	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-24	12833-12836	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-25	12837-12843	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-26	12844-12853	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-27	12854-12858	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-28	12859-12862	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
59-29	12862-12863	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Exclusion criteria were kept deliberately minimal as minor psychopathology may be a clinical marker of vulnerability and an important characteristic of the participant in the familial risk group.
60-1	12864-12873	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-2	12874-12882	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-3	12883-12887	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-4	12888-12892	kept	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-5	12893-12905	deliberately	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-6	12906-12913	minimal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-7	12914-12916	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-8	12917-12922	minor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-9	12923-12938	psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-10	12939-12942	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-11	12943-12945	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-12	12946-12947	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-13	12948-12956	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-14	12957-12963	marker	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-15	12964-12966	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-16	12967-12980	vulnerability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-17	12981-12984	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-18	12985-12987	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-19	12988-12997	important	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-20	12998-13012	characteristic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-21	13013-13015	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-22	13016-13019	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-23	13020-13031	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-24	13032-13034	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-25	13035-13038	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-26	13039-13047	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-27	13048-13052	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-28	13053-13058	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]
60-29	13058-13059	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]

#Text=Further details can be found in the supplementary material (SM).
61-1	13060-13067	Further	_
61-2	13068-13075	details	_
61-3	13076-13079	can	_
61-4	13080-13082	be	_
61-5	13083-13088	found	_
61-6	13089-13091	in	_
61-7	13092-13095	the	_
61-8	13096-13109	supplementary	_
61-9	13110-13118	material	_
61-10	13119-13120	(	_
61-11	13120-13122	SM	_
61-12	13122-13123	)	_
61-13	13123-13124	.	_

#Text=In addition to stimulant drug dependence, 12 F+S+ participants further met diagnostic criteria for alcohol dependence, and 22 F+S+ participants for opioid dependence.
62-1	13125-13127	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-2	13128-13136	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-3	13137-13139	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-4	13140-13149	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-5	13150-13154	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-6	13155-13165	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-7	13165-13166	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-8	13167-13169	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-9	13170-13171	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-10	13171-13172	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-11	13172-13173	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-12	13173-13174	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-13	13175-13187	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-14	13188-13195	further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-15	13196-13199	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-16	13200-13210	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-17	13211-13219	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-18	13220-13223	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-19	13224-13231	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[34]
62-20	13232-13242	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[34]
62-21	13242-13243	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-22	13244-13247	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-23	13248-13250	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-24	13251-13252	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-25	13252-13253	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-26	13253-13254	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-27	13254-13255	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-28	13256-13268	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-29	13269-13272	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
62-30	13273-13279	opioid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[35]
62-31	13280-13290	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse[35]
62-32	13290-13291	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]

#Text=Consistent with prior literature, participants with familial risk reported a high prevalence of childhood adversity when compared with control participants (F1,159 = 29.12, p < 0.001), as determined by Childhood Trauma Questionnaire (CTQ) abuse scores.
63-1	13292-13302	Consistent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-2	13303-13307	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-3	13308-13313	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-4	13314-13324	literature	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-5	13324-13325	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-6	13326-13338	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-7	13339-13343	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-8	13344-13352	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-9	13353-13357	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-10	13358-13366	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-11	13367-13368	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-12	13369-13373	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-13	13374-13384	prevalence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-14	13385-13387	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-15	13388-13397	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-16	13398-13407	adversity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-17	13408-13412	when	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-18	13413-13421	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-19	13422-13426	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-20	13427-13434	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[36]
63-21	13435-13447	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[36]
63-22	13448-13449	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-23	13449-13455	F1,159	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-24	13456-13457	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-25	13458-13463	29.12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-26	13463-13464	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-27	13465-13466	p	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-28	13467-13468	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-29	13469-13474	0.001	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-30	13474-13475	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-31	13475-13476	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-32	13477-13479	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-33	13480-13490	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-34	13491-13493	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
63-35	13494-13503	Childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-36	13504-13510	Trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-37	13511-13524	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-38	13525-13526	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-39	13526-13529	CTQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-40	13529-13530	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-41	13531-13536	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-42	13537-13543	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]|http://maven.renci.org/NeuroBridge/neurobridge#ChildhoodTraumaQuestionnaire[37]
63-43	13543-13544	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]

#Text=Differences in familial relationship between sibling pairs and unrelated control groups (i.e., sibling pairs with familial risk were related, whereas control participants without familial risk were not) was investigated post-hoc.
64-1	13545-13556	Differences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-2	13557-13559	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-3	13560-13568	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-4	13569-13581	relationship	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-5	13582-13589	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-6	13590-13597	sibling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-7	13598-13603	pairs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-8	13604-13607	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-9	13608-13617	unrelated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-10	13618-13625	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-11	13626-13632	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-12	13633-13634	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-13	13634-13637	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-14	13637-13638	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-15	13638-13639	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-16	13640-13647	sibling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-17	13648-13653	pairs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-18	13654-13658	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-19	13659-13667	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-20	13668-13672	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-21	13673-13677	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-22	13678-13685	related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-23	13685-13686	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-24	13687-13694	whereas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-25	13695-13702	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-26	13703-13715	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-27	13716-13723	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-28	13724-13732	familial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-29	13733-13737	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-30	13738-13742	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-31	13743-13746	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-32	13746-13747	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-33	13748-13751	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-34	13752-13764	investigated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-35	13765-13773	post-hoc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
64-36	13773-13774	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]

#Text=Prior to testing, stimulant-positive urine samples were provided by all except three F+S+ participants, indicating the use of stimulant drugs in the last 72 h.
65-1	13775-13780	Prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-2	13781-13783	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-3	13784-13791	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-4	13791-13792	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-5	13793-13811	stimulant-positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-6	13812-13817	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-7	13818-13825	samples	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-8	13826-13830	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-9	13831-13839	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-10	13840-13842	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-11	13843-13846	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-12	13847-13853	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-13	13854-13859	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-14	13860-13861	F	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-15	13861-13862	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-16	13862-13863	S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-17	13863-13864	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-18	13865-13877	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-19	13877-13878	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-20	13879-13889	indicating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-21	13890-13893	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-22	13894-13897	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-23	13898-13900	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-24	13901-13910	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-25	13911-13916	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-26	13917-13919	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-27	13920-13923	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-28	13924-13928	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-29	13929-13931	72	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-30	13932-13933	h	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
65-31	13933-13934	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]

#Text=Drug-negative urine samples were provided by all other participants.
66-1	13935-13948	Drug-negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-2	13949-13954	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-3	13955-13962	samples	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-4	13963-13967	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-5	13968-13976	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-6	13977-13979	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-7	13980-13983	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-8	13984-13989	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-9	13990-14002	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]
66-10	14002-14003	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[33]

#Text=This study was approved by the NHS Cambridgeshire2 Research Ethics Committee (08/H0308/310PI:KDE), and written informed consent was obtained from all participants prior to study enrollment.
67-1	14004-14008	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-2	14009-14014	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-3	14015-14018	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-4	14019-14027	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-5	14028-14030	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-6	14031-14034	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-7	14035-14038	NHS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-8	14039-14054	Cambridgeshire2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-9	14055-14063	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-10	14064-14070	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-11	14071-14080	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-12	14081-14082	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-13	14082-14084	08	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-14	14084-14085	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-15	14085-14090	H0308	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-16	14090-14091	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-17	14091-14096	310PI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-18	14096-14097	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-19	14097-14100	KDE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-20	14100-14101	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-21	14101-14102	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-22	14103-14106	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-23	14107-14114	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-24	14115-14123	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-25	14124-14131	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-26	14132-14135	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-27	14136-14144	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-28	14145-14149	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-29	14150-14153	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-30	14154-14166	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-31	14167-14172	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-32	14173-14175	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-33	14176-14181	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-34	14182-14192	enrollment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]
67-35	14192-14193	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[38]

#Text=This sample is described in more detail in the SM; separate data from this sample have been published previously.
68-1	14194-14198	This	_
68-2	14199-14205	sample	_
68-3	14206-14208	is	_
68-4	14209-14218	described	_
68-5	14219-14221	in	_
68-6	14222-14226	more	_
68-7	14227-14233	detail	_
68-8	14234-14236	in	_
68-9	14237-14240	the	_
68-10	14241-14243	SM	_
68-11	14243-14244	;	_
68-12	14245-14253	separate	_
68-13	14254-14258	data	_
68-14	14259-14263	from	_
68-15	14264-14268	this	_
68-16	14269-14275	sample	_
68-17	14276-14280	have	_
68-18	14281-14285	been	_
68-19	14286-14295	published	_
68-20	14296-14306	previously	_
68-21	14306-14307	.	_

#Text=MID-task design
#Text=Schematic representation of the MID-paradigm depicting screen sequence, contrast used, and key performance variable intervals.
69-1	14308-14316	MID-task	_
69-2	14317-14323	design	_
69-3	14324-14333	Schematic	_
69-4	14334-14348	representation	_
69-5	14349-14351	of	_
69-6	14352-14355	the	_
69-7	14356-14368	MID-paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
69-8	14369-14378	depicting	_
69-9	14379-14385	screen	_
69-10	14386-14394	sequence	_
69-11	14394-14395	,	_
69-12	14396-14404	contrast	_
69-13	14405-14409	used	_
69-14	14409-14410	,	_
69-15	14411-14414	and	_
69-16	14415-14418	key	_
69-17	14419-14430	performance	_
69-18	14431-14439	variable	_
69-19	14440-14449	intervals	_
69-20	14449-14450	.	_

#Text=The sequence presented screens including an anticipatory cue, inter-stimulus (IS) interval, target stimulus, feedback, and fixation cross.
70-1	14451-14454	The	_
70-2	14455-14463	sequence	_
70-3	14464-14473	presented	_
70-4	14474-14481	screens	_
70-5	14482-14491	including	_
70-6	14492-14494	an	_
70-7	14495-14507	anticipatory	_
70-8	14508-14511	cue	_
70-9	14511-14512	,	_
70-10	14513-14527	inter-stimulus	_
70-11	14528-14529	(	_
70-12	14529-14531	IS	_
70-13	14531-14532	)	_
70-14	14533-14541	interval	_
70-15	14541-14542	,	_
70-16	14543-14549	target	_
70-17	14550-14558	stimulus	_
70-18	14558-14559	,	_
70-19	14560-14568	feedback	_
70-20	14568-14569	,	_
70-21	14570-14573	and	_
70-22	14574-14582	fixation	_
70-23	14583-14588	cross	_
70-24	14588-14589	.	_

#Text=The neutral cue (no reward) was represented by an empty circle, the small gain (10 pence) cue was represented by a circle transected by a single horizontal line, and the large gain (50 pence) cue was represented by a circle transected by two horizontal lines.
71-1	14590-14593	The	_
71-2	14594-14601	neutral	_
71-3	14602-14605	cue	_
71-4	14606-14607	(	_
71-5	14607-14609	no	_
71-6	14610-14616	reward	_
71-7	14616-14617	)	_
71-8	14618-14621	was	_
71-9	14622-14633	represented	_
71-10	14634-14636	by	_
71-11	14637-14639	an	_
71-12	14640-14645	empty	_
71-13	14646-14652	circle	_
71-14	14652-14653	,	_
71-15	14654-14657	the	_
71-16	14658-14663	small	_
71-17	14664-14668	gain	_
71-18	14669-14670	(	_
71-19	14670-14672	10	_
71-20	14673-14678	pence	_
71-21	14678-14679	)	_
71-22	14680-14683	cue	_
71-23	14684-14687	was	_
71-24	14688-14699	represented	_
71-25	14700-14702	by	_
71-26	14703-14704	a	_
71-27	14705-14711	circle	_
71-28	14712-14722	transected	_
71-29	14723-14725	by	_
71-30	14726-14727	a	_
71-31	14728-14734	single	_
71-32	14735-14745	horizontal	_
71-33	14746-14750	line	_
71-34	14750-14751	,	_
71-35	14752-14755	and	_
71-36	14756-14759	the	_
71-37	14760-14765	large	_
71-38	14766-14770	gain	_
71-39	14771-14772	(	_
71-40	14772-14774	50	_
71-41	14775-14780	pence	_
71-42	14780-14781	)	_
71-43	14782-14785	cue	_
71-44	14786-14789	was	_
71-45	14790-14801	represented	_
71-46	14802-14804	by	_
71-47	14805-14806	a	_
71-48	14807-14813	circle	_
71-49	14814-14824	transected	_
71-50	14825-14827	by	_
71-51	14828-14831	two	_
71-52	14832-14842	horizontal	_
71-53	14843-14848	lines	_
71-54	14848-14849	.	_

#Text=Successful feedback was depicted by an image of a 10p or 50p coin with the words “you’ve won 10p!”
72-1	14850-14860	Successful	_
72-2	14861-14869	feedback	_
72-3	14870-14873	was	_
72-4	14874-14882	depicted	_
72-5	14883-14885	by	_
72-6	14886-14888	an	_
72-7	14889-14894	image	_
72-8	14895-14897	of	_
72-9	14898-14899	a	_
72-10	14900-14903	10p	_
72-11	14904-14906	or	_
72-12	14907-14910	50p	_
72-13	14911-14915	coin	_
72-14	14916-14920	with	_
72-15	14921-14924	the	_
72-16	14925-14930	words	_
72-17	14931-14932	“	_
72-18	14932-14935	you	_
72-19	14935-14936	’	_
72-20	14936-14938	ve	_
72-21	14939-14942	won	_
72-22	14943-14946	10p	_
72-23	14946-14947	!	_
72-24	14947-14948	”	_

#Text=and “you’ve won 50p!”
73-1	14949-14952	and	_
73-2	14953-14954	“	_
73-3	14954-14957	you	_
73-4	14957-14958	’	_
73-5	14958-14960	ve	_
73-6	14961-14964	won	_
73-7	14965-14968	50p	_
73-8	14968-14969	!	_
73-9	14969-14970	”	_

#Text=respectively (depending on the magnitude of the previous anticipation cue).
74-1	14971-14983	respectively	_
74-2	14984-14985	(	_
74-3	14985-14994	depending	_
74-4	14995-14997	on	_
74-5	14998-15001	the	_
74-6	15002-15011	magnitude	_
74-7	15012-15014	of	_
74-8	15015-15018	the	_
74-9	15019-15027	previous	_
74-10	15028-15040	anticipation	_
74-11	15041-15044	cue	_
74-12	15044-15045	)	_
74-13	15045-15046	.	_

#Text=Unsuccessful feedback (too late or too early) and successful neutral reward feedback, was depicted as an empty circle with the words “you’ve won 0p!”
75-1	15047-15059	Unsuccessful	_
75-2	15060-15068	feedback	_
75-3	15069-15070	(	_
75-4	15070-15073	too	_
75-5	15074-15078	late	_
75-6	15079-15081	or	_
75-7	15082-15085	too	_
75-8	15086-15091	early	_
75-9	15091-15092	)	_
75-10	15093-15096	and	_
75-11	15097-15107	successful	_
75-12	15108-15115	neutral	_
75-13	15116-15122	reward	_
75-14	15123-15131	feedback	_
75-15	15131-15132	,	_
75-16	15133-15136	was	_
75-17	15137-15145	depicted	_
75-18	15146-15148	as	_
75-19	15149-15151	an	_
75-20	15152-15157	empty	_
75-21	15158-15164	circle	_
75-22	15165-15169	with	_
75-23	15170-15173	the	_
75-24	15174-15179	words	_
75-25	15180-15181	“	_
75-26	15181-15184	you	_
75-27	15184-15185	’	_
75-28	15185-15187	ve	_
75-29	15188-15191	won	_
75-30	15192-15194	0p	_
75-31	15194-15195	!	_
75-32	15195-15196	”	_

#Text=We used the MID-task to examine the neural correlates of reward anticipation (Fig. 1).
76-1	15197-15199	We	_
76-2	15200-15204	used	_
76-3	15205-15208	the	_
76-4	15209-15217	MID-task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
76-5	15218-15220	to	_
76-6	15221-15228	examine	_
76-7	15229-15232	the	_
76-8	15233-15239	neural	_
76-9	15240-15250	correlates	_
76-10	15251-15253	of	_
76-11	15254-15260	reward	_
76-12	15261-15273	anticipation	_
76-13	15274-15275	(	_
76-14	15275-15278	Fig	_
76-15	15278-15279	.	_
76-16	15280-15281	1	_
76-17	15281-15282	)	_
76-18	15282-15283	.	_

#Text=The task consisted of three phases: anticipation, target, and feedback.
77-1	15284-15287	The	_
77-2	15288-15292	task	_
77-3	15293-15302	consisted	_
77-4	15303-15305	of	_
77-5	15306-15311	three	_
77-6	15312-15318	phases	_
77-7	15318-15319	:	_
77-8	15320-15332	anticipation	_
77-9	15332-15333	,	_
77-10	15334-15340	target	_
77-11	15340-15341	,	_
77-12	15342-15345	and	_
77-13	15346-15354	feedback	_
77-14	15354-15355	.	_

#Text=A cue presented in the anticipation phase notified participants of the potential to receive a monetary or neutral reward.
78-1	15356-15357	A	_
78-2	15358-15361	cue	_
78-3	15362-15371	presented	_
78-4	15372-15374	in	_
78-5	15375-15378	the	_
78-6	15379-15391	anticipation	_
78-7	15392-15397	phase	_
78-8	15398-15406	notified	_
78-9	15407-15419	participants	_
78-10	15420-15422	of	_
78-11	15423-15426	the	_
78-12	15427-15436	potential	_
78-13	15437-15439	to	_
78-14	15440-15447	receive	_
78-15	15448-15449	a	_
78-16	15450-15458	monetary	_
78-17	15459-15461	or	_
78-18	15462-15469	neutral	_
78-19	15470-15476	reward	_
78-20	15476-15477	.	_

#Text=The target stimulus, presented following the anticipation phase, prompted participants to respond by pressing a button.
79-1	15478-15481	The	_
79-2	15482-15488	target	_
79-3	15489-15497	stimulus	_
79-4	15497-15498	,	_
79-5	15499-15508	presented	_
79-6	15509-15518	following	_
79-7	15519-15522	the	_
79-8	15523-15535	anticipation	_
79-9	15536-15541	phase	_
79-10	15541-15542	,	_
79-11	15543-15551	prompted	_
79-12	15552-15564	participants	_
79-13	15565-15567	to	_
79-14	15568-15575	respond	_
79-15	15576-15578	by	_
79-16	15579-15587	pressing	_
79-17	15588-15589	a	_
79-18	15590-15596	button	_
79-19	15596-15597	.	_

#Text=Finally, during the feedback phase participants were informed about the outcome of their behavioral response.
80-1	15598-15605	Finally	_
80-2	15605-15606	,	_
80-3	15607-15613	during	_
80-4	15614-15617	the	_
80-5	15618-15626	feedback	_
80-6	15627-15632	phase	_
80-7	15633-15645	participants	_
80-8	15646-15650	were	_
80-9	15651-15659	informed	_
80-10	15660-15665	about	_
80-11	15666-15669	the	_
80-12	15670-15677	outcome	_
80-13	15678-15680	of	_
80-14	15681-15686	their	_
80-15	15687-15697	behavioral	_
80-16	15698-15706	response	_
80-17	15706-15707	.	_

#Text=During the anticipatory phase, three cues, indicating either a neutral or rewarding outcome, were randomly displayed (Fig. 1).
81-1	15708-15714	During	_
81-2	15715-15718	the	_
81-3	15719-15731	anticipatory	_
81-4	15732-15737	phase	_
81-5	15737-15738	,	_
81-6	15739-15744	three	_
81-7	15745-15749	cues	_
81-8	15749-15750	,	_
81-9	15751-15761	indicating	_
81-10	15762-15768	either	_
81-11	15769-15770	a	_
81-12	15771-15778	neutral	_
81-13	15779-15781	or	_
81-14	15782-15791	rewarding	_
81-15	15792-15799	outcome	_
81-16	15799-15800	,	_
81-17	15801-15805	were	_
81-18	15806-15814	randomly	_
81-19	15815-15824	displayed	_
81-20	15825-15826	(	_
81-21	15826-15829	Fig	_
81-22	15829-15830	.	_
81-23	15831-15832	1	_
81-24	15832-15833	)	_
81-25	15833-15834	.	_

#Text=The anticipatory cue was presented for 250 ms, notified participants of the potential to win a monetary or a neutral reward, and was followed by a jittered black anticipation screen for 3000–5000 ms.
82-1	15835-15838	The	_
82-2	15839-15851	anticipatory	_
82-3	15852-15855	cue	_
82-4	15856-15859	was	_
82-5	15860-15869	presented	_
82-6	15870-15873	for	_
82-7	15874-15877	250	_
82-8	15878-15880	ms	_
82-9	15880-15881	,	_
82-10	15882-15890	notified	_
82-11	15891-15903	participants	_
82-12	15904-15906	of	_
82-13	15907-15910	the	_
82-14	15911-15920	potential	_
82-15	15921-15923	to	_
82-16	15924-15927	win	_
82-17	15928-15929	a	_
82-18	15930-15938	monetary	_
82-19	15939-15941	or	_
82-20	15942-15943	a	_
82-21	15944-15951	neutral	_
82-22	15952-15958	reward	_
82-23	15958-15959	,	_
82-24	15960-15963	and	_
82-25	15964-15967	was	_
82-26	15968-15976	followed	_
82-27	15977-15979	by	_
82-28	15980-15981	a	_
82-29	15982-15990	jittered	_
82-30	15991-15996	black	_
82-31	15997-16009	anticipation	_
82-32	16010-16016	screen	_
82-33	16017-16020	for	_
82-34	16021-16025	3000	_
82-35	16025-16026	–	_
82-36	16026-16030	5000	_
82-37	16031-16033	ms	_
82-38	16033-16034	.	_

#Text=The target stimulus, always a white square, was then presented for 100–400 ms, during which the participant had to respond by pressing a button.
83-1	16035-16038	The	_
83-2	16039-16045	target	_
83-3	16046-16054	stimulus	_
83-4	16054-16055	,	_
83-5	16056-16062	always	_
83-6	16063-16064	a	_
83-7	16065-16070	white	_
83-8	16071-16077	square	_
83-9	16077-16078	,	_
83-10	16079-16082	was	_
83-11	16083-16087	then	_
83-12	16088-16097	presented	_
83-13	16098-16101	for	_
83-14	16102-16105	100	_
83-15	16105-16106	–	_
83-16	16106-16109	400	_
83-17	16110-16112	ms	_
83-18	16112-16113	,	_
83-19	16114-16120	during	_
83-20	16121-16126	which	_
83-21	16127-16130	the	_
83-22	16131-16142	participant	_
83-23	16143-16146	had	_
83-24	16147-16149	to	_
83-25	16150-16157	respond	_
83-26	16158-16160	by	_
83-27	16161-16169	pressing	_
83-28	16170-16171	a	_
83-29	16172-16178	button	_
83-30	16178-16179	.	_

#Text=Immediately following the target stimulus, either successful or unsuccessful feedback, contingent on participant response, was presented for 1650 ms.
84-1	16180-16191	Immediately	_
84-2	16192-16201	following	_
84-3	16202-16205	the	_
84-4	16206-16212	target	_
84-5	16213-16221	stimulus	_
84-6	16221-16222	,	_
84-7	16223-16229	either	_
84-8	16230-16240	successful	_
84-9	16241-16243	or	_
84-10	16244-16256	unsuccessful	_
84-11	16257-16265	feedback	_
84-12	16265-16266	,	_
84-13	16267-16277	contingent	_
84-14	16278-16280	on	_
84-15	16281-16292	participant	_
84-16	16293-16301	response	_
84-17	16301-16302	,	_
84-18	16303-16306	was	_
84-19	16307-16316	presented	_
84-20	16317-16320	for	_
84-21	16321-16325	1650	_
84-22	16326-16328	ms	_
84-23	16328-16329	.	_

#Text=Feedback screens were followed by a fixation cross screen, which was presented for 5000–2700 ms until the next trial commenced.
85-1	16330-16338	Feedback	_
85-2	16339-16346	screens	_
85-3	16347-16351	were	_
85-4	16352-16360	followed	_
85-5	16361-16363	by	_
85-6	16364-16365	a	_
85-7	16366-16374	fixation	_
85-8	16375-16380	cross	_
85-9	16381-16387	screen	_
85-10	16387-16388	,	_
85-11	16389-16394	which	_
85-12	16395-16398	was	_
85-13	16399-16408	presented	_
85-14	16409-16412	for	_
85-15	16413-16417	5000	_
85-16	16417-16418	–	_
85-17	16418-16422	2700	_
85-18	16423-16425	ms	_
85-19	16426-16431	until	_
85-20	16432-16435	the	_
85-21	16436-16440	next	_
85-22	16441-16446	trial	_
85-23	16447-16456	commenced	_
85-24	16456-16457	.	_

#Text=Responses were deemed successful if performed during presentation of the target on the screen.
86-1	16458-16467	Responses	_
86-2	16468-16472	were	_
86-3	16473-16479	deemed	_
86-4	16480-16490	successful	_
86-5	16491-16493	if	_
86-6	16494-16503	performed	_
86-7	16504-16510	during	_
86-8	16511-16523	presentation	_
86-9	16524-16526	of	_
86-10	16527-16530	the	_
86-11	16531-16537	target	_
86-12	16538-16540	on	_
86-13	16541-16544	the	_
86-14	16545-16551	screen	_
86-15	16551-16552	.	_

#Text=The time between the presentation of the cue and the target stimulus represents the anticipatory phase, during which neural responses were recorded (Fig. 1).
87-1	16553-16556	The	_
87-2	16557-16561	time	_
87-3	16562-16569	between	_
87-4	16570-16573	the	_
87-5	16574-16586	presentation	_
87-6	16587-16589	of	_
87-7	16590-16593	the	_
87-8	16594-16597	cue	_
87-9	16598-16601	and	_
87-10	16602-16605	the	_
87-11	16606-16612	target	_
87-12	16613-16621	stimulus	_
87-13	16622-16632	represents	_
87-14	16633-16636	the	_
87-15	16637-16649	anticipatory	_
87-16	16650-16655	phase	_
87-17	16655-16656	,	_
87-18	16657-16663	during	_
87-19	16664-16669	which	_
87-20	16670-16676	neural	_
87-21	16677-16686	responses	_
87-22	16687-16691	were	_
87-23	16692-16700	recorded	_
87-24	16701-16702	(	_
87-25	16702-16705	Fig	_
87-26	16705-16706	.	_
87-27	16707-16708	1	_
87-28	16708-16709	)	_
87-29	16709-16710	.	_

#Text=Prior to scanning, all participants underwent 66 training trials to ensure they had a clear understanding of how to complete the task.
88-1	16711-16716	Prior	_
88-2	16717-16719	to	_
88-3	16720-16728	scanning	_
88-4	16728-16729	,	_
88-5	16730-16733	all	_
88-6	16734-16746	participants	_
88-7	16747-16756	underwent	_
88-8	16757-16759	66	_
88-9	16760-16768	training	_
88-10	16769-16775	trials	_
88-11	16776-16778	to	_
88-12	16779-16785	ensure	_
88-13	16786-16790	they	_
88-14	16791-16794	had	_
88-15	16795-16796	a	_
88-16	16797-16802	clear	_
88-17	16803-16816	understanding	_
88-18	16817-16819	of	_
88-19	16820-16823	how	_
88-20	16824-16826	to	_
88-21	16827-16835	complete	_
88-22	16836-16839	the	_
88-23	16840-16844	task	_
88-24	16844-16845	.	_

#Text=Participants were told prior to scanning that their total earnings were contingent upon task performance.
89-1	16846-16858	Participants	_
89-2	16859-16863	were	_
89-3	16864-16868	told	_
89-4	16869-16874	prior	_
89-5	16875-16877	to	_
89-6	16878-16886	scanning	_
89-7	16887-16891	that	_
89-8	16892-16897	their	_
89-9	16898-16903	total	_
89-10	16904-16912	earnings	_
89-11	16913-16917	were	_
89-12	16918-16928	contingent	_
89-13	16929-16933	upon	_
89-14	16934-16938	task	_
89-15	16939-16950	performance	_
89-16	16950-16951	.	_

#Text=The duration of the anticipation phase was based on participants’ performance to maintain a 66% success rate.
90-1	16952-16955	The	_
90-2	16956-16964	duration	_
90-3	16965-16967	of	_
90-4	16968-16971	the	_
90-5	16972-16984	anticipation	_
90-6	16985-16990	phase	_
90-7	16991-16994	was	_
90-8	16995-17000	based	_
90-9	17001-17003	on	_
90-10	17004-17016	participants	_
90-11	17016-17017	’	_
90-12	17018-17029	performance	_
90-13	17030-17032	to	_
90-14	17033-17041	maintain	_
90-15	17042-17043	a	_
90-16	17044-17047	66%	_
90-17	17048-17055	success	_
90-18	17056-17060	rate	_
90-19	17060-17061	.	_

#Text=In total, 66 trials were completed by each participant.
91-1	17062-17064	In	_
91-2	17065-17070	total	_
91-3	17070-17071	,	_
91-4	17072-17074	66	_
91-5	17075-17081	trials	_
91-6	17082-17086	were	_
91-7	17087-17096	completed	_
91-8	17097-17099	by	_
91-9	17100-17104	each	_
91-10	17105-17116	participant	_
91-11	17116-17117	.	_

#Text=Participants also completed an additional, but separate version of this task, which included drug-related cues, the results of which are not reported here.
92-1	17118-17130	Participants	_
92-2	17131-17135	also	_
92-3	17136-17145	completed	_
92-4	17146-17148	an	_
92-5	17149-17159	additional	_
92-6	17159-17160	,	_
92-7	17161-17164	but	_
92-8	17165-17173	separate	_
92-9	17174-17181	version	_
92-10	17182-17184	of	_
92-11	17185-17189	this	_
92-12	17190-17194	task	_
92-13	17194-17195	,	_
92-14	17196-17201	which	_
92-15	17202-17210	included	_
92-16	17211-17223	drug-related	_
92-17	17224-17228	cues	_
92-18	17228-17229	,	_
92-19	17230-17233	the	_
92-20	17234-17241	results	_
92-21	17242-17244	of	_
92-22	17245-17250	which	_
92-23	17251-17254	are	_
92-24	17255-17258	not	_
92-25	17259-17267	reported	_
92-26	17268-17272	here	_
92-27	17272-17273	.	_

#Text=Statistical analysis
#Text=Behavioral data were analyzed using the Statistical Package for Social Science (SPSS v.22; IBM Chicago, Illinois).
93-1	17274-17285	Statistical	_
93-2	17286-17294	analysis	_
93-3	17295-17305	Behavioral	_
93-4	17306-17310	data	_
93-5	17311-17315	were	_
93-6	17316-17324	analyzed	_
93-7	17325-17330	using	_
93-8	17331-17334	the	_
93-9	17335-17346	Statistical	_
93-10	17347-17354	Package	_
93-11	17355-17358	for	_
93-12	17359-17365	Social	_
93-13	17366-17373	Science	_
93-14	17374-17375	(	_
93-15	17375-17379	SPSS	_
93-16	17380-17381	v	_
93-17	17381-17384	.22	_
93-18	17384-17385	;	_
93-19	17386-17389	IBM	_
93-20	17390-17397	Chicago	_
93-21	17397-17398	,	_
93-22	17399-17407	Illinois	_
93-23	17407-17408	)	_
93-24	17408-17409	.	_

#Text=We employed a univariate analysis of variance model with two fixed between-subject factors: familial risk (participants with and without addiction in the family) and stimulants (participants with and without stimulant drug use).
94-1	17410-17412	We	_
94-2	17413-17421	employed	_
94-3	17422-17423	a	_
94-4	17424-17434	univariate	_
94-5	17435-17443	analysis	_
94-6	17444-17446	of	_
94-7	17447-17455	variance	_
94-8	17456-17461	model	_
94-9	17462-17466	with	_
94-10	17467-17470	two	_
94-11	17471-17476	fixed	_
94-12	17477-17492	between-subject	_
94-13	17493-17500	factors	_
94-14	17500-17501	:	_
94-15	17502-17510	familial	_
94-16	17511-17515	risk	_
94-17	17516-17517	(	_
94-18	17517-17529	participants	_
94-19	17530-17534	with	_
94-20	17535-17538	and	_
94-21	17539-17546	without	_
94-22	17547-17556	addiction	_
94-23	17557-17559	in	_
94-24	17560-17563	the	_
94-25	17564-17570	family	_
94-26	17570-17571	)	_
94-27	17572-17575	and	_
94-28	17576-17586	stimulants	_
94-29	17587-17588	(	_
94-30	17588-17600	participants	_
94-31	17601-17605	with	_
94-32	17606-17609	and	_
94-33	17610-17617	without	_
94-34	17618-17627	stimulant	_
94-35	17628-17632	drug	_
94-36	17633-17636	use	_
94-37	17636-17637	)	_
94-38	17637-17638	.	_

#Text=This statistical model allowed the separate investigation of familial risk and stimulant drug use as well as possible interactions between these two factors.
95-1	17639-17643	This	_
95-2	17644-17655	statistical	_
95-3	17656-17661	model	_
95-4	17662-17669	allowed	_
95-5	17670-17673	the	_
95-6	17674-17682	separate	_
95-7	17683-17696	investigation	_
95-8	17697-17699	of	_
95-9	17700-17708	familial	_
95-10	17709-17713	risk	_
95-11	17714-17717	and	_
95-12	17718-17727	stimulant	_
95-13	17728-17732	drug	_
95-14	17733-17736	use	_
95-15	17737-17739	as	_
95-16	17740-17744	well	_
95-17	17745-17747	as	_
95-18	17748-17756	possible	_
95-19	17757-17769	interactions	_
95-20	17770-17777	between	_
95-21	17778-17783	these	_
95-22	17784-17787	two	_
95-23	17788-17795	factors	_
95-24	17795-17796	.	_

#Text=Analyzing distinct and interacting effects within the same model not only mitigates Type I error but can also reveal interactions between these two factors.
96-1	17797-17806	Analyzing	_
96-2	17807-17815	distinct	_
96-3	17816-17819	and	_
96-4	17820-17831	interacting	_
96-5	17832-17839	effects	_
96-6	17840-17846	within	_
96-7	17847-17850	the	_
96-8	17851-17855	same	_
96-9	17856-17861	model	_
96-10	17862-17865	not	_
96-11	17866-17870	only	_
96-12	17871-17880	mitigates	_
96-13	17881-17885	Type	_
96-14	17886-17887	I	_
96-15	17888-17893	error	_
96-16	17894-17897	but	_
96-17	17898-17901	can	_
96-18	17902-17906	also	_
96-19	17907-17913	reveal	_
96-20	17914-17926	interactions	_
96-21	17927-17934	between	_
96-22	17935-17940	these	_
96-23	17941-17944	two	_
96-24	17945-17952	factors	_
96-25	17952-17953	.	_

#Text=This is particularly important as the development of addiction is likely contingent on both the use of drugs and familial risk-factors.
97-1	17954-17958	This	_
97-2	17959-17961	is	_
97-3	17962-17974	particularly	_
97-4	17975-17984	important	_
97-5	17985-17987	as	_
97-6	17988-17991	the	_
97-7	17992-18003	development	_
97-8	18004-18006	of	_
97-9	18007-18016	addiction	_
97-10	18017-18019	is	_
97-11	18020-18026	likely	_
97-12	18027-18037	contingent	_
97-13	18038-18040	on	_
97-14	18041-18045	both	_
97-15	18046-18049	the	_
97-16	18050-18053	use	_
97-17	18054-18056	of	_
97-18	18057-18062	drugs	_
97-19	18063-18066	and	_
97-20	18067-18075	familial	_
97-21	18076-18088	risk-factors	_
97-22	18088-18089	.	_

#Text=Gender and monthly disposable income were included as covariates in all analyses due to their reported involvement in reward processing and the development of addiction, and to control for group differences (gender: χ2 = 7.01, p = 0.008, income: F1,155 = 5.40, p = 0.021).
98-1	18090-18096	Gender	_
98-2	18097-18100	and	_
98-3	18101-18108	monthly	_
98-4	18109-18119	disposable	_
98-5	18120-18126	income	_
98-6	18127-18131	were	_
98-7	18132-18140	included	_
98-8	18141-18143	as	_
98-9	18144-18154	covariates	_
98-10	18155-18157	in	_
98-11	18158-18161	all	_
98-12	18162-18170	analyses	_
98-13	18171-18174	due	_
98-14	18175-18177	to	_
98-15	18178-18183	their	_
98-16	18184-18192	reported	_
98-17	18193-18204	involvement	_
98-18	18205-18207	in	_
98-19	18208-18214	reward	_
98-20	18215-18225	processing	_
98-21	18226-18229	and	_
98-22	18230-18233	the	_
98-23	18234-18245	development	_
98-24	18246-18248	of	_
98-25	18249-18258	addiction	_
98-26	18258-18259	,	_
98-27	18260-18263	and	_
98-28	18264-18266	to	_
98-29	18267-18274	control	_
98-30	18275-18278	for	_
98-31	18279-18284	group	_
98-32	18285-18296	differences	_
98-33	18297-18298	(	_
98-34	18298-18304	gender	_
98-35	18304-18305	:	_
98-36	18306-18308	χ2	_
98-37	18309-18310	=	_
98-38	18311-18315	7.01	_
98-39	18315-18316	,	_
98-40	18317-18318	p	_
98-41	18319-18320	=	_
98-42	18321-18326	0.008	_
98-43	18326-18327	,	_
98-44	18328-18334	income	_
98-45	18334-18335	:	_
98-46	18336-18342	F1,155	_
98-47	18343-18344	=	_
98-48	18345-18349	5.40	_
98-49	18349-18350	,	_
98-50	18351-18352	p	_
98-51	18353-18354	=	_
98-52	18355-18360	0.021	_
98-53	18360-18361	)	_
98-54	18361-18362	.	_

#Text=These differences were driven by male dominance in the F+S+ group and less monthly disposable income in participants with familial risk, irrespective of drug use.
99-1	18363-18368	These	_
99-2	18369-18380	differences	_
99-3	18381-18385	were	_
99-4	18386-18392	driven	_
99-5	18393-18395	by	_
99-6	18396-18400	male	_
99-7	18401-18410	dominance	_
99-8	18411-18413	in	_
99-9	18414-18417	the	_
99-10	18418-18419	F	_
99-11	18419-18420	+	_
99-12	18420-18421	S	_
99-13	18421-18422	+	_
99-14	18423-18428	group	_
99-15	18429-18432	and	_
99-16	18433-18437	less	_
99-17	18438-18445	monthly	_
99-18	18446-18456	disposable	_
99-19	18457-18463	income	_
99-20	18464-18466	in	_
99-21	18467-18479	participants	_
99-22	18480-18484	with	_
99-23	18485-18493	familial	_
99-24	18494-18498	risk	_
99-25	18498-18499	,	_
99-26	18500-18512	irrespective	_
99-27	18513-18515	of	_
99-28	18516-18520	drug	_
99-29	18521-18524	use	_
99-30	18524-18525	.	_

#Text=Participants with less money to spend demonstrated decreased response times (r = −0.18, p = 0.022).
100-1	18526-18538	Participants	_
100-2	18539-18543	with	_
100-3	18544-18548	less	_
100-4	18549-18554	money	_
100-5	18555-18557	to	_
100-6	18558-18563	spend	_
100-7	18564-18576	demonstrated	_
100-8	18577-18586	decreased	_
100-9	18587-18595	response	_
100-10	18596-18601	times	_
100-11	18602-18603	(	_
100-12	18603-18604	r	_
100-13	18605-18606	=	_
100-14	18607-18608	−	_
100-15	18608-18612	0.18	_
100-16	18612-18613	,	_
100-17	18614-18615	p	_
100-18	18616-18617	=	_
100-19	18618-18623	0.022	_
100-20	18623-18624	)	_
100-21	18624-18625	.	_

#Text=Given that age did not differ between groups (F3,155 = 2.60, p = 0.054) and was not correlated with outcome measures, it was not used as a covariate.
101-1	18626-18631	Given	_
101-2	18632-18636	that	_
101-3	18637-18640	age	_
101-4	18641-18644	did	_
101-5	18645-18648	not	_
101-6	18649-18655	differ	_
101-7	18656-18663	between	_
101-8	18664-18670	groups	_
101-9	18671-18672	(	_
101-10	18672-18678	F3,155	_
101-11	18679-18680	=	_
101-12	18681-18685	2.60	_
101-13	18685-18686	,	_
101-14	18687-18688	p	_
101-15	18689-18690	=	_
101-16	18691-18696	0.054	_
101-17	18696-18697	)	_
101-18	18698-18701	and	_
101-19	18702-18705	was	_
101-20	18706-18709	not	_
101-21	18710-18720	correlated	_
101-22	18721-18725	with	_
101-23	18726-18733	outcome	_
101-24	18734-18742	measures	_
101-25	18742-18743	,	_
101-26	18744-18746	it	_
101-27	18747-18750	was	_
101-28	18751-18754	not	_
101-29	18755-18759	used	_
101-30	18760-18762	as	_
101-31	18763-18764	a	_
101-32	18765-18774	covariate	_
101-33	18774-18775	.	_

#Text=We controlled, post-hoc, for the potentially confounding differences in the severity/duration of drug use between the two stimulant using groups, and the different relationships between participants in the groups with and without familial risk.
102-1	18776-18778	We	_
102-2	18779-18789	controlled	_
102-3	18789-18790	,	_
102-4	18791-18799	post-hoc	_
102-5	18799-18800	,	_
102-6	18801-18804	for	_
102-7	18805-18808	the	_
102-8	18809-18820	potentially	_
102-9	18821-18832	confounding	_
102-10	18833-18844	differences	_
102-11	18845-18847	in	_
102-12	18848-18851	the	_
102-13	18852-18860	severity	_
102-14	18860-18861	/	_
102-15	18861-18869	duration	_
102-16	18870-18872	of	_
102-17	18873-18877	drug	_
102-18	18878-18881	use	_
102-19	18882-18889	between	_
102-20	18890-18893	the	_
102-21	18894-18897	two	_
102-22	18898-18907	stimulant	_
102-23	18908-18913	using	_
102-24	18914-18920	groups	_
102-25	18920-18921	,	_
102-26	18922-18925	and	_
102-27	18926-18929	the	_
102-28	18930-18939	different	_
102-29	18940-18953	relationships	_
102-30	18954-18961	between	_
102-31	18962-18974	participants	_
102-32	18975-18977	in	_
102-33	18978-18981	the	_
102-34	18982-18988	groups	_
102-35	18989-18993	with	_
102-36	18994-18997	and	_
102-37	18998-19005	without	_
102-38	19006-19014	familial	_
102-39	19015-19019	risk	_
102-40	19019-19020	.	_

#Text=Accordingly, we subjected the significant neuroimaging results to a one-way ANCOVA analysis by importing mean cluster beta values (i.e., mean activation or connectivity values) into SPSS.
103-1	19021-19032	Accordingly	_
103-2	19032-19033	,	_
103-3	19034-19036	we	_
103-4	19037-19046	subjected	_
103-5	19047-19050	the	_
103-6	19051-19062	significant	_
103-7	19063-19075	neuroimaging	_
103-8	19076-19083	results	_
103-9	19084-19086	to	_
103-10	19087-19088	a	_
103-11	19089-19096	one-way	_
103-12	19097-19103	ANCOVA	_
103-13	19104-19112	analysis	_
103-14	19113-19115	by	_
103-15	19116-19125	importing	_
103-16	19126-19130	mean	_
103-17	19131-19138	cluster	_
103-18	19139-19143	beta	_
103-19	19144-19150	values	_
103-20	19151-19152	(	_
103-21	19152-19155	i.e	_
103-22	19155-19156	.	_
103-23	19156-19157	,	_
103-24	19158-19162	mean	_
103-25	19163-19173	activation	_
103-26	19174-19176	or	_
103-27	19177-19189	connectivity	_
103-28	19190-19196	values	_
103-29	19196-19197	)	_
103-30	19198-19202	into	_
103-31	19203-19207	SPSS	_
103-32	19207-19208	.	_

#Text=To control for differences in drug-taking experiences, we entered the following variables as covariates: severity of stimulant use (OCDUS score), years of stimulant drug use, alcohol consumption (AUDIT score), current/past nicotine use, and current/past cannabis use.
104-1	19209-19211	To	_
104-2	19212-19219	control	_
104-3	19220-19223	for	_
104-4	19224-19235	differences	_
104-5	19236-19238	in	_
104-6	19239-19250	drug-taking	_
104-7	19251-19262	experiences	_
104-8	19262-19263	,	_
104-9	19264-19266	we	_
104-10	19267-19274	entered	_
104-11	19275-19278	the	_
104-12	19279-19288	following	_
104-13	19289-19298	variables	_
104-14	19299-19301	as	_
104-15	19302-19312	covariates	_
104-16	19312-19313	:	_
104-17	19314-19322	severity	_
104-18	19323-19325	of	_
104-19	19326-19335	stimulant	_
104-20	19336-19339	use	_
104-21	19340-19341	(	_
104-22	19341-19346	OCDUS	_
104-23	19347-19352	score	_
104-24	19352-19353	)	_
104-25	19353-19354	,	_
104-26	19355-19360	years	_
104-27	19361-19363	of	_
104-28	19364-19373	stimulant	_
104-29	19374-19378	drug	_
104-30	19379-19382	use	_
104-31	19382-19383	,	_
104-32	19384-19391	alcohol	_
104-33	19392-19403	consumption	_
104-34	19404-19405	(	_
104-35	19405-19410	AUDIT	_
104-36	19411-19416	score	_
104-37	19416-19417	)	_
104-38	19417-19418	,	_
104-39	19419-19426	current	_
104-40	19426-19427	/	_
104-41	19427-19431	past	_
104-42	19432-19440	nicotine	_
104-43	19441-19444	use	_
104-44	19444-19445	,	_
104-45	19446-19449	and	_
104-46	19450-19457	current	_
104-47	19457-19458	/	_
104-48	19458-19462	past	_
104-49	19463-19471	cannabis	_
104-50	19472-19475	use	_
104-51	19475-19476	.	_

#Text=To control for the shared environment of the sibling pairs, we further included a measure of childhood adversity (CTQ abuse score) as a covariate in the same post-hoc ANCOVA model.
105-1	19477-19479	To	_
105-2	19480-19487	control	_
105-3	19488-19491	for	_
105-4	19492-19495	the	_
105-5	19496-19502	shared	_
105-6	19503-19514	environment	_
105-7	19515-19517	of	_
105-8	19518-19521	the	_
105-9	19522-19529	sibling	_
105-10	19530-19535	pairs	_
105-11	19535-19536	,	_
105-12	19537-19539	we	_
105-13	19540-19547	further	_
105-14	19548-19556	included	_
105-15	19557-19558	a	_
105-16	19559-19566	measure	_
105-17	19567-19569	of	_
105-18	19570-19579	childhood	_
105-19	19580-19589	adversity	_
105-20	19590-19591	(	_
105-21	19591-19594	CTQ	_
105-22	19595-19600	abuse	_
105-23	19601-19606	score	_
105-24	19606-19607	)	_
105-25	19608-19610	as	_
105-26	19611-19612	a	_
105-27	19613-19622	covariate	_
105-28	19623-19625	in	_
105-29	19626-19629	the	_
105-30	19630-19634	same	_
105-31	19635-19643	post-hoc	_
105-32	19644-19650	ANCOVA	_
105-33	19651-19656	model	_
105-34	19656-19657	.	_

#Text=We did not include these variables as covariates in the main analysis to avoid statistically controlling for aspects that were critical in defining the groups.
106-1	19658-19660	We	_
106-2	19661-19664	did	_
106-3	19665-19668	not	_
106-4	19669-19676	include	_
106-5	19677-19682	these	_
106-6	19683-19692	variables	_
106-7	19693-19695	as	_
106-8	19696-19706	covariates	_
106-9	19707-19709	in	_
106-10	19710-19713	the	_
106-11	19714-19718	main	_
106-12	19719-19727	analysis	_
106-13	19728-19730	to	_
106-14	19731-19736	avoid	_
106-15	19737-19750	statistically	_
106-16	19751-19762	controlling	_
106-17	19763-19766	for	_
106-18	19767-19774	aspects	_
106-19	19775-19779	that	_
106-20	19780-19784	were	_
106-21	19785-19793	critical	_
106-22	19794-19796	in	_
106-23	19797-19805	defining	_
106-24	19806-19809	the	_
106-25	19810-19816	groups	_
106-26	19816-19817	.	_

#Text=Behavioral data were analyzed for accuracy and latency of successful trials, and the total amount of money gained using a repeated-measures ANCOVA model with trial type (monetary versus neutral reward) as the within-subject factor and stimulants and familial risk as the two between-subject factors.
107-1	19818-19828	Behavioral	_
107-2	19829-19833	data	_
107-3	19834-19838	were	_
107-4	19839-19847	analyzed	_
107-5	19848-19851	for	_
107-6	19852-19860	accuracy	_
107-7	19861-19864	and	_
107-8	19865-19872	latency	_
107-9	19873-19875	of	_
107-10	19876-19886	successful	_
107-11	19887-19893	trials	_
107-12	19893-19894	,	_
107-13	19895-19898	and	_
107-14	19899-19902	the	_
107-15	19903-19908	total	_
107-16	19909-19915	amount	_
107-17	19916-19918	of	_
107-18	19919-19924	money	_
107-19	19925-19931	gained	_
107-20	19932-19937	using	_
107-21	19938-19939	a	_
107-22	19940-19957	repeated-measures	_
107-23	19958-19964	ANCOVA	_
107-24	19965-19970	model	_
107-25	19971-19975	with	_
107-26	19976-19981	trial	_
107-27	19982-19986	type	_
107-28	19987-19988	(	_
107-29	19988-19996	monetary	_
107-30	19997-20003	versus	_
107-31	20004-20011	neutral	_
107-32	20012-20018	reward	_
107-33	20018-20019	)	_
107-34	20020-20022	as	_
107-35	20023-20026	the	_
107-36	20027-20041	within-subject	_
107-37	20042-20048	factor	_
107-38	20049-20052	and	_
107-39	20053-20063	stimulants	_
107-40	20064-20067	and	_
107-41	20068-20076	familial	_
107-42	20077-20081	risk	_
107-43	20082-20084	as	_
107-44	20085-20088	the	_
107-45	20089-20092	two	_
107-46	20093-20108	between-subject	_
107-47	20109-20116	factors	_
107-48	20116-20117	.	_

#Text=Square-root transformation was used for best normalization.
108-1	20118-20129	Square-root	_
108-2	20130-20144	transformation	_
108-3	20145-20148	was	_
108-4	20149-20153	used	_
108-5	20154-20157	for	_
108-6	20158-20162	best	_
108-7	20163-20176	normalization	_
108-8	20176-20177	.	_

#Text=Sidak post-hoc analysis was used for all individual group comparisons.
109-1	20178-20183	Sidak	_
109-2	20184-20192	post-hoc	_
109-3	20193-20201	analysis	_
109-4	20202-20205	was	_
109-5	20206-20210	used	_
109-6	20211-20214	for	_
109-7	20215-20218	all	_
109-8	20219-20229	individual	_
109-9	20230-20235	group	_
109-10	20236-20247	comparisons	_
109-11	20247-20248	.	_

#Text=Accordingly, demographic data were analyzed using a general linear model (GLM) with stimulants and familial risk as fixed factors.
110-1	20249-20260	Accordingly	_
110-2	20260-20261	,	_
110-3	20262-20273	demographic	_
110-4	20274-20278	data	_
110-5	20279-20283	were	_
110-6	20284-20292	analyzed	_
110-7	20293-20298	using	_
110-8	20299-20300	a	_
110-9	20301-20308	general	_
110-10	20309-20315	linear	_
110-11	20316-20321	model	_
110-12	20322-20323	(	_
110-13	20323-20326	GLM	_
110-14	20326-20327	)	_
110-15	20328-20332	with	_
110-16	20333-20343	stimulants	_
110-17	20344-20347	and	_
110-18	20348-20356	familial	_
110-19	20357-20361	risk	_
110-20	20362-20364	as	_
110-21	20365-20370	fixed	_
110-22	20371-20378	factors	_
110-23	20378-20379	.	_

#Text=Demographic and task performance data were used for analyses (see Table 1).
111-1	20380-20391	Demographic	_
111-2	20392-20395	and	_
111-3	20396-20400	task	_
111-4	20401-20412	performance	_
111-5	20413-20417	data	_
111-6	20418-20422	were	_
111-7	20423-20427	used	_
111-8	20428-20431	for	_
111-9	20432-20440	analyses	_
111-10	20441-20442	(	_
111-11	20442-20445	see	_
111-12	20446-20451	Table	_
111-13	20452-20453	1	_
111-14	20453-20454	)	_
111-15	20454-20455	.	_

#Text=Pearson correlation coefficients were calculated to assess the relationships between outcome measures.
112-1	20456-20463	Pearson	_
112-2	20464-20475	correlation	_
112-3	20476-20488	coefficients	_
112-4	20489-20493	were	_
112-5	20494-20504	calculated	_
112-6	20505-20507	to	_
112-7	20508-20514	assess	_
112-8	20515-20518	the	_
112-9	20519-20532	relationships	_
112-10	20533-20540	between	_
112-11	20541-20548	outcome	_
112-12	20549-20557	measures	_
112-13	20557-20558	.	_

#Text=We also examined the relationship between self-reported impulsivity and task-related neural activation and functional connectivity using the Barratt Impulsiveness Scale (BIS-11).
113-1	20559-20561	We	_
113-2	20562-20566	also	_
113-3	20567-20575	examined	_
113-4	20576-20579	the	_
113-5	20580-20592	relationship	_
113-6	20593-20600	between	_
113-7	20601-20614	self-reported	_
113-8	20615-20626	impulsivity	_
113-9	20627-20630	and	_
113-10	20631-20643	task-related	_
113-11	20644-20650	neural	_
113-12	20651-20661	activation	_
113-13	20662-20665	and	_
113-14	20666-20676	functional	_
113-15	20677-20689	connectivity	_
113-16	20690-20695	using	_
113-17	20696-20699	the	_
113-18	20700-20707	Barratt	_
113-19	20708-20721	Impulsiveness	_
113-20	20722-20727	Scale	_
113-21	20728-20729	(	_
113-22	20729-20732	BIS	_
113-23	20732-20733	-	_
113-24	20733-20735	11	_
113-25	20735-20736	)	_
113-26	20736-20737	.	_

#Text=All tests were two-tailed and significance levels of p < 0.05 were assumed.
114-1	20738-20741	All	_
114-2	20742-20747	tests	_
114-3	20748-20752	were	_
114-4	20753-20763	two-tailed	_
114-5	20764-20767	and	_
114-6	20768-20780	significance	_
114-7	20781-20787	levels	_
114-8	20788-20790	of	_
114-9	20791-20792	p	_
114-10	20793-20794	<	_
114-11	20795-20799	0.05	_
114-12	20800-20804	were	_
114-13	20805-20812	assumed	_
114-14	20812-20813	.	_

#Text=Neuroimaging data acquisition and analysis
#Text=Further details on neuroimaging data acquisition and analysis can be found in the SM.
115-1	20814-20826	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[39]
115-2	20827-20831	data	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[39]
115-3	20832-20843	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[39]
115-4	20844-20847	and	_
115-5	20848-20856	analysis	_
115-6	20857-20864	Further	_
115-7	20865-20872	details	_
115-8	20873-20875	on	_
115-9	20876-20888	neuroimaging	_
115-10	20889-20893	data	_
115-11	20894-20905	acquisition	_
115-12	20906-20909	and	_
115-13	20910-20918	analysis	_
115-14	20919-20922	can	_
115-15	20923-20925	be	_
115-16	20926-20931	found	_
115-17	20932-20934	in	_
115-18	20935-20938	the	_
115-19	20939-20941	SM	_
115-20	20941-20942	.	_

#Text=Briefly, neuroimaging data were acquired at the Wolfson Brain Imaging Centre, University of Cambridge, in one run on a Siemens TIM-Trio 3-Tesla scanner (Siemens Medical Solutions, Erlangen, Germany).
116-1	20943-20950	Briefly	_
116-2	20950-20951	,	_
116-3	20952-20964	neuroimaging	_
116-4	20965-20969	data	_
116-5	20970-20974	were	_
116-6	20975-20983	acquired	_
116-7	20984-20986	at	_
116-8	20987-20990	the	_
116-9	20991-20998	Wolfson	_
116-10	20999-21004	Brain	_
116-11	21005-21012	Imaging	_
116-12	21013-21019	Centre	_
116-13	21019-21020	,	_
116-14	21021-21031	University	_
116-15	21032-21034	of	_
116-16	21035-21044	Cambridge	_
116-17	21044-21045	,	_
116-18	21046-21048	in	_
116-19	21049-21052	one	_
116-20	21053-21056	run	_
116-21	21057-21059	on	_
116-22	21060-21061	a	_
116-23	21062-21069	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
116-24	21070-21078	TIM-Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
116-25	21079-21080	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
116-26	21080-21081	-	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
116-27	21081-21086	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
116-28	21087-21094	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[40]
116-29	21095-21096	(	_
116-30	21096-21103	Siemens	_
116-31	21104-21111	Medical	_
116-32	21112-21121	Solutions	_
116-33	21121-21122	,	_
116-34	21123-21131	Erlangen	_
116-35	21131-21132	,	_
116-36	21133-21140	Germany	_
116-37	21140-21141	)	_
116-38	21141-21142	.	_

#Text=The scans were analyzed in FMRIB’s Software Library (FSL, v-5.0.9, https://fsl.fmrib.ox.ac.uk/fsl) and consisted of two main stages: (1) task activation analysis to identify brain regions involved in reward processing and effects of interest (i.e., main effects of familial risk, stimulant drug use, and their interaction); (2) post-hoc psychophysiological interaction (PPI) analysis to further explore functional connectivity related to reward anticipation and effects of interest.
117-1	21143-21146	The	_
117-2	21147-21152	scans	_
117-3	21153-21157	were	_
117-4	21158-21166	analyzed	_
117-5	21167-21169	in	_
117-6	21170-21175	FMRIB	_
117-7	21175-21176	’	_
117-8	21176-21177	s	_
117-9	21178-21186	Software	_
117-10	21187-21194	Library	_
117-11	21195-21196	(	_
117-12	21196-21199	FSL	_
117-13	21199-21200	,	_
117-14	21201-21202	v	_
117-15	21202-21203	-	_
117-16	21203-21208	5.0.9	_
117-17	21208-21209	,	_
117-18	21210-21215	https	_
117-19	21215-21216	:	_
117-20	21216-21217	/	_
117-21	21217-21218	/	_
117-22	21218-21236	fsl.fmrib.ox.ac.uk	_
117-23	21236-21237	/	_
117-24	21237-21240	fsl	_
117-25	21240-21241	)	_
117-26	21242-21245	and	_
117-27	21246-21255	consisted	_
117-28	21256-21258	of	_
117-29	21259-21262	two	_
117-30	21263-21267	main	_
117-31	21268-21274	stages	_
117-32	21274-21275	:	_
117-33	21276-21277	(	_
117-34	21277-21278	1	_
117-35	21278-21279	)	_
117-36	21280-21284	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]
117-37	21285-21295	activation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]
117-38	21296-21304	analysis	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[41]
117-39	21305-21307	to	_
117-40	21308-21316	identify	_
117-41	21317-21322	brain	_
117-42	21323-21330	regions	_
117-43	21331-21339	involved	_
117-44	21340-21342	in	_
117-45	21343-21349	reward	_
117-46	21350-21360	processing	_
117-47	21361-21364	and	_
117-48	21365-21372	effects	_
117-49	21373-21375	of	_
117-50	21376-21384	interest	_
117-51	21385-21386	(	_
117-52	21386-21389	i.e	_
117-53	21389-21390	.	_
117-54	21390-21391	,	_
117-55	21392-21396	main	_
117-56	21397-21404	effects	_
117-57	21405-21407	of	_
117-58	21408-21416	familial	_
117-59	21417-21421	risk	_
117-60	21421-21422	,	_
117-61	21423-21432	stimulant	_
117-62	21433-21437	drug	_
117-63	21438-21441	use	_
117-64	21441-21442	,	_
117-65	21443-21446	and	_
117-66	21447-21452	their	_
117-67	21453-21464	interaction	_
117-68	21464-21465	)	_
117-69	21465-21466	;	_
117-70	21467-21468	(	_
117-71	21468-21469	2	_
117-72	21469-21470	)	_
117-73	21471-21479	post-hoc	_
117-74	21480-21499	psychophysiological	_
117-75	21500-21511	interaction	_
117-76	21512-21513	(	_
117-77	21513-21516	PPI	_
117-78	21516-21517	)	_
117-79	21518-21526	analysis	_
117-80	21527-21529	to	_
117-81	21530-21537	further	_
117-82	21538-21545	explore	_
117-83	21546-21556	functional	_
117-84	21557-21569	connectivity	_
117-85	21570-21577	related	_
117-86	21578-21580	to	_
117-87	21581-21587	reward	_
117-88	21588-21600	anticipation	_
117-89	21601-21604	and	_
117-90	21605-21612	effects	_
117-91	21613-21615	of	_
117-92	21616-21624	interest	_
117-93	21624-21625	.	_

#Text=Following standard pre-processing procedures, statistical analyses were conducted at the first and second levels by using fMRI Expert Analysis Tool.
118-1	21626-21635	Following	_
118-2	21636-21644	standard	_
118-3	21645-21659	pre-processing	_
118-4	21660-21670	procedures	_
118-5	21670-21671	,	_
118-6	21672-21683	statistical	_
118-7	21684-21692	analyses	_
118-8	21693-21697	were	_
118-9	21698-21707	conducted	_
118-10	21708-21710	at	_
118-11	21711-21714	the	_
118-12	21715-21720	first	_
118-13	21721-21724	and	_
118-14	21725-21731	second	_
118-15	21732-21738	levels	_
118-16	21739-21741	by	_
118-17	21742-21747	using	_
118-18	21748-21752	fMRI	_
118-19	21753-21759	Expert	_
118-20	21760-21768	Analysis	_
118-21	21769-21773	Tool	_
118-22	21773-21774	.	_

#Text=At the first level, GLM analysis was conducted for each participant.
119-1	21775-21777	At	_
119-2	21778-21781	the	_
119-3	21782-21787	first	_
119-4	21788-21793	level	_
119-5	21793-21794	,	_
119-6	21795-21798	GLM	_
119-7	21799-21807	analysis	_
119-8	21808-21811	was	_
119-9	21812-21821	conducted	_
119-10	21822-21825	for	_
119-11	21826-21830	each	_
119-12	21831-21842	participant	_
119-13	21842-21843	.	_

#Text=As reward magnitude showed no behavioral differences in latency, accuracy, or brain activation, small and large rewards were collapsed resulting in a single monetary reward type.
120-1	21844-21846	As	_
120-2	21847-21853	reward	_
120-3	21854-21863	magnitude	_
120-4	21864-21870	showed	_
120-5	21871-21873	no	_
120-6	21874-21884	behavioral	_
120-7	21885-21896	differences	_
120-8	21897-21899	in	_
120-9	21900-21907	latency	_
120-10	21907-21908	,	_
120-11	21909-21917	accuracy	_
120-12	21917-21918	,	_
120-13	21919-21921	or	_
120-14	21922-21927	brain	_
120-15	21928-21938	activation	_
120-16	21938-21939	,	_
120-17	21940-21945	small	_
120-18	21946-21949	and	_
120-19	21950-21955	large	_
120-20	21956-21963	rewards	_
120-21	21964-21968	were	_
120-22	21969-21978	collapsed	_
120-23	21979-21988	resulting	_
120-24	21989-21991	in	_
120-25	21992-21993	a	_
120-26	21994-22000	single	_
120-27	22001-22009	monetary	_
120-28	22010-22016	reward	_
120-29	22017-22021	type	_
120-30	22021-22022	.	_

#Text=Contrasts of interest included: anticipation of monetary reward versus neutral reward, successful feedback, and unsuccessful feedback (results on feedback are reported in the SM), consistent with prior literature.
121-1	22023-22032	Contrasts	_
121-2	22033-22035	of	_
121-3	22036-22044	interest	_
121-4	22045-22053	included	_
121-5	22053-22054	:	_
121-6	22055-22067	anticipation	_
121-7	22068-22070	of	_
121-8	22071-22079	monetary	_
121-9	22080-22086	reward	_
121-10	22087-22093	versus	_
121-11	22094-22101	neutral	_
121-12	22102-22108	reward	_
121-13	22108-22109	,	_
121-14	22110-22120	successful	_
121-15	22121-22129	feedback	_
121-16	22129-22130	,	_
121-17	22131-22134	and	_
121-18	22135-22147	unsuccessful	_
121-19	22148-22156	feedback	_
121-20	22157-22158	(	_
121-21	22158-22165	results	_
121-22	22166-22168	on	_
121-23	22169-22177	feedback	_
121-24	22178-22181	are	_
121-25	22182-22190	reported	_
121-26	22191-22193	in	_
121-27	22194-22197	the	_
121-28	22198-22200	SM	_
121-29	22200-22201	)	_
121-30	22201-22202	,	_
121-31	22203-22213	consistent	_
121-32	22214-22218	with	_
121-33	22219-22224	prior	_
121-34	22225-22235	literature	_
121-35	22235-22236	.	_

#Text=At the second level, the main effect of each contrast collapsed across groups was computed using one-sample t-tests, with gender and monthly disposable income as covariates, to reveal task activation patterns.
122-1	22237-22239	At	_
122-2	22240-22243	the	_
122-3	22244-22250	second	_
122-4	22251-22256	level	_
122-5	22256-22257	,	_
122-6	22258-22261	the	_
122-7	22262-22266	main	_
122-8	22267-22273	effect	_
122-9	22274-22276	of	_
122-10	22277-22281	each	_
122-11	22282-22290	contrast	_
122-12	22291-22300	collapsed	_
122-13	22301-22307	across	_
122-14	22308-22314	groups	_
122-15	22315-22318	was	_
122-16	22319-22327	computed	_
122-17	22328-22333	using	_
122-18	22334-22344	one-sample	_
122-19	22345-22352	t-tests	_
122-20	22352-22353	,	_
122-21	22354-22358	with	_
122-22	22359-22365	gender	_
122-23	22366-22369	and	_
122-24	22370-22377	monthly	_
122-25	22378-22388	disposable	_
122-26	22389-22395	income	_
122-27	22396-22398	as	_
122-28	22399-22409	covariates	_
122-29	22409-22410	,	_
122-30	22411-22413	to	_
122-31	22414-22420	reveal	_
122-32	22421-22425	task	_
122-33	22426-22436	activation	_
122-34	22437-22445	patterns	_
122-35	22445-22446	.	_

#Text=The ANCOVA model was used to assess main effects of stimulants and familial risk in the four groups as well as their interaction for each contrast.
123-1	22447-22450	The	_
123-2	22451-22457	ANCOVA	_
123-3	22458-22463	model	_
123-4	22464-22467	was	_
123-5	22468-22472	used	_
123-6	22473-22475	to	_
123-7	22476-22482	assess	_
123-8	22483-22487	main	_
123-9	22488-22495	effects	_
123-10	22496-22498	of	_
123-11	22499-22509	stimulants	_
123-12	22510-22513	and	_
123-13	22514-22522	familial	_
123-14	22523-22527	risk	_
123-15	22528-22530	in	_
123-16	22531-22534	the	_
123-17	22535-22539	four	_
123-18	22540-22546	groups	_
123-19	22547-22549	as	_
123-20	22550-22554	well	_
123-21	22555-22557	as	_
123-22	22558-22563	their	_
123-23	22564-22575	interaction	_
123-24	22576-22579	for	_
123-25	22580-22584	each	_
123-26	22585-22593	contrast	_
123-27	22593-22594	.	_

#Text=In the second stage, owing to observed task-related activation in the putamen, post-hoc exploratory PPI analysis was used between striatal seed regions of interests (ROI) and whole brain.
124-1	22595-22597	In	_
124-2	22598-22601	the	_
124-3	22602-22608	second	_
124-4	22609-22614	stage	_
124-5	22614-22615	,	_
124-6	22616-22621	owing	_
124-7	22622-22624	to	_
124-8	22625-22633	observed	_
124-9	22634-22646	task-related	_
124-10	22647-22657	activation	_
124-11	22658-22660	in	_
124-12	22661-22664	the	_
124-13	22665-22672	putamen	_
124-14	22672-22673	,	_
124-15	22674-22682	post-hoc	_
124-16	22683-22694	exploratory	_
124-17	22695-22698	PPI	_
124-18	22699-22707	analysis	_
124-19	22708-22711	was	_
124-20	22712-22716	used	_
124-21	22717-22724	between	_
124-22	22725-22733	striatal	_
124-23	22734-22738	seed	_
124-24	22739-22746	regions	_
124-25	22747-22749	of	_
124-26	22750-22759	interests	_
124-27	22760-22761	(	_
124-28	22761-22764	ROI	_
124-29	22764-22765	)	_
124-30	22766-22769	and	_
124-31	22770-22775	whole	_
124-32	22776-22781	brain	_
124-33	22781-22782	.	_

#Text=The seed ROI was defined by the peak coordinates of the significant putamen cluster extracted from a group level with a 4 mm radius.
125-1	22783-22786	The	_
125-2	22787-22791	seed	_
125-3	22792-22795	ROI	_
125-4	22796-22799	was	_
125-5	22800-22807	defined	_
125-6	22808-22810	by	_
125-7	22811-22814	the	_
125-8	22815-22819	peak	_
125-9	22820-22831	coordinates	_
125-10	22832-22834	of	_
125-11	22835-22838	the	_
125-12	22839-22850	significant	_
125-13	22851-22858	putamen	_
125-14	22859-22866	cluster	_
125-15	22867-22876	extracted	_
125-16	22877-22881	from	_
125-17	22882-22883	a	_
125-18	22884-22889	group	_
125-19	22890-22895	level	_
125-20	22896-22900	with	_
125-21	22901-22902	a	_
125-22	22903-22904	4	_
125-23	22905-22907	mm	_
125-24	22908-22914	radius	_
125-25	22914-22915	.	_

#Text=For all analyses, significant effects were defined, after voxelwise testing and family-wise error (FWE) correction for multiple comparison, as clusters with a voxel height of Z > 2.58 (i.e., p < 0.005) and cluster-corrected p-value of 0.00015 (using FSL’s easythresh function).
126-1	22916-22919	For	_
126-2	22920-22923	all	_
126-3	22924-22932	analyses	_
126-4	22932-22933	,	_
126-5	22934-22945	significant	_
126-6	22946-22953	effects	_
126-7	22954-22958	were	_
126-8	22959-22966	defined	_
126-9	22966-22967	,	_
126-10	22968-22973	after	_
126-11	22974-22983	voxelwise	_
126-12	22984-22991	testing	_
126-13	22992-22995	and	_
126-14	22996-23007	family-wise	_
126-15	23008-23013	error	_
126-16	23014-23015	(	_
126-17	23015-23018	FWE	_
126-18	23018-23019	)	_
126-19	23020-23030	correction	_
126-20	23031-23034	for	_
126-21	23035-23043	multiple	_
126-22	23044-23054	comparison	_
126-23	23054-23055	,	_
126-24	23056-23058	as	_
126-25	23059-23067	clusters	_
126-26	23068-23072	with	_
126-27	23073-23074	a	_
126-28	23075-23080	voxel	_
126-29	23081-23087	height	_
126-30	23088-23090	of	_
126-31	23091-23092	Z	_
126-32	23093-23094	>	_
126-33	23095-23099	2.58	_
126-34	23100-23101	(	_
126-35	23101-23104	i.e	_
126-36	23104-23105	.	_
126-37	23105-23106	,	_
126-38	23107-23108	p	_
126-39	23109-23110	<	_
126-40	23111-23116	0.005	_
126-41	23116-23117	)	_
126-42	23118-23121	and	_
126-43	23122-23139	cluster-corrected	_
126-44	23140-23147	p-value	_
126-45	23148-23150	of	_
126-46	23151-23158	0.00015	_
126-47	23159-23160	(	_
126-48	23160-23165	using	_
126-49	23166-23169	FSL	_
126-50	23169-23170	’	_
126-51	23170-23171	s	_
126-52	23172-23182	easythresh	_
126-53	23183-23191	function	_
126-54	23191-23192	)	_
126-55	23192-23193	.	_

#Text=Due to recent discussions regarding the control of false positives in cluster inference, we employed a relatively more stringent threshold than the conventional Z > 2.3 (i.e., p < .01).
127-1	23194-23197	Due	_
127-2	23198-23200	to	_
127-3	23201-23207	recent	_
127-4	23208-23219	discussions	_
127-5	23220-23229	regarding	_
127-6	23230-23233	the	_
127-7	23234-23241	control	_
127-8	23242-23244	of	_
127-9	23245-23250	false	_
127-10	23251-23260	positives	_
127-11	23261-23263	in	_
127-12	23264-23271	cluster	_
127-13	23272-23281	inference	_
127-14	23281-23282	,	_
127-15	23283-23285	we	_
127-16	23286-23294	employed	_
127-17	23295-23296	a	_
127-18	23297-23307	relatively	_
127-19	23308-23312	more	_
127-20	23313-23322	stringent	_
127-21	23323-23332	threshold	_
127-22	23333-23337	than	_
127-23	23338-23341	the	_
127-24	23342-23354	conventional	_
127-25	23355-23356	Z	_
127-26	23357-23358	>	_
127-27	23359-23362	2.3	_
127-28	23363-23364	(	_
127-29	23364-23367	i.e	_
127-30	23367-23368	.	_
127-31	23368-23369	,	_
127-32	23370-23371	p	_
127-33	23372-23373	<	_
127-34	23374-23377	.01	_
127-35	23377-23378	)	_
127-36	23378-23379	.	_

#Text=Of the nine participants that were excluded post-hoc, five were due to excessive head motion during scanning (1 F−S−, 3 F+S+, 1 F+S−), one due to poor data quality (1 F+S−), and three due to incomplete behavioral data (1 F+S +, 1 F+S−, 1 F−S+), resulting in a remaining sample of 160 participants.
128-1	23380-23382	Of	_
128-2	23383-23386	the	_
128-3	23387-23391	nine	_
128-4	23392-23404	participants	_
128-5	23405-23409	that	_
128-6	23410-23414	were	_
128-7	23415-23423	excluded	_
128-8	23424-23432	post-hoc	_
128-9	23432-23433	,	_
128-10	23434-23438	five	_
128-11	23439-23443	were	_
128-12	23444-23447	due	_
128-13	23448-23450	to	_
128-14	23451-23460	excessive	_
128-15	23461-23465	head	_
128-16	23466-23472	motion	_
128-17	23473-23479	during	_
128-18	23480-23488	scanning	_
128-19	23489-23490	(	_
128-20	23490-23491	1	_
128-21	23492-23493	F	_
128-22	23493-23494	−	_
128-23	23494-23495	S	_
128-24	23495-23496	−	_
128-25	23496-23497	,	_
128-26	23498-23499	3	_
128-27	23500-23501	F	_
128-28	23501-23502	+	_
128-29	23502-23503	S	_
128-30	23503-23504	+	_
128-31	23504-23505	,	_
128-32	23506-23507	1	_
128-33	23508-23509	F	_
128-34	23509-23510	+	_
128-35	23510-23511	S	_
128-36	23511-23512	−	_
128-37	23512-23513	)	_
128-38	23513-23514	,	_
128-39	23515-23518	one	_
128-40	23519-23522	due	_
128-41	23523-23525	to	_
128-42	23526-23530	poor	_
128-43	23531-23535	data	_
128-44	23536-23543	quality	_
128-45	23544-23545	(	_
128-46	23545-23546	1	_
128-47	23547-23548	F	_
128-48	23548-23549	+	_
128-49	23549-23550	S	_
128-50	23550-23551	−	_
128-51	23551-23552	)	_
128-52	23552-23553	,	_
128-53	23554-23557	and	_
128-54	23558-23563	three	_
128-55	23564-23567	due	_
128-56	23568-23570	to	_
128-57	23571-23581	incomplete	_
128-58	23582-23592	behavioral	_
128-59	23593-23597	data	_
128-60	23598-23599	(	_
128-61	23599-23600	1	_
128-62	23601-23602	F	_
128-63	23602-23603	+	_
128-64	23603-23604	S	_
128-65	23605-23606	+	_
128-66	23606-23607	,	_
128-67	23608-23609	1	_
128-68	23610-23611	F	_
128-69	23611-23612	+	_
128-70	23612-23613	S	_
128-71	23613-23614	−	_
128-72	23614-23615	,	_
128-73	23616-23617	1	_
128-74	23618-23619	F	_
128-75	23619-23620	−	_
128-76	23620-23621	S	_
128-77	23621-23622	+	_
128-78	23622-23623	)	_
128-79	23623-23624	,	_
128-80	23625-23634	resulting	_
128-81	23635-23637	in	_
128-82	23638-23639	a	_
128-83	23640-23649	remaining	_
128-84	23650-23656	sample	_
128-85	23657-23659	of	_
128-86	23660-23663	160	_
128-87	23664-23676	participants	_
128-88	23676-23677	.	_

#Text=Baseline demographic characteristics did not differ between excluded and included participants.
129-1	23678-23686	Baseline	_
129-2	23687-23698	demographic	_
129-3	23699-23714	characteristics	_
129-4	23715-23718	did	_
129-5	23719-23722	not	_
129-6	23723-23729	differ	_
129-7	23730-23737	between	_
129-8	23738-23746	excluded	_
129-9	23747-23750	and	_
129-10	23751-23759	included	_
129-11	23760-23772	participants	_
129-12	23772-23773	.	_

#Text=Results
#Text=Task performance
#Text=Mean response latency in anticipation of monetary and neutral rewards.
130-1	23774-23781	Results	_
130-2	23782-23786	Task	_
130-3	23787-23798	performance	_
130-4	23799-23803	Mean	_
130-5	23804-23812	response	_
130-6	23813-23820	latency	_
130-7	23821-23823	in	_
130-8	23824-23836	anticipation	_
130-9	23837-23839	of	_
130-10	23840-23848	monetary	_
130-11	23849-23852	and	_
130-12	23853-23860	neutral	_
130-13	23861-23868	rewards	_
130-14	23868-23869	.	_

#Text=All participantes responded faster in anticipation of monetary reward compared to neutral reward
#Text=In keeping with the MID-task design to minimize behavioral differences, we did not find a main effect of familial risk or stimulants on performance measures (Table 1).
131-1	23870-23873	All	_
131-2	23874-23887	participantes	_
131-3	23888-23897	responded	_
131-4	23898-23904	faster	_
131-5	23905-23907	in	_
131-6	23908-23920	anticipation	_
131-7	23921-23923	of	_
131-8	23924-23932	monetary	_
131-9	23933-23939	reward	_
131-10	23940-23948	compared	_
131-11	23949-23951	to	_
131-12	23952-23959	neutral	_
131-13	23960-23966	reward	_
131-14	23967-23969	In	_
131-15	23970-23977	keeping	_
131-16	23978-23982	with	_
131-17	23983-23986	the	_
131-18	23987-23995	MID-task	_
131-19	23996-24002	design	_
131-20	24003-24005	to	_
131-21	24006-24014	minimize	_
131-22	24015-24025	behavioral	_
131-23	24026-24037	differences	_
131-24	24037-24038	,	_
131-25	24039-24041	we	_
131-26	24042-24045	did	_
131-27	24046-24049	not	_
131-28	24050-24054	find	_
131-29	24055-24056	a	_
131-30	24057-24061	main	_
131-31	24062-24068	effect	_
131-32	24069-24071	of	_
131-33	24072-24080	familial	_
131-34	24081-24085	risk	_
131-35	24086-24088	or	_
131-36	24089-24099	stimulants	_
131-37	24100-24102	on	_
131-38	24103-24114	performance	_
131-39	24115-24123	measures	_
131-40	24124-24125	(	_
131-41	24125-24130	Table	_
131-42	24131-24132	1	_
131-43	24132-24133	)	_
131-44	24133-24134	.	_

#Text=However, since the MID-task included both monetary and neutral reward trials, we analyzed, post-hoc, the effect of trial valence on accuracy and latency of successful trials.
132-1	24135-24142	However	_
132-2	24142-24143	,	_
132-3	24144-24149	since	_
132-4	24150-24153	the	_
132-5	24154-24162	MID-task	_
132-6	24163-24171	included	_
132-7	24172-24176	both	_
132-8	24177-24185	monetary	_
132-9	24186-24189	and	_
132-10	24190-24197	neutral	_
132-11	24198-24204	reward	_
132-12	24205-24211	trials	_
132-13	24211-24212	,	_
132-14	24213-24215	we	_
132-15	24216-24224	analyzed	_
132-16	24224-24225	,	_
132-17	24226-24234	post-hoc	_
132-18	24234-24235	,	_
132-19	24236-24239	the	_
132-20	24240-24246	effect	_
132-21	24247-24249	of	_
132-22	24250-24255	trial	_
132-23	24256-24263	valence	_
132-24	24264-24266	on	_
132-25	24267-24275	accuracy	_
132-26	24276-24279	and	_
132-27	24280-24287	latency	_
132-28	24288-24290	of	_
132-29	24291-24301	successful	_
132-30	24302-24308	trials	_
132-31	24308-24309	.	_

#Text=In accordance with prior work, we observed across all groups, a main effect of trial valence on the number of successful responses (F1,155 = 218.55, p < 0.001), and mean response times (F1,155 = 22.23, p < 0.001; Fig. 2), such that participants responded faster and with more accuracy to the prospect of a monetary reward compared with a neutral reward.
133-1	24310-24312	In	_
133-2	24313-24323	accordance	_
133-3	24324-24328	with	_
133-4	24329-24334	prior	_
133-5	24335-24339	work	_
133-6	24339-24340	,	_
133-7	24341-24343	we	_
133-8	24344-24352	observed	_
133-9	24353-24359	across	_
133-10	24360-24363	all	_
133-11	24364-24370	groups	_
133-12	24370-24371	,	_
133-13	24372-24373	a	_
133-14	24374-24378	main	_
133-15	24379-24385	effect	_
133-16	24386-24388	of	_
133-17	24389-24394	trial	_
133-18	24395-24402	valence	_
133-19	24403-24405	on	_
133-20	24406-24409	the	_
133-21	24410-24416	number	_
133-22	24417-24419	of	_
133-23	24420-24430	successful	_
133-24	24431-24440	responses	_
133-25	24441-24442	(	_
133-26	24442-24448	F1,155	_
133-27	24449-24450	=	_
133-28	24451-24457	218.55	_
133-29	24457-24458	,	_
133-30	24459-24460	p	_
133-31	24461-24462	<	_
133-32	24463-24468	0.001	_
133-33	24468-24469	)	_
133-34	24469-24470	,	_
133-35	24471-24474	and	_
133-36	24475-24479	mean	_
133-37	24480-24488	response	_
133-38	24489-24494	times	_
133-39	24495-24496	(	_
133-40	24496-24502	F1,155	_
133-41	24503-24504	=	_
133-42	24505-24510	22.23	_
133-43	24510-24511	,	_
133-44	24512-24513	p	_
133-45	24514-24515	<	_
133-46	24516-24521	0.001	_
133-47	24521-24522	;	_
133-48	24523-24526	Fig	_
133-49	24526-24527	.	_
133-50	24528-24529	2	_
133-51	24529-24530	)	_
133-52	24530-24531	,	_
133-53	24532-24536	such	_
133-54	24537-24541	that	_
133-55	24542-24554	participants	_
133-56	24555-24564	responded	_
133-57	24565-24571	faster	_
133-58	24572-24575	and	_
133-59	24576-24580	with	_
133-60	24581-24585	more	_
133-61	24586-24594	accuracy	_
133-62	24595-24597	to	_
133-63	24598-24601	the	_
133-64	24602-24610	prospect	_
133-65	24611-24613	of	_
133-66	24614-24615	a	_
133-67	24616-24624	monetary	_
133-68	24625-24631	reward	_
133-69	24632-24640	compared	_
133-70	24641-24645	with	_
133-71	24646-24647	a	_
133-72	24648-24655	neutral	_
133-73	24656-24662	reward	_
133-74	24662-24663	.	_

#Text=Detailed performance data are summarized in Table 1.
134-1	24664-24672	Detailed	_
134-2	24673-24684	performance	_
134-3	24685-24689	data	_
134-4	24690-24693	are	_
134-5	24694-24704	summarized	_
134-6	24705-24707	in	_
134-7	24708-24713	Table	_
134-8	24714-24715	1	_
134-9	24715-24716	.	_

#Text=Task-related brain activation
#Text=Peak Z-values and MNI-coordinates.
135-1	24717-24729	Task-related	_
135-2	24730-24735	brain	_
135-3	24736-24746	activation	_
135-4	24747-24751	Peak	_
135-5	24752-24760	Z-values	_
135-6	24761-24764	and	_
135-7	24765-24780	MNI-coordinates	_
135-8	24780-24781	.	_

#Text=Brain region\tBA\tPeak Z-value\tPeak coordinates\t \tx\ty\tz\t \tA.
136-1	24782-24787	Brain	_
136-2	24788-24794	region	_
136-3	24795-24797	BA	_
136-4	24798-24802	Peak	_
136-5	24803-24810	Z-value	_
136-6	24811-24815	Peak	_
136-7	24816-24827	coordinates	_
136-8	24830-24831	x	_
136-9	24832-24833	y	_
136-10	24834-24835	z	_
136-11	24838-24839	A	_
136-12	24839-24840	.	_

#Text=Task-related activation\t \tAnticipation condition\t \tTask activation\t \tOrbital frontal cortex*\t13\t5.98\t30\t22\t−10\t \tOccipital pole\t18\t7.41\t−22\t−96\t4\t \tStimulant use > no stimulant use\t \tRight dorsolateral putamen\t-\t3.49\t26\t−12\t10\t \tLeft dorsolateral putamen\t-\t3.52\t−24\t0\t10\t \tRight precentral gyrus\t8\t4.32\t42\t4\t34\t \tLeft precentral gyrus\t6/4\t3.87\t−34\t−8\t42\t \tRight supramarginal gyrus\t7\t4.37\t40\t−44\t40\t \tFamilial risk < no familial risk\t \tOccipital pole\t18\t3.76\t−2\t−94\t−16\t \tB.
137-1	24841-24853	Task-related	_
137-2	24854-24864	activation	_
137-3	24867-24879	Anticipation	_
137-4	24880-24889	condition	_
137-5	24892-24896	Task	_
137-6	24897-24907	activation	_
137-7	24910-24917	Orbital	_
137-8	24918-24925	frontal	_
137-9	24926-24932	cortex	_
137-10	24932-24933	*	_
137-11	24934-24936	13	_
137-12	24937-24941	5.98	_
137-13	24942-24944	30	_
137-14	24945-24947	22	_
137-15	24948-24949	−	_
137-16	24949-24951	10	_
137-17	24954-24963	Occipital	_
137-18	24964-24968	pole	_
137-19	24969-24971	18	_
137-20	24972-24976	7.41	_
137-21	24977-24978	−	_
137-22	24978-24980	22	_
137-23	24981-24982	−	_
137-24	24982-24984	96	_
137-25	24985-24986	4	_
137-26	24989-24998	Stimulant	_
137-27	24999-25002	use	_
137-28	25003-25004	>	_
137-29	25005-25007	no	_
137-30	25008-25017	stimulant	_
137-31	25018-25021	use	_
137-32	25024-25029	Right	_
137-33	25030-25042	dorsolateral	_
137-34	25043-25050	putamen	_
137-35	25051-25052	-	_
137-36	25053-25057	3.49	_
137-37	25058-25060	26	_
137-38	25061-25062	−	_
137-39	25062-25064	12	_
137-40	25065-25067	10	_
137-41	25070-25074	Left	_
137-42	25075-25087	dorsolateral	_
137-43	25088-25095	putamen	_
137-44	25096-25097	-	_
137-45	25098-25102	3.52	_
137-46	25103-25104	−	_
137-47	25104-25106	24	_
137-48	25107-25108	0	_
137-49	25109-25111	10	_
137-50	25114-25119	Right	_
137-51	25120-25130	precentral	_
137-52	25131-25136	gyrus	_
137-53	25137-25138	8	_
137-54	25139-25143	4.32	_
137-55	25144-25146	42	_
137-56	25147-25148	4	_
137-57	25149-25151	34	_
137-58	25154-25158	Left	_
137-59	25159-25169	precentral	_
137-60	25170-25175	gyrus	_
137-61	25176-25177	6	_
137-62	25177-25178	/	_
137-63	25178-25179	4	_
137-64	25180-25184	3.87	_
137-65	25185-25186	−	_
137-66	25186-25188	34	_
137-67	25189-25190	−	_
137-68	25190-25191	8	_
137-69	25192-25194	42	_
137-70	25197-25202	Right	_
137-71	25203-25216	supramarginal	_
137-72	25217-25222	gyrus	_
137-73	25223-25224	7	_
137-74	25225-25229	4.37	_
137-75	25230-25232	40	_
137-76	25233-25234	−	_
137-77	25234-25236	44	_
137-78	25237-25239	40	_
137-79	25242-25250	Familial	_
137-80	25251-25255	risk	_
137-81	25256-25257	<	_
137-82	25258-25260	no	_
137-83	25261-25269	familial	_
137-84	25270-25274	risk	_
137-85	25277-25286	Occipital	_
137-86	25287-25291	pole	_
137-87	25292-25294	18	_
137-88	25295-25299	3.76	_
137-89	25300-25301	−	_
137-90	25301-25302	2	_
137-91	25303-25304	−	_
137-92	25304-25306	94	_
137-93	25307-25308	−	_
137-94	25308-25310	16	_
137-95	25313-25314	B	_
137-96	25314-25315	.	_

#Text=Task-related putamen connectivity\t \tStimulant use < no stimulant use\t \tMiddle frontal gyrus\t8\t4.04\t44\t12\t40\t \tSuperior frontal gyrus\t6\t3.33\t−22\t4\t56\t \tFamilial risk > no familial risk\t \tMedial frontal cortex\t10\t3.52\t2\t50\t−10\t \tFrontal Pole\t10\t3.55\t40\t50\t−8\t \tTemporal pole\t36\t3.84\t−20\t4\t−28\t \tBrainstem\t-\t3.68\t8\t−24\t−30\t \tFamilial risk < no familial risk\t \tAnterior cingulate cortex\t24\t3.45\t4\t−2\t38\t \tStimulant use X familial risk\t \tLeft precentral gyrus\t4\t4.38\t−38\t−14\t48\t \tRight precentral gyrus\t6\t3.64\t30\t−4\t50\t \tPostcentral gyrus\t4/1\t4.38\t66\t−6\t30\t \tLateral occipital cortex\t19\t3.70\t−18\t−88\t30\t \tLateral occipital cortex\t19\t3.59\t26\t−68\t32\t \t
#Text=Regions are listed in order of cluster size from largest to smallest.
138-1	25316-25328	Task-related	_
138-2	25329-25336	putamen	_
138-3	25337-25349	connectivity	_
138-4	25352-25361	Stimulant	_
138-5	25362-25365	use	_
138-6	25366-25367	<	_
138-7	25368-25370	no	_
138-8	25371-25380	stimulant	_
138-9	25381-25384	use	_
138-10	25387-25393	Middle	_
138-11	25394-25401	frontal	_
138-12	25402-25407	gyrus	_
138-13	25408-25409	8	_
138-14	25410-25414	4.04	_
138-15	25415-25417	44	_
138-16	25418-25420	12	_
138-17	25421-25423	40	_
138-18	25426-25434	Superior	_
138-19	25435-25442	frontal	_
138-20	25443-25448	gyrus	_
138-21	25449-25450	6	_
138-22	25451-25455	3.33	_
138-23	25456-25457	−	_
138-24	25457-25459	22	_
138-25	25460-25461	4	_
138-26	25462-25464	56	_
138-27	25467-25475	Familial	_
138-28	25476-25480	risk	_
138-29	25481-25482	>	_
138-30	25483-25485	no	_
138-31	25486-25494	familial	_
138-32	25495-25499	risk	_
138-33	25502-25508	Medial	_
138-34	25509-25516	frontal	_
138-35	25517-25523	cortex	_
138-36	25524-25526	10	_
138-37	25527-25531	3.52	_
138-38	25532-25533	2	_
138-39	25534-25536	50	_
138-40	25537-25538	−	_
138-41	25538-25540	10	_
138-42	25543-25550	Frontal	_
138-43	25551-25555	Pole	_
138-44	25556-25558	10	_
138-45	25559-25563	3.55	_
138-46	25564-25566	40	_
138-47	25567-25569	50	_
138-48	25570-25571	−	_
138-49	25571-25572	8	_
138-50	25575-25583	Temporal	_
138-51	25584-25588	pole	_
138-52	25589-25591	36	_
138-53	25592-25596	3.84	_
138-54	25597-25598	−	_
138-55	25598-25600	20	_
138-56	25601-25602	4	_
138-57	25603-25604	−	_
138-58	25604-25606	28	_
138-59	25609-25618	Brainstem	_
138-60	25619-25620	-	_
138-61	25621-25625	3.68	_
138-62	25626-25627	8	_
138-63	25628-25629	−	_
138-64	25629-25631	24	_
138-65	25632-25633	−	_
138-66	25633-25635	30	_
138-67	25638-25646	Familial	_
138-68	25647-25651	risk	_
138-69	25652-25653	<	_
138-70	25654-25656	no	_
138-71	25657-25665	familial	_
138-72	25666-25670	risk	_
138-73	25673-25681	Anterior	_
138-74	25682-25691	cingulate	_
138-75	25692-25698	cortex	_
138-76	25699-25701	24	_
138-77	25702-25706	3.45	_
138-78	25707-25708	4	_
138-79	25709-25710	−	_
138-80	25710-25711	2	_
138-81	25712-25714	38	_
138-82	25717-25726	Stimulant	_
138-83	25727-25730	use	_
138-84	25731-25732	X	_
138-85	25733-25741	familial	_
138-86	25742-25746	risk	_
138-87	25749-25753	Left	_
138-88	25754-25764	precentral	_
138-89	25765-25770	gyrus	_
138-90	25771-25772	4	_
138-91	25773-25777	4.38	_
138-92	25778-25779	−	_
138-93	25779-25781	38	_
138-94	25782-25783	−	_
138-95	25783-25785	14	_
138-96	25786-25788	48	_
138-97	25791-25796	Right	_
138-98	25797-25807	precentral	_
138-99	25808-25813	gyrus	_
138-100	25814-25815	6	_
138-101	25816-25820	3.64	_
138-102	25821-25823	30	_
138-103	25824-25825	−	_
138-104	25825-25826	4	_
138-105	25827-25829	50	_
138-106	25832-25843	Postcentral	_
138-107	25844-25849	gyrus	_
138-108	25850-25851	4	_
138-109	25851-25852	/	_
138-110	25852-25853	1	_
138-111	25854-25858	4.38	_
138-112	25859-25861	66	_
138-113	25862-25863	−	_
138-114	25863-25864	6	_
138-115	25865-25867	30	_
138-116	25870-25877	Lateral	_
138-117	25878-25887	occipital	_
138-118	25888-25894	cortex	_
138-119	25895-25897	19	_
138-120	25898-25902	3.70	_
138-121	25903-25904	−	_
138-122	25904-25906	18	_
138-123	25907-25908	−	_
138-124	25908-25910	88	_
138-125	25911-25913	30	_
138-126	25916-25923	Lateral	_
138-127	25924-25933	occipital	_
138-128	25934-25940	cortex	_
138-129	25941-25943	19	_
138-130	25944-25948	3.59	_
138-131	25949-25951	26	_
138-132	25952-25953	−	_
138-133	25953-25955	68	_
138-134	25956-25958	32	_
138-135	25962-25969	Regions	_
138-136	25970-25973	are	_
138-137	25974-25980	listed	_
138-138	25981-25983	in	_
138-139	25984-25989	order	_
138-140	25990-25992	of	_
138-141	25993-26000	cluster	_
138-142	26001-26005	size	_
138-143	26006-26010	from	_
138-144	26011-26018	largest	_
138-145	26019-26021	to	_
138-146	26022-26030	smallest	_
138-147	26030-26031	.	_

#Text=(A) Summary of fMRI results for the monetary MID-condition.
139-1	26032-26033	(	_
139-2	26033-26034	A	_
139-3	26034-26035	)	_
139-4	26036-26043	Summary	_
139-5	26044-26046	of	_
139-6	26047-26051	fMRI	_
139-7	26052-26059	results	_
139-8	26060-26063	for	_
139-9	26064-26067	the	_
139-10	26068-26076	monetary	_
139-11	26077-26090	MID-condition	_
139-12	26090-26091	.	_

#Text=(B) PPI results showing the difference in functional connectivity with a seed in the bilateral putamen (MNI-coordinates: 26, −12, 10, and −24, 0, 10) during the reward anticipation
#Text=BA Broadmann Area
#Text=*This cluster extended to the paracingulate gyrus, anterior cingulate cortex (ACC), insula, pallidum, striatum, and thalamus
#Text=Brain function during the anticipation of monetary reward versus neutral reward.
140-1	26092-26093	(	_
140-2	26093-26094	B	_
140-3	26094-26095	)	_
140-4	26096-26099	PPI	_
140-5	26100-26107	results	_
140-6	26108-26115	showing	_
140-7	26116-26119	the	_
140-8	26120-26130	difference	_
140-9	26131-26133	in	_
140-10	26134-26144	functional	_
140-11	26145-26157	connectivity	_
140-12	26158-26162	with	_
140-13	26163-26164	a	_
140-14	26165-26169	seed	_
140-15	26170-26172	in	_
140-16	26173-26176	the	_
140-17	26177-26186	bilateral	_
140-18	26187-26194	putamen	_
140-19	26195-26196	(	_
140-20	26196-26211	MNI-coordinates	_
140-21	26211-26212	:	_
140-22	26213-26215	26	_
140-23	26215-26216	,	_
140-24	26217-26218	−	_
140-25	26218-26220	12	_
140-26	26220-26221	,	_
140-27	26222-26224	10	_
140-28	26224-26225	,	_
140-29	26226-26229	and	_
140-30	26230-26231	−	_
140-31	26231-26233	24	_
140-32	26233-26234	,	_
140-33	26235-26236	0	_
140-34	26236-26237	,	_
140-35	26238-26240	10	_
140-36	26240-26241	)	_
140-37	26242-26248	during	_
140-38	26249-26252	the	_
140-39	26253-26259	reward	_
140-40	26260-26272	anticipation	_
140-41	26273-26275	BA	_
140-42	26276-26285	Broadmann	_
140-43	26286-26290	Area	_
140-44	26291-26292	*	_
140-45	26292-26296	This	_
140-46	26297-26304	cluster	_
140-47	26305-26313	extended	_
140-48	26314-26316	to	_
140-49	26317-26320	the	_
140-50	26321-26334	paracingulate	_
140-51	26335-26340	gyrus	_
140-52	26340-26341	,	_
140-53	26342-26350	anterior	_
140-54	26351-26360	cingulate	_
140-55	26361-26367	cortex	_
140-56	26368-26369	(	_
140-57	26369-26372	ACC	_
140-58	26372-26373	)	_
140-59	26373-26374	,	_
140-60	26375-26381	insula	_
140-61	26381-26382	,	_
140-62	26383-26391	pallidum	_
140-63	26391-26392	,	_
140-64	26393-26401	striatum	_
140-65	26401-26402	,	_
140-66	26403-26406	and	_
140-67	26407-26415	thalamus	_
140-68	26416-26421	Brain	_
140-69	26422-26430	function	_
140-70	26431-26437	during	_
140-71	26438-26441	the	_
140-72	26442-26454	anticipation	_
140-73	26455-26457	of	_
140-74	26458-26466	monetary	_
140-75	26467-26473	reward	_
140-76	26474-26480	versus	_
140-77	26481-26488	neutral	_
140-78	26489-26495	reward	_
140-79	26495-26496	.	_

#Text=Yellow depicts relatively greater changes in activation or functional connectivity.
141-1	26497-26503	Yellow	_
141-2	26504-26511	depicts	_
141-3	26512-26522	relatively	_
141-4	26523-26530	greater	_
141-5	26531-26538	changes	_
141-6	26539-26541	in	_
141-7	26542-26552	activation	_
141-8	26553-26555	or	_
141-9	26556-26566	functional	_
141-10	26567-26579	connectivity	_
141-11	26579-26580	.	_

#Text=Z-coordinates represented in MNI space. a MID-task activation across all groups.
142-1	26581-26594	Z-coordinates	_
142-2	26595-26606	represented	_
142-3	26607-26609	in	_
142-4	26610-26613	MNI	_
142-5	26614-26619	space	_
142-6	26619-26620	.	_
142-7	26621-26622	a	_
142-8	26623-26631	MID-task	_
142-9	26632-26642	activation	_
142-10	26643-26649	across	_
142-11	26650-26653	all	_
142-12	26654-26660	groups	_
142-13	26660-26661	.	_

#Text=Thresholded statistical map shown (p < 0.00015; FWE corrected for multiple comparisons). b Effect of stimulant drug use on task-related brain activation.
143-1	26662-26673	Thresholded	_
143-2	26674-26685	statistical	_
143-3	26686-26689	map	_
143-4	26690-26695	shown	_
143-5	26696-26697	(	_
143-6	26697-26698	p	_
143-7	26699-26700	<	_
143-8	26701-26708	0.00015	_
143-9	26708-26709	;	_
143-10	26710-26713	FWE	_
143-11	26714-26723	corrected	_
143-12	26724-26727	for	_
143-13	26728-26736	multiple	_
143-14	26737-26748	comparisons	_
143-15	26748-26749	)	_
143-16	26749-26750	.	_
143-17	26751-26752	b	_
143-18	26753-26759	Effect	_
143-19	26760-26762	of	_
143-20	26763-26772	stimulant	_
143-21	26773-26777	drug	_
143-22	26778-26781	use	_
143-23	26782-26784	on	_
143-24	26785-26797	task-related	_
143-25	26798-26803	brain	_
143-26	26804-26814	activation	_
143-27	26814-26815	.	_

#Text=Thresholded statistical map showing areas of increased activation in stimulant drug users compared with non-users (p < 0.00015; FWE corrected for multiple comparisons). c Effect of familial risk on putamen functional connectivity to the whole brain.
144-1	26816-26827	Thresholded	_
144-2	26828-26839	statistical	_
144-3	26840-26843	map	_
144-4	26844-26851	showing	_
144-5	26852-26857	areas	_
144-6	26858-26860	of	_
144-7	26861-26870	increased	_
144-8	26871-26881	activation	_
144-9	26882-26884	in	_
144-10	26885-26894	stimulant	_
144-11	26895-26899	drug	_
144-12	26900-26905	users	_
144-13	26906-26914	compared	_
144-14	26915-26919	with	_
144-15	26920-26929	non-users	_
144-16	26930-26931	(	_
144-17	26931-26932	p	_
144-18	26933-26934	<	_
144-19	26935-26942	0.00015	_
144-20	26942-26943	;	_
144-21	26944-26947	FWE	_
144-22	26948-26957	corrected	_
144-23	26958-26961	for	_
144-24	26962-26970	multiple	_
144-25	26971-26982	comparisons	_
144-26	26982-26983	)	_
144-27	26983-26984	.	_
144-28	26985-26986	c	_
144-29	26987-26993	Effect	_
144-30	26994-26996	of	_
144-31	26997-27005	familial	_
144-32	27006-27010	risk	_
144-33	27011-27013	on	_
144-34	27014-27021	putamen	_
144-35	27022-27032	functional	_
144-36	27033-27045	connectivity	_
144-37	27046-27048	to	_
144-38	27049-27052	the	_
144-39	27053-27058	whole	_
144-40	27059-27064	brain	_
144-41	27064-27065	.	_

#Text=Thresholded statistical map showing areas of altered functional connectivity in familial groups compared with non-familial groups (p < 0.00015; FWE corrected for multiple comparisons)
#Text=All significant clusters resulting from the whole brain neuroimaging analysis are reported in Table 2.
145-1	27066-27077	Thresholded	_
145-2	27078-27089	statistical	_
145-3	27090-27093	map	_
145-4	27094-27101	showing	_
145-5	27102-27107	areas	_
145-6	27108-27110	of	_
145-7	27111-27118	altered	_
145-8	27119-27129	functional	_
145-9	27130-27142	connectivity	_
145-10	27143-27145	in	_
145-11	27146-27154	familial	_
145-12	27155-27161	groups	_
145-13	27162-27170	compared	_
145-14	27171-27175	with	_
145-15	27176-27188	non-familial	_
145-16	27189-27195	groups	_
145-17	27196-27197	(	_
145-18	27197-27198	p	_
145-19	27199-27200	<	_
145-20	27201-27208	0.00015	_
145-21	27208-27209	;	_
145-22	27210-27213	FWE	_
145-23	27214-27223	corrected	_
145-24	27224-27227	for	_
145-25	27228-27236	multiple	_
145-26	27237-27248	comparisons	_
145-27	27248-27249	)	_
145-28	27250-27253	All	_
145-29	27254-27265	significant	_
145-30	27266-27274	clusters	_
145-31	27275-27284	resulting	_
145-32	27285-27289	from	_
145-33	27290-27293	the	_
145-34	27294-27299	whole	_
145-35	27300-27305	brain	_
145-36	27306-27318	neuroimaging	_
145-37	27319-27327	analysis	_
145-38	27328-27331	are	_
145-39	27332-27340	reported	_
145-40	27341-27343	in	_
145-41	27344-27349	Table	_
145-42	27350-27351	2	_
145-43	27351-27352	.	_

#Text=Results describe brain function during reward anticipation and are reported at cluster-corrected levels using the aforementioned thresholds (see Methods for details).
146-1	27353-27360	Results	_
146-2	27361-27369	describe	_
146-3	27370-27375	brain	_
146-4	27376-27384	function	_
146-5	27385-27391	during	_
146-6	27392-27398	reward	_
146-7	27399-27411	anticipation	_
146-8	27412-27415	and	_
146-9	27416-27419	are	_
146-10	27420-27428	reported	_
146-11	27429-27431	at	_
146-12	27432-27449	cluster-corrected	_
146-13	27450-27456	levels	_
146-14	27457-27462	using	_
146-15	27463-27466	the	_
146-16	27467-27481	aforementioned	_
146-17	27482-27492	thresholds	_
146-18	27493-27494	(	_
146-19	27494-27497	see	_
146-20	27498-27505	Methods	_
146-21	27506-27509	for	_
146-22	27510-27517	details	_
146-23	27517-27518	)	_
146-24	27518-27519	.	_

#Text=Consistent with prior work, the MID-task activated reward-related regions in all participants.
147-1	27520-27530	Consistent	_
147-2	27531-27535	with	_
147-3	27536-27541	prior	_
147-4	27542-27546	work	_
147-5	27546-27547	,	_
147-6	27548-27551	the	_
147-7	27552-27560	MID-task	_
147-8	27561-27570	activated	_
147-9	27571-27585	reward-related	_
147-10	27586-27593	regions	_
147-11	27594-27596	in	_
147-12	27597-27600	all	_
147-13	27601-27613	participants	_
147-14	27613-27614	.	_

#Text=Significant clusters of task-related activation encompassed the ventromedial orbitofrontal cortex (OFC) and occipital pole, extending to the paracingulate gyrus, anterior cingulate cortex (ACC), insula, pallidum, striatum, and thalamus (Fig. 3a; Table 2).
148-1	27615-27626	Significant	_
148-2	27627-27635	clusters	_
148-3	27636-27638	of	_
148-4	27639-27651	task-related	_
148-5	27652-27662	activation	_
148-6	27663-27674	encompassed	_
148-7	27675-27678	the	_
148-8	27679-27691	ventromedial	_
148-9	27692-27705	orbitofrontal	_
148-10	27706-27712	cortex	_
148-11	27713-27714	(	_
148-12	27714-27717	OFC	_
148-13	27717-27718	)	_
148-14	27719-27722	and	_
148-15	27723-27732	occipital	_
148-16	27733-27737	pole	_
148-17	27737-27738	,	_
148-18	27739-27748	extending	_
148-19	27749-27751	to	_
148-20	27752-27755	the	_
148-21	27756-27769	paracingulate	_
148-22	27770-27775	gyrus	_
148-23	27775-27776	,	_
148-24	27777-27785	anterior	_
148-25	27786-27795	cingulate	_
148-26	27796-27802	cortex	_
148-27	27803-27804	(	_
148-28	27804-27807	ACC	_
148-29	27807-27808	)	_
148-30	27808-27809	,	_
148-31	27810-27816	insula	_
148-32	27816-27817	,	_
148-33	27818-27826	pallidum	_
148-34	27826-27827	,	_
148-35	27828-27836	striatum	_
148-36	27836-27837	,	_
148-37	27838-27841	and	_
148-38	27842-27850	thalamus	_
148-39	27851-27852	(	_
148-40	27852-27855	Fig	_
148-41	27855-27856	.	_
148-42	27857-27859	3a	_
148-43	27859-27860	;	_
148-44	27861-27866	Table	_
148-45	27867-27868	2	_
148-46	27868-27869	)	_
148-47	27869-27870	.	_

#Text=Whole brain neuroimaging analysis revealed significant main effects of both stimulant drug use and familial risk on task-related brain activation.
149-1	27871-27876	Whole	_
149-2	27877-27882	brain	_
149-3	27883-27895	neuroimaging	_
149-4	27896-27904	analysis	_
149-5	27905-27913	revealed	_
149-6	27914-27925	significant	_
149-7	27926-27930	main	_
149-8	27931-27938	effects	_
149-9	27939-27941	of	_
149-10	27942-27946	both	_
149-11	27947-27956	stimulant	_
149-12	27957-27961	drug	_
149-13	27962-27965	use	_
149-14	27966-27969	and	_
149-15	27970-27978	familial	_
149-16	27979-27983	risk	_
149-17	27984-27986	on	_
149-18	27987-27999	task-related	_
149-19	28000-28005	brain	_
149-20	28006-28016	activation	_
149-21	28016-28017	.	_

#Text=We observed a main effect of stimulants in the bilateral precentral gyri, right supramarginal gyrus, and bilateral putamen.
150-1	28018-28020	We	_
150-2	28021-28029	observed	_
150-3	28030-28031	a	_
150-4	28032-28036	main	_
150-5	28037-28043	effect	_
150-6	28044-28046	of	_
150-7	28047-28057	stimulants	_
150-8	28058-28060	in	_
150-9	28061-28064	the	_
150-10	28065-28074	bilateral	_
150-11	28075-28085	precentral	_
150-12	28086-28090	gyri	_
150-13	28090-28091	,	_
150-14	28092-28097	right	_
150-15	28098-28111	supramarginal	_
150-16	28112-28117	gyrus	_
150-17	28117-28118	,	_
150-18	28119-28122	and	_
150-19	28123-28132	bilateral	_
150-20	28133-28140	putamen	_
150-21	28140-28141	.	_

#Text=This effect was due to increased activation in these regions in stimulant drug users when compared with non-users (Fig. 3b).
151-1	28142-28146	This	_
151-2	28147-28153	effect	_
151-3	28154-28157	was	_
151-4	28158-28161	due	_
151-5	28162-28164	to	_
151-6	28165-28174	increased	_
151-7	28175-28185	activation	_
151-8	28186-28188	in	_
151-9	28189-28194	these	_
151-10	28195-28202	regions	_
151-11	28203-28205	in	_
151-12	28206-28215	stimulant	_
151-13	28216-28220	drug	_
151-14	28221-28226	users	_
151-15	28227-28231	when	_
151-16	28232-28240	compared	_
151-17	28241-28245	with	_
151-18	28246-28255	non-users	_
151-19	28256-28257	(	_
151-20	28257-28260	Fig	_
151-21	28260-28261	.	_
151-22	28262-28264	3b	_
151-23	28264-28265	)	_
151-24	28265-28266	.	_

#Text=Notably, peak putamen clusters were located in the dorsolateral part of the putamen (MNI-coordinates x, y, z: 26, −12, 10 and −24, 0, 10).
152-1	28267-28274	Notably	_
152-2	28274-28275	,	_
152-3	28276-28280	peak	_
152-4	28281-28288	putamen	_
152-5	28289-28297	clusters	_
152-6	28298-28302	were	_
152-7	28303-28310	located	_
152-8	28311-28313	in	_
152-9	28314-28317	the	_
152-10	28318-28330	dorsolateral	_
152-11	28331-28335	part	_
152-12	28336-28338	of	_
152-13	28339-28342	the	_
152-14	28343-28350	putamen	_
152-15	28351-28352	(	_
152-16	28352-28367	MNI-coordinates	_
152-17	28368-28369	x	_
152-18	28369-28370	,	_
152-19	28371-28372	y	_
152-20	28372-28373	,	_
152-21	28374-28375	z	_
152-22	28375-28376	:	_
152-23	28377-28379	26	_
152-24	28379-28380	,	_
152-25	28381-28382	−	_
152-26	28382-28384	12	_
152-27	28384-28385	,	_
152-28	28386-28388	10	_
152-29	28389-28392	and	_
152-30	28393-28394	−	_
152-31	28394-28396	24	_
152-32	28396-28397	,	_
152-33	28398-28399	0	_
152-34	28399-28400	,	_
152-35	28401-28403	10	_
152-36	28403-28404	)	_
152-37	28404-28405	.	_

#Text=We also observed a main effect of familial risk in the left occipital pole, which was driven by greater task-related activation in participants without familial risk compared with participants with familial risk (Table 2).
153-1	28406-28408	We	_
153-2	28409-28413	also	_
153-3	28414-28422	observed	_
153-4	28423-28424	a	_
153-5	28425-28429	main	_
153-6	28430-28436	effect	_
153-7	28437-28439	of	_
153-8	28440-28448	familial	_
153-9	28449-28453	risk	_
153-10	28454-28456	in	_
153-11	28457-28460	the	_
153-12	28461-28465	left	_
153-13	28466-28475	occipital	_
153-14	28476-28480	pole	_
153-15	28480-28481	,	_
153-16	28482-28487	which	_
153-17	28488-28491	was	_
153-18	28492-28498	driven	_
153-19	28499-28501	by	_
153-20	28502-28509	greater	_
153-21	28510-28522	task-related	_
153-22	28523-28533	activation	_
153-23	28534-28536	in	_
153-24	28537-28549	participants	_
153-25	28550-28557	without	_
153-26	28558-28566	familial	_
153-27	28567-28571	risk	_
153-28	28572-28580	compared	_
153-29	28581-28585	with	_
153-30	28586-28598	participants	_
153-31	28599-28603	with	_
153-32	28604-28612	familial	_
153-33	28613-28617	risk	_
153-34	28618-28619	(	_
153-35	28619-28624	Table	_
153-36	28625-28626	2	_
153-37	28626-28627	)	_
153-38	28627-28628	.	_

#Text=We observed no interaction between stimulants and familial risk in task-related brain activation.
154-1	28629-28631	We	_
154-2	28632-28640	observed	_
154-3	28641-28643	no	_
154-4	28644-28655	interaction	_
154-5	28656-28663	between	_
154-6	28664-28674	stimulants	_
154-7	28675-28678	and	_
154-8	28679-28687	familial	_
154-9	28688-28692	risk	_
154-10	28693-28695	in	_
154-11	28696-28708	task-related	_
154-12	28709-28714	brain	_
154-13	28715-28725	activation	_
154-14	28725-28726	.	_

#Text=Following the whole brain neuroimaging analysis, we subjected all significant clusters (Table 2) to an additional post-hoc analysis to address potentially confounding factors regarding drug-taking experiences and familial risk.
155-1	28727-28736	Following	_
155-2	28737-28740	the	_
155-3	28741-28746	whole	_
155-4	28747-28752	brain	_
155-5	28753-28765	neuroimaging	_
155-6	28766-28774	analysis	_
155-7	28774-28775	,	_
155-8	28776-28778	we	_
155-9	28779-28788	subjected	_
155-10	28789-28792	all	_
155-11	28793-28804	significant	_
155-12	28805-28813	clusters	_
155-13	28814-28815	(	_
155-14	28815-28820	Table	_
155-15	28821-28822	2	_
155-16	28822-28823	)	_
155-17	28824-28826	to	_
155-18	28827-28829	an	_
155-19	28830-28840	additional	_
155-20	28841-28849	post-hoc	_
155-21	28850-28858	analysis	_
155-22	28859-28861	to	_
155-23	28862-28869	address	_
155-24	28870-28881	potentially	_
155-25	28882-28893	confounding	_
155-26	28894-28901	factors	_
155-27	28902-28911	regarding	_
155-28	28912-28923	drug-taking	_
155-29	28924-28935	experiences	_
155-30	28936-28939	and	_
155-31	28940-28948	familial	_
155-32	28949-28953	risk	_
155-33	28953-28954	.	_

#Text=The significant main effect of stimulants in the bilateral precentral gyri (right: F1,158 = 6.07, p = 0.015; left: F1,158 = 7.76, p = 0.006), right supramarginal gyrus (F1,158 = 6.35, p = 0.013), and bilateral putamen (right: F1,158 = 14.72, p < 0.001; left: F1,158 = 8.17, p = 0.005), and the main effect of familial risk in the left occipital pole (F1,158 = 8.32, p = 0.005), all survived this additional post-hoc analysis.
156-1	28955-28958	The	_
156-2	28959-28970	significant	_
156-3	28971-28975	main	_
156-4	28976-28982	effect	_
156-5	28983-28985	of	_
156-6	28986-28996	stimulants	_
156-7	28997-28999	in	_
156-8	29000-29003	the	_
156-9	29004-29013	bilateral	_
156-10	29014-29024	precentral	_
156-11	29025-29029	gyri	_
156-12	29030-29031	(	_
156-13	29031-29036	right	_
156-14	29036-29037	:	_
156-15	29038-29044	F1,158	_
156-16	29045-29046	=	_
156-17	29047-29051	6.07	_
156-18	29051-29052	,	_
156-19	29053-29054	p	_
156-20	29055-29056	=	_
156-21	29057-29062	0.015	_
156-22	29062-29063	;	_
156-23	29064-29068	left	_
156-24	29068-29069	:	_
156-25	29070-29076	F1,158	_
156-26	29077-29078	=	_
156-27	29079-29083	7.76	_
156-28	29083-29084	,	_
156-29	29085-29086	p	_
156-30	29087-29088	=	_
156-31	29089-29094	0.006	_
156-32	29094-29095	)	_
156-33	29095-29096	,	_
156-34	29097-29102	right	_
156-35	29103-29116	supramarginal	_
156-36	29117-29122	gyrus	_
156-37	29123-29124	(	_
156-38	29124-29130	F1,158	_
156-39	29131-29132	=	_
156-40	29133-29137	6.35	_
156-41	29137-29138	,	_
156-42	29139-29140	p	_
156-43	29141-29142	=	_
156-44	29143-29148	0.013	_
156-45	29148-29149	)	_
156-46	29149-29150	,	_
156-47	29151-29154	and	_
156-48	29155-29164	bilateral	_
156-49	29165-29172	putamen	_
156-50	29173-29174	(	_
156-51	29174-29179	right	_
156-52	29179-29180	:	_
156-53	29181-29187	F1,158	_
156-54	29188-29189	=	_
156-55	29190-29195	14.72	_
156-56	29195-29196	,	_
156-57	29197-29198	p	_
156-58	29199-29200	<	_
156-59	29201-29206	0.001	_
156-60	29206-29207	;	_
156-61	29208-29212	left	_
156-62	29212-29213	:	_
156-63	29214-29220	F1,158	_
156-64	29221-29222	=	_
156-65	29223-29227	8.17	_
156-66	29227-29228	,	_
156-67	29229-29230	p	_
156-68	29231-29232	=	_
156-69	29233-29238	0.005	_
156-70	29238-29239	)	_
156-71	29239-29240	,	_
156-72	29241-29244	and	_
156-73	29245-29248	the	_
156-74	29249-29253	main	_
156-75	29254-29260	effect	_
156-76	29261-29263	of	_
156-77	29264-29272	familial	_
156-78	29273-29277	risk	_
156-79	29278-29280	in	_
156-80	29281-29284	the	_
156-81	29285-29289	left	_
156-82	29290-29299	occipital	_
156-83	29300-29304	pole	_
156-84	29305-29306	(	_
156-85	29306-29312	F1,158	_
156-86	29313-29314	=	_
156-87	29315-29319	8.32	_
156-88	29319-29320	,	_
156-89	29321-29322	p	_
156-90	29323-29324	=	_
156-91	29325-29330	0.005	_
156-92	29330-29331	)	_
156-93	29331-29332	,	_
156-94	29333-29336	all	_
156-95	29337-29345	survived	_
156-96	29346-29350	this	_
156-97	29351-29361	additional	_
156-98	29362-29370	post-hoc	_
156-99	29371-29379	analysis	_
156-100	29379-29380	.	_

#Text=Task-related brain functional connectivity
#Text=In view of the main effect of stimulants on task-related activation of the bilateral putamen and the purported role of the putamen in drug addiction, we performed a PPI analysis to further explore the role of this region in reward anticipation.
157-1	29381-29393	Task-related	_
157-2	29394-29399	brain	_
157-3	29400-29410	functional	_
157-4	29411-29423	connectivity	_
157-5	29424-29426	In	_
157-6	29427-29431	view	_
157-7	29432-29434	of	_
157-8	29435-29438	the	_
157-9	29439-29443	main	_
157-10	29444-29450	effect	_
157-11	29451-29453	of	_
157-12	29454-29464	stimulants	_
157-13	29465-29467	on	_
157-14	29468-29480	task-related	_
157-15	29481-29491	activation	_
157-16	29492-29494	of	_
157-17	29495-29498	the	_
157-18	29499-29508	bilateral	_
157-19	29509-29516	putamen	_
157-20	29517-29520	and	_
157-21	29521-29524	the	_
157-22	29525-29534	purported	_
157-23	29535-29539	role	_
157-24	29540-29542	of	_
157-25	29543-29546	the	_
157-26	29547-29554	putamen	_
157-27	29555-29557	in	_
157-28	29558-29562	drug	_
157-29	29563-29572	addiction	_
157-30	29572-29573	,	_
157-31	29574-29576	we	_
157-32	29577-29586	performed	_
157-33	29587-29588	a	_
157-34	29589-29592	PPI	_
157-35	29593-29601	analysis	_
157-36	29602-29604	to	_
157-37	29605-29612	further	_
157-38	29613-29620	explore	_
157-39	29621-29624	the	_
157-40	29625-29629	role	_
157-41	29630-29632	of	_
157-42	29633-29637	this	_
157-43	29638-29644	region	_
157-44	29645-29647	in	_
157-45	29648-29654	reward	_
157-46	29655-29667	anticipation	_
157-47	29667-29668	.	_

#Text=The GLM analysis, which used both stimulants and familial risk as the fixed factors, when conducted on PPI results, revealed an effect of familial risk on putamen functional connectivity strength to the right medial prefrontal cortex (mPFC), frontal pole, right ACC, left temporal lobe extending into the OFC, and brainstem.
158-1	29669-29672	The	_
158-2	29673-29676	GLM	_
158-3	29677-29685	analysis	_
158-4	29685-29686	,	_
158-5	29687-29692	which	_
158-6	29693-29697	used	_
158-7	29698-29702	both	_
158-8	29703-29713	stimulants	_
158-9	29714-29717	and	_
158-10	29718-29726	familial	_
158-11	29727-29731	risk	_
158-12	29732-29734	as	_
158-13	29735-29738	the	_
158-14	29739-29744	fixed	_
158-15	29745-29752	factors	_
158-16	29752-29753	,	_
158-17	29754-29758	when	_
158-18	29759-29768	conducted	_
158-19	29769-29771	on	_
158-20	29772-29775	PPI	_
158-21	29776-29783	results	_
158-22	29783-29784	,	_
158-23	29785-29793	revealed	_
158-24	29794-29796	an	_
158-25	29797-29803	effect	_
158-26	29804-29806	of	_
158-27	29807-29815	familial	_
158-28	29816-29820	risk	_
158-29	29821-29823	on	_
158-30	29824-29831	putamen	_
158-31	29832-29842	functional	_
158-32	29843-29855	connectivity	_
158-33	29856-29864	strength	_
158-34	29865-29867	to	_
158-35	29868-29871	the	_
158-36	29872-29877	right	_
158-37	29878-29884	medial	_
158-38	29885-29895	prefrontal	_
158-39	29896-29902	cortex	_
158-40	29903-29904	(	_
158-41	29904-29908	mPFC	_
158-42	29908-29909	)	_
158-43	29909-29910	,	_
158-44	29911-29918	frontal	_
158-45	29919-29923	pole	_
158-46	29923-29924	,	_
158-47	29925-29930	right	_
158-48	29931-29934	ACC	_
158-49	29934-29935	,	_
158-50	29936-29940	left	_
158-51	29941-29949	temporal	_
158-52	29950-29954	lobe	_
158-53	29955-29964	extending	_
158-54	29965-29969	into	_
158-55	29970-29973	the	_
158-56	29974-29977	OFC	_
158-57	29977-29978	,	_
158-58	29979-29982	and	_
158-59	29983-29992	brainstem	_
158-60	29992-29993	.	_

#Text=These results reflected increased putamen functional connectivity to the frontal pole, temporal pole, and brainstem, and decreased putamen functional connectivity to the ACC in individuals with familial risk compared with those without familial risk (Fig. 3c, Table 2).
159-1	29994-29999	These	_
159-2	30000-30007	results	_
159-3	30008-30017	reflected	_
159-4	30018-30027	increased	_
159-5	30028-30035	putamen	_
159-6	30036-30046	functional	_
159-7	30047-30059	connectivity	_
159-8	30060-30062	to	_
159-9	30063-30066	the	_
159-10	30067-30074	frontal	_
159-11	30075-30079	pole	_
159-12	30079-30080	,	_
159-13	30081-30089	temporal	_
159-14	30090-30094	pole	_
159-15	30094-30095	,	_
159-16	30096-30099	and	_
159-17	30100-30109	brainstem	_
159-18	30109-30110	,	_
159-19	30111-30114	and	_
159-20	30115-30124	decreased	_
159-21	30125-30132	putamen	_
159-22	30133-30143	functional	_
159-23	30144-30156	connectivity	_
159-24	30157-30159	to	_
159-25	30160-30163	the	_
159-26	30164-30167	ACC	_
159-27	30168-30170	in	_
159-28	30171-30182	individuals	_
159-29	30183-30187	with	_
159-30	30188-30196	familial	_
159-31	30197-30201	risk	_
159-32	30202-30210	compared	_
159-33	30211-30215	with	_
159-34	30216-30221	those	_
159-35	30222-30229	without	_
159-36	30230-30238	familial	_
159-37	30239-30243	risk	_
159-38	30244-30245	(	_
159-39	30245-30248	Fig	_
159-40	30248-30249	.	_
159-41	30250-30252	3c	_
159-42	30252-30253	,	_
159-43	30254-30259	Table	_
159-44	30260-30261	2	_
159-45	30261-30262	)	_
159-46	30262-30263	.	_

#Text=In addition to the main effect of familial risk, an effect of stimulants was observed in functional connectivity strength between the putamen and the right middle frontal gyrus/superior frontal gyrus, such that stimulant drug users showed decreased functional connectivity in this pathway (Table 2).
160-1	30264-30266	In	_
160-2	30267-30275	addition	_
160-3	30276-30278	to	_
160-4	30279-30282	the	_
160-5	30283-30287	main	_
160-6	30288-30294	effect	_
160-7	30295-30297	of	_
160-8	30298-30306	familial	_
160-9	30307-30311	risk	_
160-10	30311-30312	,	_
160-11	30313-30315	an	_
160-12	30316-30322	effect	_
160-13	30323-30325	of	_
160-14	30326-30336	stimulants	_
160-15	30337-30340	was	_
160-16	30341-30349	observed	_
160-17	30350-30352	in	_
160-18	30353-30363	functional	_
160-19	30364-30376	connectivity	_
160-20	30377-30385	strength	_
160-21	30386-30393	between	_
160-22	30394-30397	the	_
160-23	30398-30405	putamen	_
160-24	30406-30409	and	_
160-25	30410-30413	the	_
160-26	30414-30419	right	_
160-27	30420-30426	middle	_
160-28	30427-30434	frontal	_
160-29	30435-30440	gyrus	_
160-30	30440-30441	/	_
160-31	30441-30449	superior	_
160-32	30450-30457	frontal	_
160-33	30458-30463	gyrus	_
160-34	30463-30464	,	_
160-35	30465-30469	such	_
160-36	30470-30474	that	_
160-37	30475-30484	stimulant	_
160-38	30485-30489	drug	_
160-39	30490-30495	users	_
160-40	30496-30502	showed	_
160-41	30503-30512	decreased	_
160-42	30513-30523	functional	_
160-43	30524-30536	connectivity	_
160-44	30537-30539	in	_
160-45	30540-30544	this	_
160-46	30545-30552	pathway	_
160-47	30553-30554	(	_
160-48	30554-30559	Table	_
160-49	30560-30561	2	_
160-50	30561-30562	)	_
160-51	30562-30563	.	_

#Text=We also observed an interaction between familial risk and stimulants on putamen functional connectivity to the bilateral precentral gyrus, bilateral lateral occipital cortex, and right postcentral gyrus.
161-1	30564-30566	We	_
161-2	30567-30571	also	_
161-3	30572-30580	observed	_
161-4	30581-30583	an	_
161-5	30584-30595	interaction	_
161-6	30596-30603	between	_
161-7	30604-30612	familial	_
161-8	30613-30617	risk	_
161-9	30618-30621	and	_
161-10	30622-30632	stimulants	_
161-11	30633-30635	on	_
161-12	30636-30643	putamen	_
161-13	30644-30654	functional	_
161-14	30655-30667	connectivity	_
161-15	30668-30670	to	_
161-16	30671-30674	the	_
161-17	30675-30684	bilateral	_
161-18	30685-30695	precentral	_
161-19	30696-30701	gyrus	_
161-20	30701-30702	,	_
161-21	30703-30712	bilateral	_
161-22	30713-30720	lateral	_
161-23	30721-30730	occipital	_
161-24	30731-30737	cortex	_
161-25	30737-30738	,	_
161-26	30739-30742	and	_
161-27	30743-30748	right	_
161-28	30749-30760	postcentral	_
161-29	30761-30766	gyrus	_
161-30	30766-30767	.	_

#Text=The interaction effect was due to increased putamen functional connectivity in F−S+ participants and F+S− participants when compared with F+S+ and F–S– participants (Table 2).
162-1	30768-30771	The	_
162-2	30772-30783	interaction	_
162-3	30784-30790	effect	_
162-4	30791-30794	was	_
162-5	30795-30798	due	_
162-6	30799-30801	to	_
162-7	30802-30811	increased	_
162-8	30812-30819	putamen	_
162-9	30820-30830	functional	_
162-10	30831-30843	connectivity	_
162-11	30844-30846	in	_
162-12	30847-30848	F	_
162-13	30848-30849	−	_
162-14	30849-30850	S	_
162-15	30850-30851	+	_
162-16	30852-30864	participants	_
162-17	30865-30868	and	_
162-18	30869-30870	F	_
162-19	30870-30871	+	_
162-20	30871-30872	S	_
162-21	30872-30873	−	_
162-22	30874-30886	participants	_
162-23	30887-30891	when	_
162-24	30892-30900	compared	_
162-25	30901-30905	with	_
162-26	30906-30907	F	_
162-27	30907-30908	+	_
162-28	30908-30909	S	_
162-29	30909-30910	+	_
162-30	30911-30914	and	_
162-31	30915-30918	F–S	_
162-32	30918-30919	–	_
162-33	30920-30932	participants	_
162-34	30933-30934	(	_
162-35	30934-30939	Table	_
162-36	30940-30941	2	_
162-37	30941-30942	)	_
162-38	30942-30943	.	_

#Text=Like the previous neuroimaging analysis, we subjected all significant clusters resulting from the PPI analysis to an additional post-hoc analysis to control for potentially confounding effects resulting from variations in stimulant drug-taking experiences and familial risk across the groups.
163-1	30944-30948	Like	_
163-2	30949-30952	the	_
163-3	30953-30961	previous	_
163-4	30962-30974	neuroimaging	_
163-5	30975-30983	analysis	_
163-6	30983-30984	,	_
163-7	30985-30987	we	_
163-8	30988-30997	subjected	_
163-9	30998-31001	all	_
163-10	31002-31013	significant	_
163-11	31014-31022	clusters	_
163-12	31023-31032	resulting	_
163-13	31033-31037	from	_
163-14	31038-31041	the	_
163-15	31042-31045	PPI	_
163-16	31046-31054	analysis	_
163-17	31055-31057	to	_
163-18	31058-31060	an	_
163-19	31061-31071	additional	_
163-20	31072-31080	post-hoc	_
163-21	31081-31089	analysis	_
163-22	31090-31092	to	_
163-23	31093-31100	control	_
163-24	31101-31104	for	_
163-25	31105-31116	potentially	_
163-26	31117-31128	confounding	_
163-27	31129-31136	effects	_
163-28	31137-31146	resulting	_
163-29	31147-31151	from	_
163-30	31152-31162	variations	_
163-31	31163-31165	in	_
163-32	31166-31175	stimulant	_
163-33	31176-31187	drug-taking	_
163-34	31188-31199	experiences	_
163-35	31200-31203	and	_
163-36	31204-31212	familial	_
163-37	31213-31217	risk	_
163-38	31218-31224	across	_
163-39	31225-31228	the	_
163-40	31229-31235	groups	_
163-41	31235-31236	.	_

#Text=These additional post-hoc analyses confirmed a significant main effect of familial risk in functional connectivity between the putamen and the right mPFC (F1,158 = 6.88, p = 0.010), frontal pole (F1,158 = 11.01, p = 0.001), right ACC (F1,158 = 7.31, p = 0.008), left temporal lobe extending to the OFC (F1,158 = 18.31, p < 0.001), and brainstem (F1,158 = 6.02, p = 0.015).
164-1	31237-31242	These	_
164-2	31243-31253	additional	_
164-3	31254-31262	post-hoc	_
164-4	31263-31271	analyses	_
164-5	31272-31281	confirmed	_
164-6	31282-31283	a	_
164-7	31284-31295	significant	_
164-8	31296-31300	main	_
164-9	31301-31307	effect	_
164-10	31308-31310	of	_
164-11	31311-31319	familial	_
164-12	31320-31324	risk	_
164-13	31325-31327	in	_
164-14	31328-31338	functional	_
164-15	31339-31351	connectivity	_
164-16	31352-31359	between	_
164-17	31360-31363	the	_
164-18	31364-31371	putamen	_
164-19	31372-31375	and	_
164-20	31376-31379	the	_
164-21	31380-31385	right	_
164-22	31386-31390	mPFC	_
164-23	31391-31392	(	_
164-24	31392-31398	F1,158	_
164-25	31399-31400	=	_
164-26	31401-31405	6.88	_
164-27	31405-31406	,	_
164-28	31407-31408	p	_
164-29	31409-31410	=	_
164-30	31411-31416	0.010	_
164-31	31416-31417	)	_
164-32	31417-31418	,	_
164-33	31419-31426	frontal	_
164-34	31427-31431	pole	_
164-35	31432-31433	(	_
164-36	31433-31439	F1,158	_
164-37	31440-31441	=	_
164-38	31442-31447	11.01	_
164-39	31447-31448	,	_
164-40	31449-31450	p	_
164-41	31451-31452	=	_
164-42	31453-31458	0.001	_
164-43	31458-31459	)	_
164-44	31459-31460	,	_
164-45	31461-31466	right	_
164-46	31467-31470	ACC	_
164-47	31471-31472	(	_
164-48	31472-31478	F1,158	_
164-49	31479-31480	=	_
164-50	31481-31485	7.31	_
164-51	31485-31486	,	_
164-52	31487-31488	p	_
164-53	31489-31490	=	_
164-54	31491-31496	0.008	_
164-55	31496-31497	)	_
164-56	31497-31498	,	_
164-57	31499-31503	left	_
164-58	31504-31512	temporal	_
164-59	31513-31517	lobe	_
164-60	31518-31527	extending	_
164-61	31528-31530	to	_
164-62	31531-31534	the	_
164-63	31535-31538	OFC	_
164-64	31539-31540	(	_
164-65	31540-31546	F1,158	_
164-66	31547-31548	=	_
164-67	31549-31554	18.31	_
164-68	31554-31555	,	_
164-69	31556-31557	p	_
164-70	31558-31559	<	_
164-71	31560-31565	0.001	_
164-72	31565-31566	)	_
164-73	31566-31567	,	_
164-74	31568-31571	and	_
164-75	31572-31581	brainstem	_
164-76	31582-31583	(	_
164-77	31583-31589	F1,158	_
164-78	31590-31591	=	_
164-79	31592-31596	6.02	_
164-80	31596-31597	,	_
164-81	31598-31599	p	_
164-82	31600-31601	=	_
164-83	31602-31607	0.015	_
164-84	31607-31608	)	_
164-85	31608-31609	.	_

#Text=However, the main effect of stimulants, encompassing the middle frontal gyrus (F1,158 = 2.54, p = 0.113) and superior frontal gyrus (F1,158 = 3.63, p = 0.059), did not reach significance.
165-1	31610-31617	However	_
165-2	31617-31618	,	_
165-3	31619-31622	the	_
165-4	31623-31627	main	_
165-5	31628-31634	effect	_
165-6	31635-31637	of	_
165-7	31638-31648	stimulants	_
165-8	31648-31649	,	_
165-9	31650-31662	encompassing	_
165-10	31663-31666	the	_
165-11	31667-31673	middle	_
165-12	31674-31681	frontal	_
165-13	31682-31687	gyrus	_
165-14	31688-31689	(	_
165-15	31689-31695	F1,158	_
165-16	31696-31697	=	_
165-17	31698-31702	2.54	_
165-18	31702-31703	,	_
165-19	31704-31705	p	_
165-20	31706-31707	=	_
165-21	31708-31713	0.113	_
165-22	31713-31714	)	_
165-23	31715-31718	and	_
165-24	31719-31727	superior	_
165-25	31728-31735	frontal	_
165-26	31736-31741	gyrus	_
165-27	31742-31743	(	_
165-28	31743-31749	F1,158	_
165-29	31750-31751	=	_
165-30	31752-31756	3.63	_
165-31	31756-31757	,	_
165-32	31758-31759	p	_
165-33	31760-31761	=	_
165-34	31762-31767	0.059	_
165-35	31767-31768	)	_
165-36	31768-31769	,	_
165-37	31770-31773	did	_
165-38	31774-31777	not	_
165-39	31778-31783	reach	_
165-40	31784-31796	significance	_
165-41	31796-31797	.	_

#Text=The significant familial risk-by-stimulant interaction effects in functional connectivity between the putamen and the bilateral precentral gyrus (Right: F1,158 = 12.96, p < 0.001; Left: F1,158 = 12.07, p = 0.001), occipital cortex (Right: F1,158 = 16.77, p < 0.001; Left: F1,158 = 18.33, p = 0.005), and right postcentral gyrus (F1,158 = 14.38, p < 0.001) all survived additional post-hoc analyses.
166-1	31798-31801	The	_
166-2	31802-31813	significant	_
166-3	31814-31822	familial	_
166-4	31823-31840	risk-by-stimulant	_
166-5	31841-31852	interaction	_
166-6	31853-31860	effects	_
166-7	31861-31863	in	_
166-8	31864-31874	functional	_
166-9	31875-31887	connectivity	_
166-10	31888-31895	between	_
166-11	31896-31899	the	_
166-12	31900-31907	putamen	_
166-13	31908-31911	and	_
166-14	31912-31915	the	_
166-15	31916-31925	bilateral	_
166-16	31926-31936	precentral	_
166-17	31937-31942	gyrus	_
166-18	31943-31944	(	_
166-19	31944-31949	Right	_
166-20	31949-31950	:	_
166-21	31951-31957	F1,158	_
166-22	31958-31959	=	_
166-23	31960-31965	12.96	_
166-24	31965-31966	,	_
166-25	31967-31968	p	_
166-26	31969-31970	<	_
166-27	31971-31976	0.001	_
166-28	31976-31977	;	_
166-29	31978-31982	Left	_
166-30	31982-31983	:	_
166-31	31984-31990	F1,158	_
166-32	31991-31992	=	_
166-33	31993-31998	12.07	_
166-34	31998-31999	,	_
166-35	32000-32001	p	_
166-36	32002-32003	=	_
166-37	32004-32009	0.001	_
166-38	32009-32010	)	_
166-39	32010-32011	,	_
166-40	32012-32021	occipital	_
166-41	32022-32028	cortex	_
166-42	32029-32030	(	_
166-43	32030-32035	Right	_
166-44	32035-32036	:	_
166-45	32037-32043	F1,158	_
166-46	32044-32045	=	_
166-47	32046-32051	16.77	_
166-48	32051-32052	,	_
166-49	32053-32054	p	_
166-50	32055-32056	<	_
166-51	32057-32062	0.001	_
166-52	32062-32063	;	_
166-53	32064-32068	Left	_
166-54	32068-32069	:	_
166-55	32070-32076	F1,158	_
166-56	32077-32078	=	_
166-57	32079-32084	18.33	_
166-58	32084-32085	,	_
166-59	32086-32087	p	_
166-60	32088-32089	=	_
166-61	32090-32095	0.005	_
166-62	32095-32096	)	_
166-63	32096-32097	,	_
166-64	32098-32101	and	_
166-65	32102-32107	right	_
166-66	32108-32119	postcentral	_
166-67	32120-32125	gyrus	_
166-68	32126-32127	(	_
166-69	32127-32133	F1,158	_
166-70	32134-32135	=	_
166-71	32136-32141	14.38	_
166-72	32141-32142	,	_
166-73	32143-32144	p	_
166-74	32145-32146	<	_
166-75	32147-32152	0.001	_
166-76	32152-32153	)	_
166-77	32154-32157	all	_
166-78	32158-32166	survived	_
166-79	32167-32177	additional	_
166-80	32178-32186	post-hoc	_
166-81	32187-32195	analyses	_
166-82	32195-32196	.	_

#Text=No measures of task-related neural activation or functional connectivity were related to self-reported impulsivity, as measured by BIS-11 total score (p > 0.05; see Table S1).
167-1	32197-32199	No	_
167-2	32200-32208	measures	_
167-3	32209-32211	of	_
167-4	32212-32224	task-related	_
167-5	32225-32231	neural	_
167-6	32232-32242	activation	_
167-7	32243-32245	or	_
167-8	32246-32256	functional	_
167-9	32257-32269	connectivity	_
167-10	32270-32274	were	_
167-11	32275-32282	related	_
167-12	32283-32285	to	_
167-13	32286-32299	self-reported	_
167-14	32300-32311	impulsivity	_
167-15	32311-32312	,	_
167-16	32313-32315	as	_
167-17	32316-32324	measured	_
167-18	32325-32327	by	_
167-19	32328-32331	BIS	_
167-20	32331-32332	-	_
167-21	32332-32334	11	_
167-22	32335-32340	total	_
167-23	32341-32346	score	_
167-24	32347-32348	(	_
167-25	32348-32349	p	_
167-26	32350-32351	>	_
167-27	32352-32356	0.05	_
167-28	32356-32357	;	_
167-29	32358-32361	see	_
167-30	32362-32367	Table	_
167-31	32368-32370	S1	_
167-32	32370-32371	)	_
167-33	32371-32372	.	_

#Text=Discussion
#Text=The aim of the study was to disentangle the distinct and interacting effects of stimulant drug use and familial risk on reward processing.
168-1	32373-32383	Discussion	_
168-2	32384-32387	The	_
168-3	32388-32391	aim	_
168-4	32392-32394	of	_
168-5	32395-32398	the	_
168-6	32399-32404	study	_
168-7	32405-32408	was	_
168-8	32409-32411	to	_
168-9	32412-32423	disentangle	_
168-10	32424-32427	the	_
168-11	32428-32436	distinct	_
168-12	32437-32440	and	_
168-13	32441-32452	interacting	_
168-14	32453-32460	effects	_
168-15	32461-32463	of	_
168-16	32464-32473	stimulant	_
168-17	32474-32478	drug	_
168-18	32479-32482	use	_
168-19	32483-32486	and	_
168-20	32487-32495	familial	_
168-21	32496-32500	risk	_
168-22	32501-32503	on	_
168-23	32504-32510	reward	_
168-24	32511-32521	processing	_
168-25	32521-32522	.	_

#Text=Risk associated with stimulant drug use encompasses both pre-existing factors related to the initiation of stimulant use and the effects of regular stimulant use.
169-1	32523-32527	Risk	_
169-2	32528-32538	associated	_
169-3	32539-32543	with	_
169-4	32544-32553	stimulant	_
169-5	32554-32558	drug	_
169-6	32559-32562	use	_
169-7	32563-32574	encompasses	_
169-8	32575-32579	both	_
169-9	32580-32592	pre-existing	_
169-10	32593-32600	factors	_
169-11	32601-32608	related	_
169-12	32609-32611	to	_
169-13	32612-32615	the	_
169-14	32616-32626	initiation	_
169-15	32627-32629	of	_
169-16	32630-32639	stimulant	_
169-17	32640-32643	use	_
169-18	32644-32647	and	_
169-19	32648-32651	the	_
169-20	32652-32659	effects	_
169-21	32660-32662	of	_
169-22	32663-32670	regular	_
169-23	32671-32680	stimulant	_
169-24	32681-32684	use	_
169-25	32684-32685	.	_

#Text=In contrast to previous studies, which investigated these effects separately, often using region of interest approaches, we examined these effects within a single model in the whole brain.
170-1	32686-32688	In	_
170-2	32689-32697	contrast	_
170-3	32698-32700	to	_
170-4	32701-32709	previous	_
170-5	32710-32717	studies	_
170-6	32717-32718	,	_
170-7	32719-32724	which	_
170-8	32725-32737	investigated	_
170-9	32738-32743	these	_
170-10	32744-32751	effects	_
170-11	32752-32762	separately	_
170-12	32762-32763	,	_
170-13	32764-32769	often	_
170-14	32770-32775	using	_
170-15	32776-32782	region	_
170-16	32783-32785	of	_
170-17	32786-32794	interest	_
170-18	32795-32805	approaches	_
170-19	32805-32806	,	_
170-20	32807-32809	we	_
170-21	32810-32818	examined	_
170-22	32819-32824	these	_
170-23	32825-32832	effects	_
170-24	32833-32839	within	_
170-25	32840-32841	a	_
170-26	32842-32848	single	_
170-27	32849-32854	model	_
170-28	32855-32857	in	_
170-29	32858-32861	the	_
170-30	32862-32867	whole	_
170-31	32868-32873	brain	_
170-32	32873-32874	.	_

#Text=Using this approach, we found that although task performance did not differ between groups, involvement of underlying corticostriatal circuitries indicated possible vulnerability and resilience factors related to stimulant drug addiction.
171-1	32875-32880	Using	_
171-2	32881-32885	this	_
171-3	32886-32894	approach	_
171-4	32894-32895	,	_
171-5	32896-32898	we	_
171-6	32899-32904	found	_
171-7	32905-32909	that	_
171-8	32910-32918	although	_
171-9	32919-32923	task	_
171-10	32924-32935	performance	_
171-11	32936-32939	did	_
171-12	32940-32943	not	_
171-13	32944-32950	differ	_
171-14	32951-32958	between	_
171-15	32959-32965	groups	_
171-16	32965-32966	,	_
171-17	32967-32978	involvement	_
171-18	32979-32981	of	_
171-19	32982-32992	underlying	_
171-20	32993-33008	corticostriatal	_
171-21	33009-33020	circuitries	_
171-22	33021-33030	indicated	_
171-23	33031-33039	possible	_
171-24	33040-33053	vulnerability	_
171-25	33054-33057	and	_
171-26	33058-33068	resilience	_
171-27	33069-33076	factors	_
171-28	33077-33084	related	_
171-29	33085-33087	to	_
171-30	33088-33097	stimulant	_
171-31	33098-33102	drug	_
171-32	33103-33112	addiction	_
171-33	33112-33113	.	_

#Text=We found significantly increased task-related activation in the dorsolateral putamen, a region implicated in motor control, rather than the ventral striatum, which is associated with reward processing and reinforcement.
172-1	33114-33116	We	_
172-2	33117-33122	found	_
172-3	33123-33136	significantly	_
172-4	33137-33146	increased	_
172-5	33147-33159	task-related	_
172-6	33160-33170	activation	_
172-7	33171-33173	in	_
172-8	33174-33177	the	_
172-9	33178-33190	dorsolateral	_
172-10	33191-33198	putamen	_
172-11	33198-33199	,	_
172-12	33200-33201	a	_
172-13	33202-33208	region	_
172-14	33209-33219	implicated	_
172-15	33220-33222	in	_
172-16	33223-33228	motor	_
172-17	33229-33236	control	_
172-18	33236-33237	,	_
172-19	33238-33244	rather	_
172-20	33245-33249	than	_
172-21	33250-33253	the	_
172-22	33254-33261	ventral	_
172-23	33262-33270	striatum	_
172-24	33270-33271	,	_
172-25	33272-33277	which	_
172-26	33278-33280	is	_
172-27	33281-33291	associated	_
172-28	33292-33296	with	_
172-29	33297-33303	reward	_
172-30	33304-33314	processing	_
172-31	33315-33318	and	_
172-32	33319-33332	reinforcement	_
172-33	33332-33333	.	_

#Text=Regular use of stimulant drugs was significantly associated with increased task-related activation in motor circuitry.
173-1	33334-33341	Regular	_
173-2	33342-33345	use	_
173-3	33346-33348	of	_
173-4	33349-33358	stimulant	_
173-5	33359-33364	drugs	_
173-6	33365-33368	was	_
173-7	33369-33382	significantly	_
173-8	33383-33393	associated	_
173-9	33394-33398	with	_
173-10	33399-33408	increased	_
173-11	33409-33421	task-related	_
173-12	33422-33432	activation	_
173-13	33433-33435	in	_
173-14	33436-33441	motor	_
173-15	33442-33451	circuitry	_
173-16	33451-33452	.	_

#Text=By contrast, familial risk was associated with altered corticostriatal functional connectivity between the putamen and brain regions implicated in reward processing, specifically the mPFC, OFC, and ACC.
174-1	33453-33455	By	_
174-2	33456-33464	contrast	_
174-3	33464-33465	,	_
174-4	33466-33474	familial	_
174-5	33475-33479	risk	_
174-6	33480-33483	was	_
174-7	33484-33494	associated	_
174-8	33495-33499	with	_
174-9	33500-33507	altered	_
174-10	33508-33523	corticostriatal	_
174-11	33524-33534	functional	_
174-12	33535-33547	connectivity	_
174-13	33548-33555	between	_
174-14	33556-33559	the	_
174-15	33560-33567	putamen	_
174-16	33568-33571	and	_
174-17	33572-33577	brain	_
174-18	33578-33585	regions	_
174-19	33586-33596	implicated	_
174-20	33597-33599	in	_
174-21	33600-33606	reward	_
174-22	33607-33617	processing	_
174-23	33617-33618	,	_
174-24	33619-33631	specifically	_
174-25	33632-33635	the	_
174-26	33636-33640	mPFC	_
174-27	33640-33641	,	_
174-28	33642-33645	OFC	_
174-29	33645-33646	,	_
174-30	33647-33650	and	_
174-31	33651-33654	ACC	_
174-32	33654-33655	.	_

#Text=We also identified an interaction between familial risk and stimulant drug use in functional connectivity strength for the putamen and precentral and postcentral gyri, such that at-risk individuals (due to either familial risk or stimulant drug use) who did not develop addiction, showed increased functional connectivity strength within these regions.
175-1	33656-33658	We	_
175-2	33659-33663	also	_
175-3	33664-33674	identified	_
175-4	33675-33677	an	_
175-5	33678-33689	interaction	_
175-6	33690-33697	between	_
175-7	33698-33706	familial	_
175-8	33707-33711	risk	_
175-9	33712-33715	and	_
175-10	33716-33725	stimulant	_
175-11	33726-33730	drug	_
175-12	33731-33734	use	_
175-13	33735-33737	in	_
175-14	33738-33748	functional	_
175-15	33749-33761	connectivity	_
175-16	33762-33770	strength	_
175-17	33771-33774	for	_
175-18	33775-33778	the	_
175-19	33779-33786	putamen	_
175-20	33787-33790	and	_
175-21	33791-33801	precentral	_
175-22	33802-33805	and	_
175-23	33806-33817	postcentral	_
175-24	33818-33822	gyri	_
175-25	33822-33823	,	_
175-26	33824-33828	such	_
175-27	33829-33833	that	_
175-28	33834-33841	at-risk	_
175-29	33842-33853	individuals	_
175-30	33854-33855	(	_
175-31	33855-33858	due	_
175-32	33859-33861	to	_
175-33	33862-33868	either	_
175-34	33869-33877	familial	_
175-35	33878-33882	risk	_
175-36	33883-33885	or	_
175-37	33886-33895	stimulant	_
175-38	33896-33900	drug	_
175-39	33901-33904	use	_
175-40	33904-33905	)	_
175-41	33906-33909	who	_
175-42	33910-33913	did	_
175-43	33914-33917	not	_
175-44	33918-33925	develop	_
175-45	33926-33935	addiction	_
175-46	33935-33936	,	_
175-47	33937-33943	showed	_
175-48	33944-33953	increased	_
175-49	33954-33964	functional	_
175-50	33965-33977	connectivity	_
175-51	33978-33986	strength	_
175-52	33987-33993	within	_
175-53	33994-33999	these	_
175-54	34000-34007	regions	_
175-55	34007-34008	.	_

#Text=Together, our findings indicate that the two risk factors associated with stimulant drug use, i.e., familial and stimulant-related risk, are reflected by distinct functional brain changes during reward anticipation.
176-1	34009-34017	Together	_
176-2	34017-34018	,	_
176-3	34019-34022	our	_
176-4	34023-34031	findings	_
176-5	34032-34040	indicate	_
176-6	34041-34045	that	_
176-7	34046-34049	the	_
176-8	34050-34053	two	_
176-9	34054-34058	risk	_
176-10	34059-34066	factors	_
176-11	34067-34077	associated	_
176-12	34078-34082	with	_
176-13	34083-34092	stimulant	_
176-14	34093-34097	drug	_
176-15	34098-34101	use	_
176-16	34101-34102	,	_
176-17	34103-34106	i.e	_
176-18	34106-34107	.	_
176-19	34107-34108	,	_
176-20	34109-34117	familial	_
176-21	34118-34121	and	_
176-22	34122-34139	stimulant-related	_
176-23	34140-34144	risk	_
176-24	34144-34145	,	_
176-25	34146-34149	are	_
176-26	34150-34159	reflected	_
176-27	34160-34162	by	_
176-28	34163-34171	distinct	_
176-29	34172-34182	functional	_
176-30	34183-34188	brain	_
176-31	34189-34196	changes	_
176-32	34197-34203	during	_
176-33	34204-34210	reward	_
176-34	34211-34223	anticipation	_
176-35	34223-34224	.	_

#Text=Effects of stimulant drug use on reward processing
#Text=Although stimulant drug use was associated with differences in brain activation, it had no behaviorally measurable effects on MID-task performance.
177-1	34225-34232	Effects	_
177-2	34233-34235	of	_
177-3	34236-34245	stimulant	_
177-4	34246-34250	drug	_
177-5	34251-34254	use	_
177-6	34255-34257	on	_
177-7	34258-34264	reward	_
177-8	34265-34275	processing	_
177-9	34276-34284	Although	_
177-10	34285-34294	stimulant	_
177-11	34295-34299	drug	_
177-12	34300-34303	use	_
177-13	34304-34307	was	_
177-14	34308-34318	associated	_
177-15	34319-34323	with	_
177-16	34324-34335	differences	_
177-17	34336-34338	in	_
177-18	34339-34344	brain	_
177-19	34345-34355	activation	_
177-20	34355-34356	,	_
177-21	34357-34359	it	_
177-22	34360-34363	had	_
177-23	34364-34366	no	_
177-24	34367-34379	behaviorally	_
177-25	34380-34390	measurable	_
177-26	34391-34398	effects	_
177-27	34399-34401	on	_
177-28	34402-34410	MID-task	_
177-29	34411-34422	performance	_
177-30	34422-34423	.	_

#Text=There are several approaches to interpreting neuroimaging findings not reflected in behavioral task performance.
178-1	34424-34429	There	_
178-2	34430-34433	are	_
178-3	34434-34441	several	_
178-4	34442-34452	approaches	_
178-5	34453-34455	to	_
178-6	34456-34468	interpreting	_
178-7	34469-34481	neuroimaging	_
178-8	34482-34490	findings	_
178-9	34491-34494	not	_
178-10	34495-34504	reflected	_
178-11	34505-34507	in	_
178-12	34508-34518	behavioral	_
178-13	34519-34523	task	_
178-14	34524-34535	performance	_
178-15	34535-34536	.	_

#Text=Given that the MID-task was designed to preclude behavioral differences, our findings may suggest underlying cognitive abnormalities that cannot be attributed to non-specific performance measures.
179-1	34537-34542	Given	_
179-2	34543-34547	that	_
179-3	34548-34551	the	_
179-4	34552-34560	MID-task	_
179-5	34561-34564	was	_
179-6	34565-34573	designed	_
179-7	34574-34576	to	_
179-8	34577-34585	preclude	_
179-9	34586-34596	behavioral	_
179-10	34597-34608	differences	_
179-11	34608-34609	,	_
179-12	34610-34613	our	_
179-13	34614-34622	findings	_
179-14	34623-34626	may	_
179-15	34627-34634	suggest	_
179-16	34635-34645	underlying	_
179-17	34646-34655	cognitive	_
179-18	34656-34669	abnormalities	_
179-19	34670-34674	that	_
179-20	34675-34681	cannot	_
179-21	34682-34684	be	_
179-22	34685-34695	attributed	_
179-23	34696-34698	to	_
179-24	34699-34711	non-specific	_
179-25	34712-34723	performance	_
179-26	34724-34732	measures	_
179-27	34732-34733	.	_

#Text=At a neural level, during an anticipatory period preceding a correct response, we identified in stimulant drug users compared with non-drug users, significantly increased task-related brain activation in the putamen and motor cortex (Fig. 3b)—brain regions implicated in motor response.
180-1	34734-34736	At	_
180-2	34737-34738	a	_
180-3	34739-34745	neural	_
180-4	34746-34751	level	_
180-5	34751-34752	,	_
180-6	34753-34759	during	_
180-7	34760-34762	an	_
180-8	34763-34775	anticipatory	_
180-9	34776-34782	period	_
180-10	34783-34792	preceding	_
180-11	34793-34794	a	_
180-12	34795-34802	correct	_
180-13	34803-34811	response	_
180-14	34811-34812	,	_
180-15	34813-34815	we	_
180-16	34816-34826	identified	_
180-17	34827-34829	in	_
180-18	34830-34839	stimulant	_
180-19	34840-34844	drug	_
180-20	34845-34850	users	_
180-21	34851-34859	compared	_
180-22	34860-34864	with	_
180-23	34865-34873	non-drug	_
180-24	34874-34879	users	_
180-25	34879-34880	,	_
180-26	34881-34894	significantly	_
180-27	34895-34904	increased	_
180-28	34905-34917	task-related	_
180-29	34918-34923	brain	_
180-30	34924-34934	activation	_
180-31	34935-34937	in	_
180-32	34938-34941	the	_
180-33	34942-34949	putamen	_
180-34	34950-34953	and	_
180-35	34954-34959	motor	_
180-36	34960-34966	cortex	_
180-37	34967-34968	(	_
180-38	34968-34971	Fig	_
180-39	34971-34972	.	_
180-40	34973-34975	3b	_
180-41	34975-34976	)	_
180-42	34976-34977	—	_
180-43	34977-34982	brain	_
180-44	34983-34990	regions	_
180-45	34991-35001	implicated	_
180-46	35002-35004	in	_
180-47	35005-35010	motor	_
180-48	35011-35019	response	_
180-49	35019-35020	.	_

#Text=Such activations in motor pathways during MID-task performance and cue-reactivity have been frequently reported in published work, and are unsurprising given converging lines of evidence demonstrating the activation and alteration of motor-related brain regions by stimulant drugs.
181-1	35021-35025	Such	_
181-2	35026-35037	activations	_
181-3	35038-35040	in	_
181-4	35041-35046	motor	_
181-5	35047-35055	pathways	_
181-6	35056-35062	during	_
181-7	35063-35071	MID-task	_
181-8	35072-35083	performance	_
181-9	35084-35087	and	_
181-10	35088-35102	cue-reactivity	_
181-11	35103-35107	have	_
181-12	35108-35112	been	_
181-13	35113-35123	frequently	_
181-14	35124-35132	reported	_
181-15	35133-35135	in	_
181-16	35136-35145	published	_
181-17	35146-35150	work	_
181-18	35150-35151	,	_
181-19	35152-35155	and	_
181-20	35156-35159	are	_
181-21	35160-35172	unsurprising	_
181-22	35173-35178	given	_
181-23	35179-35189	converging	_
181-24	35190-35195	lines	_
181-25	35196-35198	of	_
181-26	35199-35207	evidence	_
181-27	35208-35221	demonstrating	_
181-28	35222-35225	the	_
181-29	35226-35236	activation	_
181-30	35237-35240	and	_
181-31	35241-35251	alteration	_
181-32	35252-35254	of	_
181-33	35255-35268	motor-related	_
181-34	35269-35274	brain	_
181-35	35275-35282	regions	_
181-36	35283-35285	by	_
181-37	35286-35295	stimulant	_
181-38	35296-35301	drugs	_
181-39	35301-35302	.	_

#Text=Given that increased activation in motor pathways has been linked to stimulant drug-induced sensitization and underlying progressive recruitment of sensorimotor and dorsal striatal regions in stimulant drug users (an effect shown to persist for several months following stimulant drug exposure), it is tempting to speculate that increased activation seen in stimulant-using individuals in the current study might reflect enhanced ventral-to-dorsal progression of striatal recruitment facilitated by stimulant drugs.
182-1	35303-35308	Given	_
182-2	35309-35313	that	_
182-3	35314-35323	increased	_
182-4	35324-35334	activation	_
182-5	35335-35337	in	_
182-6	35338-35343	motor	_
182-7	35344-35352	pathways	_
182-8	35353-35356	has	_
182-9	35357-35361	been	_
182-10	35362-35368	linked	_
182-11	35369-35371	to	_
182-12	35372-35381	stimulant	_
182-13	35382-35394	drug-induced	_
182-14	35395-35408	sensitization	_
182-15	35409-35412	and	_
182-16	35413-35423	underlying	_
182-17	35424-35435	progressive	_
182-18	35436-35447	recruitment	_
182-19	35448-35450	of	_
182-20	35451-35463	sensorimotor	_
182-21	35464-35467	and	_
182-22	35468-35474	dorsal	_
182-23	35475-35483	striatal	_
182-24	35484-35491	regions	_
182-25	35492-35494	in	_
182-26	35495-35504	stimulant	_
182-27	35505-35509	drug	_
182-28	35510-35515	users	_
182-29	35516-35517	(	_
182-30	35517-35519	an	_
182-31	35520-35526	effect	_
182-32	35527-35532	shown	_
182-33	35533-35535	to	_
182-34	35536-35543	persist	_
182-35	35544-35547	for	_
182-36	35548-35555	several	_
182-37	35556-35562	months	_
182-38	35563-35572	following	_
182-39	35573-35582	stimulant	_
182-40	35583-35587	drug	_
182-41	35588-35596	exposure	_
182-42	35596-35597	)	_
182-43	35597-35598	,	_
182-44	35599-35601	it	_
182-45	35602-35604	is	_
182-46	35605-35613	tempting	_
182-47	35614-35616	to	_
182-48	35617-35626	speculate	_
182-49	35627-35631	that	_
182-50	35632-35641	increased	_
182-51	35642-35652	activation	_
182-52	35653-35657	seen	_
182-53	35658-35660	in	_
182-54	35661-35676	stimulant-using	_
182-55	35677-35688	individuals	_
182-56	35689-35691	in	_
182-57	35692-35695	the	_
182-58	35696-35703	current	_
182-59	35704-35709	study	_
182-60	35710-35715	might	_
182-61	35716-35723	reflect	_
182-62	35724-35732	enhanced	_
182-63	35733-35750	ventral-to-dorsal	_
182-64	35751-35762	progression	_
182-65	35763-35765	of	_
182-66	35766-35774	striatal	_
182-67	35775-35786	recruitment	_
182-68	35787-35798	facilitated	_
182-69	35799-35801	by	_
182-70	35802-35811	stimulant	_
182-71	35812-35817	drugs	_
182-72	35817-35818	.	_

#Text=In light of previous reports on striatal function during the MID-task, we predicted blunted ventral striatal activation in stimulant drug users.
183-1	35819-35821	In	_
183-2	35822-35827	light	_
183-3	35828-35830	of	_
183-4	35831-35839	previous	_
183-5	35840-35847	reports	_
183-6	35848-35850	on	_
183-7	35851-35859	striatal	_
183-8	35860-35868	function	_
183-9	35869-35875	during	_
183-10	35876-35879	the	_
183-11	35880-35888	MID-task	_
183-12	35888-35889	,	_
183-13	35890-35892	we	_
183-14	35893-35902	predicted	_
183-15	35903-35910	blunted	_
183-16	35911-35918	ventral	_
183-17	35919-35927	striatal	_
183-18	35928-35938	activation	_
183-19	35939-35941	in	_
183-20	35942-35951	stimulant	_
183-21	35952-35956	drug	_
183-22	35957-35962	users	_
183-23	35962-35963	.	_

#Text=However, unlike the robust changes in motor circuitry, we found no measurable effects of stimulant drug use on task-related activation patterns within the ventral striatum–widely considered to be a neural correlate for reward anticipation–even though this structure was strongly activated during the MID-task performance in all participants.
184-1	35964-35971	However	_
184-2	35971-35972	,	_
184-3	35973-35979	unlike	_
184-4	35980-35983	the	_
184-5	35984-35990	robust	_
184-6	35991-35998	changes	_
184-7	35999-36001	in	_
184-8	36002-36007	motor	_
184-9	36008-36017	circuitry	_
184-10	36017-36018	,	_
184-11	36019-36021	we	_
184-12	36022-36027	found	_
184-13	36028-36030	no	_
184-14	36031-36041	measurable	_
184-15	36042-36049	effects	_
184-16	36050-36052	of	_
184-17	36053-36062	stimulant	_
184-18	36063-36067	drug	_
184-19	36068-36071	use	_
184-20	36072-36074	on	_
184-21	36075-36087	task-related	_
184-22	36088-36098	activation	_
184-23	36099-36107	patterns	_
184-24	36108-36114	within	_
184-25	36115-36118	the	_
184-26	36119-36126	ventral	_
184-27	36127-36142	striatum–widely	_
184-28	36143-36153	considered	_
184-29	36154-36156	to	_
184-30	36157-36159	be	_
184-31	36160-36161	a	_
184-32	36162-36168	neural	_
184-33	36169-36178	correlate	_
184-34	36179-36182	for	_
184-35	36183-36189	reward	_
184-36	36190-36207	anticipation–even	_
184-37	36208-36214	though	_
184-38	36215-36219	this	_
184-39	36220-36229	structure	_
184-40	36230-36233	was	_
184-41	36234-36242	strongly	_
184-42	36243-36252	activated	_
184-43	36253-36259	during	_
184-44	36260-36263	the	_
184-45	36264-36272	MID-task	_
184-46	36273-36284	performance	_
184-47	36285-36287	in	_
184-48	36288-36291	all	_
184-49	36292-36304	participants	_
184-50	36304-36305	.	_

#Text=It is noteworthy that task-related differences in ventral striatal activation following stimulant abuse have not been consistently reported, which may be due to variations in sample characteristics and experimental design such as the recency of drug use.
185-1	36306-36308	It	_
185-2	36309-36311	is	_
185-3	36312-36322	noteworthy	_
185-4	36323-36327	that	_
185-5	36328-36340	task-related	_
185-6	36341-36352	differences	_
185-7	36353-36355	in	_
185-8	36356-36363	ventral	_
185-9	36364-36372	striatal	_
185-10	36373-36383	activation	_
185-11	36384-36393	following	_
185-12	36394-36403	stimulant	_
185-13	36404-36409	abuse	_
185-14	36410-36414	have	_
185-15	36415-36418	not	_
185-16	36419-36423	been	_
185-17	36424-36436	consistently	_
185-18	36437-36445	reported	_
185-19	36445-36446	,	_
185-20	36447-36452	which	_
185-21	36453-36456	may	_
185-22	36457-36459	be	_
185-23	36460-36463	due	_
185-24	36464-36466	to	_
185-25	36467-36477	variations	_
185-26	36478-36480	in	_
185-27	36481-36487	sample	_
185-28	36488-36503	characteristics	_
185-29	36504-36507	and	_
185-30	36508-36520	experimental	_
185-31	36521-36527	design	_
185-32	36528-36532	such	_
185-33	36533-36535	as	_
185-34	36536-36539	the	_
185-35	36540-36547	recency	_
185-36	36548-36550	of	_
185-37	36551-36555	drug	_
185-38	36556-36559	use	_
185-39	36559-36560	.	_

#Text=Accordingly, although blunted activation in the ventral striatum is frequently reported in abstinent stimulant-dependent individuals, such differences are often not observed in active drug users, consistent with present findings.
186-1	36561-36572	Accordingly	_
186-2	36572-36573	,	_
186-3	36574-36582	although	_
186-4	36583-36590	blunted	_
186-5	36591-36601	activation	_
186-6	36602-36604	in	_
186-7	36605-36608	the	_
186-8	36609-36616	ventral	_
186-9	36617-36625	striatum	_
186-10	36626-36628	is	_
186-11	36629-36639	frequently	_
186-12	36640-36648	reported	_
186-13	36649-36651	in	_
186-14	36652-36661	abstinent	_
186-15	36662-36681	stimulant-dependent	_
186-16	36682-36693	individuals	_
186-17	36693-36694	,	_
186-18	36695-36699	such	_
186-19	36700-36711	differences	_
186-20	36712-36715	are	_
186-21	36716-36721	often	_
186-22	36722-36725	not	_
186-23	36726-36734	observed	_
186-24	36735-36737	in	_
186-25	36738-36744	active	_
186-26	36745-36749	drug	_
186-27	36750-36755	users	_
186-28	36755-36756	,	_
186-29	36757-36767	consistent	_
186-30	36768-36772	with	_
186-31	36773-36780	present	_
186-32	36781-36789	findings	_
186-33	36789-36790	.	_

#Text=Effects of familial risk on reward processing
#Text=Similar to the effects of stimulant drug use, familial risk had no measurable effect on MID-task performance.
187-1	36791-36798	Effects	_
187-2	36799-36801	of	_
187-3	36802-36810	familial	_
187-4	36811-36815	risk	_
187-5	36816-36818	on	_
187-6	36819-36825	reward	_
187-7	36826-36836	processing	_
187-8	36837-36844	Similar	_
187-9	36845-36847	to	_
187-10	36848-36851	the	_
187-11	36852-36859	effects	_
187-12	36860-36862	of	_
187-13	36863-36872	stimulant	_
187-14	36873-36877	drug	_
187-15	36878-36881	use	_
187-16	36881-36882	,	_
187-17	36883-36891	familial	_
187-18	36892-36896	risk	_
187-19	36897-36900	had	_
187-20	36901-36903	no	_
187-21	36904-36914	measurable	_
187-22	36915-36921	effect	_
187-23	36922-36924	on	_
187-24	36925-36933	MID-task	_
187-25	36934-36945	performance	_
187-26	36945-36946	.	_

#Text=However, unlike stimulant drug use, familial risk also had no measurable impact on task-related brain activation in reward-related brain regions.
188-1	36947-36954	However	_
188-2	36954-36955	,	_
188-3	36956-36962	unlike	_
188-4	36963-36972	stimulant	_
188-5	36973-36977	drug	_
188-6	36978-36981	use	_
188-7	36981-36982	,	_
188-8	36983-36991	familial	_
188-9	36992-36996	risk	_
188-10	36997-37001	also	_
188-11	37002-37005	had	_
188-12	37006-37008	no	_
188-13	37009-37019	measurable	_
188-14	37020-37026	impact	_
188-15	37027-37029	on	_
188-16	37030-37042	task-related	_
188-17	37043-37048	brain	_
188-18	37049-37059	activation	_
188-19	37060-37062	in	_
188-20	37063-37077	reward-related	_
188-21	37078-37083	brain	_
188-22	37084-37091	regions	_
188-23	37091-37092	.	_

#Text=This observation is consistent with previous fMRI studies in individuals with familial risk.
189-1	37093-37097	This	_
189-2	37098-37109	observation	_
189-3	37110-37112	is	_
189-4	37113-37123	consistent	_
189-5	37124-37128	with	_
189-6	37129-37137	previous	_
189-7	37138-37142	fMRI	_
189-8	37143-37150	studies	_
189-9	37151-37153	in	_
189-10	37154-37165	individuals	_
189-11	37166-37170	with	_
189-12	37171-37179	familial	_
189-13	37180-37184	risk	_
189-14	37184-37185	.	_

#Text=Our data suggest that familial risk is conveyed in task-related corticostriatal functional connectivity (Fig. 3c).
190-1	37186-37189	Our	_
190-2	37190-37194	data	_
190-3	37195-37202	suggest	_
190-4	37203-37207	that	_
190-5	37208-37216	familial	_
190-6	37217-37221	risk	_
190-7	37222-37224	is	_
190-8	37225-37233	conveyed	_
190-9	37234-37236	in	_
190-10	37237-37249	task-related	_
190-11	37250-37265	corticostriatal	_
190-12	37266-37276	functional	_
190-13	37277-37289	connectivity	_
190-14	37290-37291	(	_
190-15	37291-37294	Fig	_
190-16	37294-37295	.	_
190-17	37296-37298	3c	_
190-18	37298-37299	)	_
190-19	37299-37300	.	_

#Text=Specifically, we observed altered functional connectivity between the putamen and the ACC, OFC, and mPFC–brain regions associated with the processing of monetary rewards–in participants with familial risk, irrespective of whether they used stimulant drugs.
191-1	37301-37313	Specifically	_
191-2	37313-37314	,	_
191-3	37315-37317	we	_
191-4	37318-37326	observed	_
191-5	37327-37334	altered	_
191-6	37335-37345	functional	_
191-7	37346-37358	connectivity	_
191-8	37359-37366	between	_
191-9	37367-37370	the	_
191-10	37371-37378	putamen	_
191-11	37379-37382	and	_
191-12	37383-37386	the	_
191-13	37387-37390	ACC	_
191-14	37390-37391	,	_
191-15	37392-37395	OFC	_
191-16	37395-37396	,	_
191-17	37397-37400	and	_
191-18	37401-37411	mPFC–brain	_
191-19	37412-37419	regions	_
191-20	37420-37430	associated	_
191-21	37431-37435	with	_
191-22	37436-37439	the	_
191-23	37440-37450	processing	_
191-24	37451-37453	of	_
191-25	37454-37462	monetary	_
191-26	37463-37473	rewards–in	_
191-27	37474-37486	participants	_
191-28	37487-37491	with	_
191-29	37492-37500	familial	_
191-30	37501-37505	risk	_
191-31	37505-37506	,	_
191-32	37507-37519	irrespective	_
191-33	37520-37522	of	_
191-34	37523-37530	whether	_
191-35	37531-37535	they	_
191-36	37536-37540	used	_
191-37	37541-37550	stimulant	_
191-38	37551-37556	drugs	_
191-39	37556-37557	.	_

#Text=These findings are interesting given a bulk of research demonstrating functional and structural pathways between the ventral putamen and frontal regions such as the mPFC, OFC, and ACC.
192-1	37558-37563	These	_
192-2	37564-37572	findings	_
192-3	37573-37576	are	_
192-4	37577-37588	interesting	_
192-5	37589-37594	given	_
192-6	37595-37596	a	_
192-7	37597-37601	bulk	_
192-8	37602-37604	of	_
192-9	37605-37613	research	_
192-10	37614-37627	demonstrating	_
192-11	37628-37638	functional	_
192-12	37639-37642	and	_
192-13	37643-37653	structural	_
192-14	37654-37662	pathways	_
192-15	37663-37670	between	_
192-16	37671-37674	the	_
192-17	37675-37682	ventral	_
192-18	37683-37690	putamen	_
192-19	37691-37694	and	_
192-20	37695-37702	frontal	_
192-21	37703-37710	regions	_
192-22	37711-37715	such	_
192-23	37716-37718	as	_
192-24	37719-37722	the	_
192-25	37723-37727	mPFC	_
192-26	37727-37728	,	_
192-27	37729-37732	OFC	_
192-28	37732-37733	,	_
192-29	37734-37737	and	_
192-30	37738-37741	ACC	_
192-31	37741-37742	.	_

#Text=Accordingly, the ventral putamen is involved in a frontal network that is recruited during response monitoring or goal-directed control required for the processing of reward.
193-1	37743-37754	Accordingly	_
193-2	37754-37755	,	_
193-3	37756-37759	the	_
193-4	37760-37767	ventral	_
193-5	37768-37775	putamen	_
193-6	37776-37778	is	_
193-7	37779-37787	involved	_
193-8	37788-37790	in	_
193-9	37791-37792	a	_
193-10	37793-37800	frontal	_
193-11	37801-37808	network	_
193-12	37809-37813	that	_
193-13	37814-37816	is	_
193-14	37817-37826	recruited	_
193-15	37827-37833	during	_
193-16	37834-37842	response	_
193-17	37843-37853	monitoring	_
193-18	37854-37856	or	_
193-19	37857-37870	goal-directed	_
193-20	37871-37878	control	_
193-21	37879-37887	required	_
193-22	37888-37891	for	_
193-23	37892-37895	the	_
193-24	37896-37906	processing	_
193-25	37907-37909	of	_
193-26	37910-37916	reward	_
193-27	37916-37917	.	_

#Text=These observations strongly suggest that the putamen, in addition to being a motor structure, is involved in higher-level cognitive functions.
194-1	37918-37923	These	_
194-2	37924-37936	observations	_
194-3	37937-37945	strongly	_
194-4	37946-37953	suggest	_
194-5	37954-37958	that	_
194-6	37959-37962	the	_
194-7	37963-37970	putamen	_
194-8	37970-37971	,	_
194-9	37972-37974	in	_
194-10	37975-37983	addition	_
194-11	37984-37986	to	_
194-12	37987-37992	being	_
194-13	37993-37994	a	_
194-14	37995-38000	motor	_
194-15	38001-38010	structure	_
194-16	38010-38011	,	_
194-17	38012-38014	is	_
194-18	38015-38023	involved	_
194-19	38024-38026	in	_
194-20	38027-38039	higher-level	_
194-21	38040-38049	cognitive	_
194-22	38050-38059	functions	_
194-23	38059-38060	.	_

#Text=In particular, the OFC, mPFC, and ACC have been implicated in an inhibition network consisting of cortical motor regions and basal ganglia structures, including the putamen.
195-1	38061-38063	In	_
195-2	38064-38074	particular	_
195-3	38074-38075	,	_
195-4	38076-38079	the	_
195-5	38080-38083	OFC	_
195-6	38083-38084	,	_
195-7	38085-38089	mPFC	_
195-8	38089-38090	,	_
195-9	38091-38094	and	_
195-10	38095-38098	ACC	_
195-11	38099-38103	have	_
195-12	38104-38108	been	_
195-13	38109-38119	implicated	_
195-14	38120-38122	in	_
195-15	38123-38125	an	_
195-16	38126-38136	inhibition	_
195-17	38137-38144	network	_
195-18	38145-38155	consisting	_
195-19	38156-38158	of	_
195-20	38159-38167	cortical	_
195-21	38168-38173	motor	_
195-22	38174-38181	regions	_
195-23	38182-38185	and	_
195-24	38186-38191	basal	_
195-25	38192-38199	ganglia	_
195-26	38200-38210	structures	_
195-27	38210-38211	,	_
195-28	38212-38221	including	_
195-29	38222-38225	the	_
195-30	38226-38233	putamen	_
195-31	38233-38234	.	_

#Text=It is possible that aberrant functioning of these corticostriatal networks confers vulnerability on individuals with family risk, altering higher-cognitive functioning and increasing their susceptibility to the development of addiction.
196-1	38235-38237	It	_
196-2	38238-38240	is	_
196-3	38241-38249	possible	_
196-4	38250-38254	that	_
196-5	38255-38263	aberrant	_
196-6	38264-38275	functioning	_
196-7	38276-38278	of	_
196-8	38279-38284	these	_
196-9	38285-38300	corticostriatal	_
196-10	38301-38309	networks	_
196-11	38310-38317	confers	_
196-12	38318-38331	vulnerability	_
196-13	38332-38334	on	_
196-14	38335-38346	individuals	_
196-15	38347-38351	with	_
196-16	38352-38358	family	_
196-17	38359-38363	risk	_
196-18	38363-38364	,	_
196-19	38365-38373	altering	_
196-20	38374-38390	higher-cognitive	_
196-21	38391-38402	functioning	_
196-22	38403-38406	and	_
196-23	38407-38417	increasing	_
196-24	38418-38423	their	_
196-25	38424-38438	susceptibility	_
196-26	38439-38441	to	_
196-27	38442-38445	the	_
196-28	38446-38457	development	_
196-29	38458-38460	of	_
196-30	38461-38470	addiction	_
196-31	38470-38471	.	_

#Text=Abnormal task-related corticostriatal functional connectivity demonstrated here, and elsewhere, in both addicted and vulnerable adolescents, adds to the body of evidence supporting endophenotypes in striatal and prefrontal cortical brain regions.
197-1	38472-38480	Abnormal	_
197-2	38481-38493	task-related	_
197-3	38494-38509	corticostriatal	_
197-4	38510-38520	functional	_
197-5	38521-38533	connectivity	_
197-6	38534-38546	demonstrated	_
197-7	38547-38551	here	_
197-8	38551-38552	,	_
197-9	38553-38556	and	_
197-10	38557-38566	elsewhere	_
197-11	38566-38567	,	_
197-12	38568-38570	in	_
197-13	38571-38575	both	_
197-14	38576-38584	addicted	_
197-15	38585-38588	and	_
197-16	38589-38599	vulnerable	_
197-17	38600-38611	adolescents	_
197-18	38611-38612	,	_
197-19	38613-38617	adds	_
197-20	38618-38620	to	_
197-21	38621-38624	the	_
197-22	38625-38629	body	_
197-23	38630-38632	of	_
197-24	38633-38641	evidence	_
197-25	38642-38652	supporting	_
197-26	38653-38667	endophenotypes	_
197-27	38668-38670	in	_
197-28	38671-38679	striatal	_
197-29	38680-38683	and	_
197-30	38684-38694	prefrontal	_
197-31	38695-38703	cortical	_
197-32	38704-38709	brain	_
197-33	38710-38717	regions	_
197-34	38717-38718	.	_

#Text=Prior findings of enlarged putamen and altered prefrontal cortical white matter in sibling pairs, along with the present findings, suggest that such endophenotypes may consist of both structural and functional striatal abnormalities.
198-1	38719-38724	Prior	_
198-2	38725-38733	findings	_
198-3	38734-38736	of	_
198-4	38737-38745	enlarged	_
198-5	38746-38753	putamen	_
198-6	38754-38757	and	_
198-7	38758-38765	altered	_
198-8	38766-38776	prefrontal	_
198-9	38777-38785	cortical	_
198-10	38786-38791	white	_
198-11	38792-38798	matter	_
198-12	38799-38801	in	_
198-13	38802-38809	sibling	_
198-14	38810-38815	pairs	_
198-15	38815-38816	,	_
198-16	38817-38822	along	_
198-17	38823-38827	with	_
198-18	38828-38831	the	_
198-19	38832-38839	present	_
198-20	38840-38848	findings	_
198-21	38848-38849	,	_
198-22	38850-38857	suggest	_
198-23	38858-38862	that	_
198-24	38863-38867	such	_
198-25	38868-38882	endophenotypes	_
198-26	38883-38886	may	_
198-27	38887-38894	consist	_
198-28	38895-38897	of	_
198-29	38898-38902	both	_
198-30	38903-38913	structural	_
198-31	38914-38917	and	_
198-32	38918-38928	functional	_
198-33	38929-38937	striatal	_
198-34	38938-38951	abnormalities	_
198-35	38951-38952	.	_

#Text=Taken together with the effects of stimulant drug use, our results suggest that stimulant drug addiction may impact the function of structures contained within brain pathways already compromised by familial risk, thereby exacerbating pre-existing functional deficits, perhaps leading to the development of addiction.
199-1	38953-38958	Taken	_
199-2	38959-38967	together	_
199-3	38968-38972	with	_
199-4	38973-38976	the	_
199-5	38977-38984	effects	_
199-6	38985-38987	of	_
199-7	38988-38997	stimulant	_
199-8	38998-39002	drug	_
199-9	39003-39006	use	_
199-10	39006-39007	,	_
199-11	39008-39011	our	_
199-12	39012-39019	results	_
199-13	39020-39027	suggest	_
199-14	39028-39032	that	_
199-15	39033-39042	stimulant	_
199-16	39043-39047	drug	_
199-17	39048-39057	addiction	_
199-18	39058-39061	may	_
199-19	39062-39068	impact	_
199-20	39069-39072	the	_
199-21	39073-39081	function	_
199-22	39082-39084	of	_
199-23	39085-39095	structures	_
199-24	39096-39105	contained	_
199-25	39106-39112	within	_
199-26	39113-39118	brain	_
199-27	39119-39127	pathways	_
199-28	39128-39135	already	_
199-29	39136-39147	compromised	_
199-30	39148-39150	by	_
199-31	39151-39159	familial	_
199-32	39160-39164	risk	_
199-33	39164-39165	,	_
199-34	39166-39173	thereby	_
199-35	39174-39186	exacerbating	_
199-36	39187-39199	pre-existing	_
199-37	39200-39210	functional	_
199-38	39211-39219	deficits	_
199-39	39219-39220	,	_
199-40	39221-39228	perhaps	_
199-41	39229-39236	leading	_
199-42	39237-39239	to	_
199-43	39240-39243	the	_
199-44	39244-39255	development	_
199-45	39256-39258	of	_
199-46	39259-39268	addiction	_
199-47	39268-39269	.	_

#Text=Interaction between stimulant drug use and familial risk during reward processing
#Text=In the present study, we observed an interaction on task-related functional connectivity between the putamen and the precentral and postcentral gyri in non-addicted stimulant drug users and non-stimulant drug users with familial risk.
200-1	39270-39281	Interaction	_
200-2	39282-39289	between	_
200-3	39290-39299	stimulant	_
200-4	39300-39304	drug	_
200-5	39305-39308	use	_
200-6	39309-39312	and	_
200-7	39313-39321	familial	_
200-8	39322-39326	risk	_
200-9	39327-39333	during	_
200-10	39334-39340	reward	_
200-11	39341-39351	processing	_
200-12	39352-39354	In	_
200-13	39355-39358	the	_
200-14	39359-39366	present	_
200-15	39367-39372	study	_
200-16	39372-39373	,	_
200-17	39374-39376	we	_
200-18	39377-39385	observed	_
200-19	39386-39388	an	_
200-20	39389-39400	interaction	_
200-21	39401-39403	on	_
200-22	39404-39416	task-related	_
200-23	39417-39427	functional	_
200-24	39428-39440	connectivity	_
200-25	39441-39448	between	_
200-26	39449-39452	the	_
200-27	39453-39460	putamen	_
200-28	39461-39464	and	_
200-29	39465-39468	the	_
200-30	39469-39479	precentral	_
200-31	39480-39483	and	_
200-32	39484-39495	postcentral	_
200-33	39496-39500	gyri	_
200-34	39501-39503	in	_
200-35	39504-39516	non-addicted	_
200-36	39517-39526	stimulant	_
200-37	39527-39531	drug	_
200-38	39532-39537	users	_
200-39	39538-39541	and	_
200-40	39542-39555	non-stimulant	_
200-41	39556-39560	drug	_
200-42	39561-39566	users	_
200-43	39567-39571	with	_
200-44	39572-39580	familial	_
200-45	39581-39585	risk	_
200-46	39585-39586	.	_

#Text=This interaction was characterized by an increase in functional connectivity strength to the precentral and postcentral gyri, which are involved in motor and somatosensory functions, possibly indicating compensatory or resiliency mechanisms.
201-1	39587-39591	This	_
201-2	39592-39603	interaction	_
201-3	39604-39607	was	_
201-4	39608-39621	characterized	_
201-5	39622-39624	by	_
201-6	39625-39627	an	_
201-7	39628-39636	increase	_
201-8	39637-39639	in	_
201-9	39640-39650	functional	_
201-10	39651-39663	connectivity	_
201-11	39664-39672	strength	_
201-12	39673-39675	to	_
201-13	39676-39679	the	_
201-14	39680-39690	precentral	_
201-15	39691-39694	and	_
201-16	39695-39706	postcentral	_
201-17	39707-39711	gyri	_
201-18	39711-39712	,	_
201-19	39713-39718	which	_
201-20	39719-39722	are	_
201-21	39723-39731	involved	_
201-22	39732-39734	in	_
201-23	39735-39740	motor	_
201-24	39741-39744	and	_
201-25	39745-39758	somatosensory	_
201-26	39759-39768	functions	_
201-27	39768-39769	,	_
201-28	39770-39778	possibly	_
201-29	39779-39789	indicating	_
201-30	39790-39802	compensatory	_
201-31	39803-39805	or	_
201-32	39806-39816	resiliency	_
201-33	39817-39827	mechanisms	_
201-34	39827-39828	.	_

#Text=Potential resilience, in the form of low sensation-seeking traits, has been previously reported in unaffected siblings, which may reflect lack of motivation to initiate drug use.
202-1	39829-39838	Potential	_
202-2	39839-39849	resilience	_
202-3	39849-39850	,	_
202-4	39851-39853	in	_
202-5	39854-39857	the	_
202-6	39858-39862	form	_
202-7	39863-39865	of	_
202-8	39866-39869	low	_
202-9	39870-39887	sensation-seeking	_
202-10	39888-39894	traits	_
202-11	39894-39895	,	_
202-12	39896-39899	has	_
202-13	39900-39904	been	_
202-14	39905-39915	previously	_
202-15	39916-39924	reported	_
202-16	39925-39927	in	_
202-17	39928-39938	unaffected	_
202-18	39939-39947	siblings	_
202-19	39947-39948	,	_
202-20	39949-39954	which	_
202-21	39955-39958	may	_
202-22	39959-39966	reflect	_
202-23	39967-39971	lack	_
202-24	39972-39974	of	_
202-25	39975-39985	motivation	_
202-26	39986-39988	to	_
202-27	39989-39997	initiate	_
202-28	39998-40002	drug	_
202-29	40003-40006	use	_
202-30	40006-40007	.	_

#Text=In previous studies, individuals with familial risk demonstrated increased striatal functional connectivity strength to attention- and motor-related structures, including the precentral and postcentral gyri, during reward anticipation.
203-1	40008-40010	In	_
203-2	40011-40019	previous	_
203-3	40020-40027	studies	_
203-4	40027-40028	,	_
203-5	40029-40040	individuals	_
203-6	40041-40045	with	_
203-7	40046-40054	familial	_
203-8	40055-40059	risk	_
203-9	40060-40072	demonstrated	_
203-10	40073-40082	increased	_
203-11	40083-40091	striatal	_
203-12	40092-40102	functional	_
203-13	40103-40115	connectivity	_
203-14	40116-40124	strength	_
203-15	40125-40127	to	_
203-16	40128-40137	attention	_
203-17	40137-40138	-	_
203-18	40139-40142	and	_
203-19	40143-40156	motor-related	_
203-20	40157-40167	structures	_
203-21	40167-40168	,	_
203-22	40169-40178	including	_
203-23	40179-40182	the	_
203-24	40183-40193	precentral	_
203-25	40194-40197	and	_
203-26	40198-40209	postcentral	_
203-27	40210-40214	gyri	_
203-28	40214-40215	,	_
203-29	40216-40222	during	_
203-30	40223-40229	reward	_
203-31	40230-40242	anticipation	_
203-32	40242-40243	.	_

#Text=However, such studies were unable to determine whether such changes represented addiction risk or resilience.
204-1	40244-40251	However	_
204-2	40251-40252	,	_
204-3	40253-40257	such	_
204-4	40258-40265	studies	_
204-5	40266-40270	were	_
204-6	40271-40277	unable	_
204-7	40278-40280	to	_
204-8	40281-40290	determine	_
204-9	40291-40298	whether	_
204-10	40299-40303	such	_
204-11	40304-40311	changes	_
204-12	40312-40323	represented	_
204-13	40324-40333	addiction	_
204-14	40334-40338	risk	_
204-15	40339-40341	or	_
204-16	40342-40352	resilience	_
204-17	40352-40353	.	_

#Text=Here we provide additional evidence that functional connectivity strength between striatal regions and motor-related structures when anticipating a reward may represent a mechanism for resilience in individuals with either familial risk or risks associated with the use of stimulants.
205-1	40354-40358	Here	_
205-2	40359-40361	we	_
205-3	40362-40369	provide	_
205-4	40370-40380	additional	_
205-5	40381-40389	evidence	_
205-6	40390-40394	that	_
205-7	40395-40405	functional	_
205-8	40406-40418	connectivity	_
205-9	40419-40427	strength	_
205-10	40428-40435	between	_
205-11	40436-40444	striatal	_
205-12	40445-40452	regions	_
205-13	40453-40456	and	_
205-14	40457-40470	motor-related	_
205-15	40471-40481	structures	_
205-16	40482-40486	when	_
205-17	40487-40499	anticipating	_
205-18	40500-40501	a	_
205-19	40502-40508	reward	_
205-20	40509-40512	may	_
205-21	40513-40522	represent	_
205-22	40523-40524	a	_
205-23	40525-40534	mechanism	_
205-24	40535-40538	for	_
205-25	40539-40549	resilience	_
205-26	40550-40552	in	_
205-27	40553-40564	individuals	_
205-28	40565-40569	with	_
205-29	40570-40576	either	_
205-30	40577-40585	familial	_
205-31	40586-40590	risk	_
205-32	40591-40593	or	_
205-33	40594-40599	risks	_
205-34	40600-40610	associated	_
205-35	40611-40615	with	_
205-36	40616-40619	the	_
205-37	40620-40623	use	_
205-38	40624-40626	of	_
205-39	40627-40637	stimulants	_
205-40	40637-40638	.	_

#Text=Such changes in motor-related structures may confer increased motor control, allowing these resilient individuals to cope with/resist the addictive properties of drug use or mitigate pre-existing impulsive tendencies.
206-1	40639-40643	Such	_
206-2	40644-40651	changes	_
206-3	40652-40654	in	_
206-4	40655-40668	motor-related	_
206-5	40669-40679	structures	_
206-6	40680-40683	may	_
206-7	40684-40690	confer	_
206-8	40691-40700	increased	_
206-9	40701-40706	motor	_
206-10	40707-40714	control	_
206-11	40714-40715	,	_
206-12	40716-40724	allowing	_
206-13	40725-40730	these	_
206-14	40731-40740	resilient	_
206-15	40741-40752	individuals	_
206-16	40753-40755	to	_
206-17	40756-40760	cope	_
206-18	40761-40765	with	_
206-19	40765-40766	/	_
206-20	40766-40772	resist	_
206-21	40773-40776	the	_
206-22	40777-40786	addictive	_
206-23	40787-40797	properties	_
206-24	40798-40800	of	_
206-25	40801-40805	drug	_
206-26	40806-40809	use	_
206-27	40810-40812	or	_
206-28	40813-40821	mitigate	_
206-29	40822-40834	pre-existing	_
206-30	40835-40844	impulsive	_
206-31	40845-40855	tendencies	_
206-32	40855-40856	.	_

#Text=Limitations and implications
#Text=To the best of our knowledge, the present results demonstrate for the first time distinct effects of stimulant drug use and familial risk on task-related putamen activation and functional connectivity of the putamen, respectively.
207-1	40857-40868	Limitations	_
207-2	40869-40872	and	_
207-3	40873-40885	implications	_
207-4	40886-40888	To	_
207-5	40889-40892	the	_
207-6	40893-40897	best	_
207-7	40898-40900	of	_
207-8	40901-40904	our	_
207-9	40905-40914	knowledge	_
207-10	40914-40915	,	_
207-11	40916-40919	the	_
207-12	40920-40927	present	_
207-13	40928-40935	results	_
207-14	40936-40947	demonstrate	_
207-15	40948-40951	for	_
207-16	40952-40955	the	_
207-17	40956-40961	first	_
207-18	40962-40966	time	_
207-19	40967-40975	distinct	_
207-20	40976-40983	effects	_
207-21	40984-40986	of	_
207-22	40987-40996	stimulant	_
207-23	40997-41001	drug	_
207-24	41002-41005	use	_
207-25	41006-41009	and	_
207-26	41010-41018	familial	_
207-27	41019-41023	risk	_
207-28	41024-41026	on	_
207-29	41027-41039	task-related	_
207-30	41040-41047	putamen	_
207-31	41048-41058	activation	_
207-32	41059-41062	and	_
207-33	41063-41073	functional	_
207-34	41074-41086	connectivity	_
207-35	41087-41089	of	_
207-36	41090-41093	the	_
207-37	41094-41101	putamen	_
207-38	41101-41102	,	_
207-39	41103-41115	respectively	_
207-40	41115-41116	.	_

#Text=Our study benefitted from a rigorous statistical approach and was conducted in a large sample with relatively stringent statistical thresholds.
208-1	41117-41120	Our	_
208-2	41121-41126	study	_
208-3	41127-41137	benefitted	_
208-4	41138-41142	from	_
208-5	41143-41144	a	_
208-6	41145-41153	rigorous	_
208-7	41154-41165	statistical	_
208-8	41166-41174	approach	_
208-9	41175-41178	and	_
208-10	41179-41182	was	_
208-11	41183-41192	conducted	_
208-12	41193-41195	in	_
208-13	41196-41197	a	_
208-14	41198-41203	large	_
208-15	41204-41210	sample	_
208-16	41211-41215	with	_
208-17	41216-41226	relatively	_
208-18	41227-41236	stringent	_
208-19	41237-41248	statistical	_
208-20	41249-41259	thresholds	_
208-21	41259-41260	.	_

#Text=However, we also acknowledge several limitations of this study.
209-1	41261-41268	However	_
209-2	41268-41269	,	_
209-3	41270-41272	we	_
209-4	41273-41277	also	_
209-5	41278-41289	acknowledge	_
209-6	41290-41297	several	_
209-7	41298-41309	limitations	_
209-8	41310-41312	of	_
209-9	41313-41317	this	_
209-10	41318-41323	study	_
209-11	41323-41324	.	_

#Text=Potentially confounding influences in stimulant drug-taking experiences and familial risk in the selected statistical model were addressed using additional post-hoc analyses, which are not always ideal for controlling for differences in incidental variables as such differences may indicate differences in other relevant variables that were not assessed.
210-1	41325-41336	Potentially	_
210-2	41337-41348	confounding	_
210-3	41349-41359	influences	_
210-4	41360-41362	in	_
210-5	41363-41372	stimulant	_
210-6	41373-41384	drug-taking	_
210-7	41385-41396	experiences	_
210-8	41397-41400	and	_
210-9	41401-41409	familial	_
210-10	41410-41414	risk	_
210-11	41415-41417	in	_
210-12	41418-41421	the	_
210-13	41422-41430	selected	_
210-14	41431-41442	statistical	_
210-15	41443-41448	model	_
210-16	41449-41453	were	_
210-17	41454-41463	addressed	_
210-18	41464-41469	using	_
210-19	41470-41480	additional	_
210-20	41481-41489	post-hoc	_
210-21	41490-41498	analyses	_
210-22	41498-41499	,	_
210-23	41500-41505	which	_
210-24	41506-41509	are	_
210-25	41510-41513	not	_
210-26	41514-41520	always	_
210-27	41521-41526	ideal	_
210-28	41527-41530	for	_
210-29	41531-41542	controlling	_
210-30	41543-41546	for	_
210-31	41547-41558	differences	_
210-32	41559-41561	in	_
210-33	41562-41572	incidental	_
210-34	41573-41582	variables	_
210-35	41583-41585	as	_
210-36	41586-41590	such	_
210-37	41591-41602	differences	_
210-38	41603-41606	may	_
210-39	41607-41615	indicate	_
210-40	41616-41627	differences	_
210-41	41628-41630	in	_
210-42	41631-41636	other	_
210-43	41637-41645	relevant	_
210-44	41646-41655	variables	_
210-45	41656-41660	that	_
210-46	41661-41665	were	_
210-47	41666-41669	not	_
210-48	41670-41678	assessed	_
210-49	41678-41679	.	_

#Text=We also acknowledge that stimulant drug users were separated based on their familial risk, yet familial risk is only one, albeit important, risk factor for the development of addiction.
211-1	41680-41682	We	_
211-2	41683-41687	also	_
211-3	41688-41699	acknowledge	_
211-4	41700-41704	that	_
211-5	41705-41714	stimulant	_
211-6	41715-41719	drug	_
211-7	41720-41725	users	_
211-8	41726-41730	were	_
211-9	41731-41740	separated	_
211-10	41741-41746	based	_
211-11	41747-41749	on	_
211-12	41750-41755	their	_
211-13	41756-41764	familial	_
211-14	41765-41769	risk	_
211-15	41769-41770	,	_
211-16	41771-41774	yet	_
211-17	41775-41783	familial	_
211-18	41784-41788	risk	_
211-19	41789-41791	is	_
211-20	41792-41796	only	_
211-21	41797-41800	one	_
211-22	41800-41801	,	_
211-23	41802-41808	albeit	_
211-24	41809-41818	important	_
211-25	41818-41819	,	_
211-26	41820-41824	risk	_
211-27	41825-41831	factor	_
211-28	41832-41835	for	_
211-29	41836-41839	the	_
211-30	41840-41851	development	_
211-31	41852-41854	of	_
211-32	41855-41864	addiction	_
211-33	41864-41865	.	_

#Text=Other possible risk factors may encompass neurobiological or socioeconomic differences that may exist between dependent and non-dependent stimulant drug users, rendering some individuals more vulnerable to developing addiction than others.
212-1	41866-41871	Other	_
212-2	41872-41880	possible	_
212-3	41881-41885	risk	_
212-4	41886-41893	factors	_
212-5	41894-41897	may	_
212-6	41898-41907	encompass	_
212-7	41908-41923	neurobiological	_
212-8	41924-41926	or	_
212-9	41927-41940	socioeconomic	_
212-10	41941-41952	differences	_
212-11	41953-41957	that	_
212-12	41958-41961	may	_
212-13	41962-41967	exist	_
212-14	41968-41975	between	_
212-15	41976-41985	dependent	_
212-16	41986-41989	and	_
212-17	41990-42003	non-dependent	_
212-18	42004-42013	stimulant	_
212-19	42014-42018	drug	_
212-20	42019-42024	users	_
212-21	42024-42025	,	_
212-22	42026-42035	rendering	_
212-23	42036-42040	some	_
212-24	42041-42052	individuals	_
212-25	42053-42057	more	_
212-26	42058-42068	vulnerable	_
212-27	42069-42071	to	_
212-28	42072-42082	developing	_
212-29	42083-42092	addiction	_
212-30	42093-42097	than	_
212-31	42098-42104	others	_
212-32	42104-42105	.	_

#Text=Furthermore, the design of our study does not allow for the identification of the specific aspects of familial or drug use risks responsible for the current findings.
213-1	42106-42117	Furthermore	_
213-2	42117-42118	,	_
213-3	42119-42122	the	_
213-4	42123-42129	design	_
213-5	42130-42132	of	_
213-6	42133-42136	our	_
213-7	42137-42142	study	_
213-8	42143-42147	does	_
213-9	42148-42151	not	_
213-10	42152-42157	allow	_
213-11	42158-42161	for	_
213-12	42162-42165	the	_
213-13	42166-42180	identification	_
213-14	42181-42183	of	_
213-15	42184-42187	the	_
213-16	42188-42196	specific	_
213-17	42197-42204	aspects	_
213-18	42205-42207	of	_
213-19	42208-42216	familial	_
213-20	42217-42219	or	_
213-21	42220-42224	drug	_
213-22	42225-42228	use	_
213-23	42229-42234	risks	_
213-24	42235-42246	responsible	_
213-25	42247-42250	for	_
213-26	42251-42254	the	_
213-27	42255-42262	current	_
213-28	42263-42271	findings	_
213-29	42271-42272	.	_

#Text=Reward-related striatal function has been associated with measures of addiction recovery and rehabilitation.
214-1	42273-42287	Reward-related	_
214-2	42288-42296	striatal	_
214-3	42297-42305	function	_
214-4	42306-42309	has	_
214-5	42310-42314	been	_
214-6	42315-42325	associated	_
214-7	42326-42330	with	_
214-8	42331-42339	measures	_
214-9	42340-42342	of	_
214-10	42343-42352	addiction	_
214-11	42353-42361	recovery	_
214-12	42362-42365	and	_
214-13	42366-42380	rehabilitation	_
214-14	42380-42381	.	_

#Text=In the absence of medically proven pharmacological treatments, therapeutic interventions for stimulant drug addiction currently rely on psychosocial and family-based approaches, which focus on previously identified familial environmental risk-factors but do not take into account associated neurobiological risk-factors.
215-1	42382-42384	In	_
215-2	42385-42388	the	_
215-3	42389-42396	absence	_
215-4	42397-42399	of	_
215-5	42400-42409	medically	_
215-6	42410-42416	proven	_
215-7	42417-42432	pharmacological	_
215-8	42433-42443	treatments	_
215-9	42443-42444	,	_
215-10	42445-42456	therapeutic	_
215-11	42457-42470	interventions	_
215-12	42471-42474	for	_
215-13	42475-42484	stimulant	_
215-14	42485-42489	drug	_
215-15	42490-42499	addiction	_
215-16	42500-42509	currently	_
215-17	42510-42514	rely	_
215-18	42515-42517	on	_
215-19	42518-42530	psychosocial	_
215-20	42531-42534	and	_
215-21	42535-42547	family-based	_
215-22	42548-42558	approaches	_
215-23	42558-42559	,	_
215-24	42560-42565	which	_
215-25	42566-42571	focus	_
215-26	42572-42574	on	_
215-27	42575-42585	previously	_
215-28	42586-42596	identified	_
215-29	42597-42605	familial	_
215-30	42606-42619	environmental	_
215-31	42620-42632	risk-factors	_
215-32	42633-42636	but	_
215-33	42637-42639	do	_
215-34	42640-42643	not	_
215-35	42644-42648	take	_
215-36	42649-42653	into	_
215-37	42654-42661	account	_
215-38	42662-42672	associated	_
215-39	42673-42688	neurobiological	_
215-40	42689-42701	risk-factors	_
215-41	42701-42702	.	_

#Text=Embedding the emerging knowledge of neurobiological vulnerability factors that are shared between family members into family-based interventions may increase therapeutic efficacy, perhaps by facilitating the delivery of prevention and intervention programs during childhood and adolescence.
216-1	42703-42712	Embedding	_
216-2	42713-42716	the	_
216-3	42717-42725	emerging	_
216-4	42726-42735	knowledge	_
216-5	42736-42738	of	_
216-6	42739-42754	neurobiological	_
216-7	42755-42768	vulnerability	_
216-8	42769-42776	factors	_
216-9	42777-42781	that	_
216-10	42782-42785	are	_
216-11	42786-42792	shared	_
216-12	42793-42800	between	_
216-13	42801-42807	family	_
216-14	42808-42815	members	_
216-15	42816-42820	into	_
216-16	42821-42833	family-based	_
216-17	42834-42847	interventions	_
216-18	42848-42851	may	_
216-19	42852-42860	increase	_
216-20	42861-42872	therapeutic	_
216-21	42873-42881	efficacy	_
216-22	42881-42882	,	_
216-23	42883-42890	perhaps	_
216-24	42891-42893	by	_
216-25	42894-42906	facilitating	_
216-26	42907-42910	the	_
216-27	42911-42919	delivery	_
216-28	42920-42922	of	_
216-29	42923-42933	prevention	_
216-30	42934-42937	and	_
216-31	42938-42950	intervention	_
216-32	42951-42959	programs	_
216-33	42960-42966	during	_
216-34	42967-42976	childhood	_
216-35	42977-42980	and	_
216-36	42981-42992	adolescence	_
216-37	42992-42993	.	_

#Text=Of particular relevance, we identified altered corticostriatal pathways as a candidate endophenotype for stimulant drug addiction.
217-1	42994-42996	Of	_
217-2	42997-43007	particular	_
217-3	43008-43017	relevance	_
217-4	43017-43018	,	_
217-5	43019-43021	we	_
217-6	43022-43032	identified	_
217-7	43033-43040	altered	_
217-8	43041-43056	corticostriatal	_
217-9	43057-43065	pathways	_
217-10	43066-43068	as	_
217-11	43069-43070	a	_
217-12	43071-43080	candidate	_
217-13	43081-43094	endophenotype	_
217-14	43095-43098	for	_
217-15	43099-43108	stimulant	_
217-16	43109-43113	drug	_
217-17	43114-43123	addiction	_
217-18	43123-43124	.	_

#Text=To fully realize the implications of this result, future research should attempt to characterize the behaviors supported by these pathways, and how they contribute to the development of addiction.
218-1	43125-43127	To	_
218-2	43128-43133	fully	_
218-3	43134-43141	realize	_
218-4	43142-43145	the	_
218-5	43146-43158	implications	_
218-6	43159-43161	of	_
218-7	43162-43166	this	_
218-8	43167-43173	result	_
218-9	43173-43174	,	_
218-10	43175-43181	future	_
218-11	43182-43190	research	_
218-12	43191-43197	should	_
218-13	43198-43205	attempt	_
218-14	43206-43208	to	_
218-15	43209-43221	characterize	_
218-16	43222-43225	the	_
218-17	43226-43235	behaviors	_
218-18	43236-43245	supported	_
218-19	43246-43248	by	_
218-20	43249-43254	these	_
218-21	43255-43263	pathways	_
218-22	43263-43264	,	_
218-23	43265-43268	and	_
218-24	43269-43272	how	_
218-25	43273-43277	they	_
218-26	43278-43288	contribute	_
218-27	43289-43291	to	_
218-28	43292-43295	the	_
218-29	43296-43307	development	_
218-30	43308-43310	of	_
218-31	43311-43320	addiction	_
218-32	43320-43321	.	_

#Text=Thus, the identification of endophenotypes, as well as resiliency mechanisms, will contribute to the synthesis of intervention strategies and the development of targeted therapies by providing distinct neural biomarkers that may help predict treatment response or successful/unsuccessful abstinence in addiction.
219-1	43322-43326	Thus	_
219-2	43326-43327	,	_
219-3	43328-43331	the	_
219-4	43332-43346	identification	_
219-5	43347-43349	of	_
219-6	43350-43364	endophenotypes	_
219-7	43364-43365	,	_
219-8	43366-43368	as	_
219-9	43369-43373	well	_
219-10	43374-43376	as	_
219-11	43377-43387	resiliency	_
219-12	43388-43398	mechanisms	_
219-13	43398-43399	,	_
219-14	43400-43404	will	_
219-15	43405-43415	contribute	_
219-16	43416-43418	to	_
219-17	43419-43422	the	_
219-18	43423-43432	synthesis	_
219-19	43433-43435	of	_
219-20	43436-43448	intervention	_
219-21	43449-43459	strategies	_
219-22	43460-43463	and	_
219-23	43464-43467	the	_
219-24	43468-43479	development	_
219-25	43480-43482	of	_
219-26	43483-43491	targeted	_
219-27	43492-43501	therapies	_
219-28	43502-43504	by	_
219-29	43505-43514	providing	_
219-30	43515-43523	distinct	_
219-31	43524-43530	neural	_
219-32	43531-43541	biomarkers	_
219-33	43542-43546	that	_
219-34	43547-43550	may	_
219-35	43551-43555	help	_
219-36	43556-43563	predict	_
219-37	43564-43573	treatment	_
219-38	43574-43582	response	_
219-39	43583-43585	or	_
219-40	43586-43596	successful	_
219-41	43596-43597	/	_
219-42	43597-43609	unsuccessful	_
219-43	43610-43620	abstinence	_
219-44	43621-43623	in	_
219-45	43624-43633	addiction	_
219-46	43633-43634	.	_

#Text=Supplementary information
#Text=Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
220-1	43635-43648	Supplementary	_
220-2	43649-43660	information	_
220-3	43661-43670	Publisher	_
220-4	43670-43671	’	_
220-5	43671-43672	s	_
220-6	43673-43677	note	_
220-7	43677-43678	:	_
220-8	43679-43687	Springer	_
220-9	43688-43694	Nature	_
220-10	43695-43702	remains	_
220-11	43703-43710	neutral	_
220-12	43711-43715	with	_
220-13	43716-43722	regard	_
220-14	43723-43725	to	_
220-15	43726-43740	jurisdictional	_
220-16	43741-43747	claims	_
220-17	43748-43750	in	_
220-18	43751-43760	published	_
220-19	43761-43765	maps	_
220-20	43766-43769	and	_
220-21	43770-43783	institutional	_
220-22	43784-43796	affiliations	_
220-23	43796-43797	.	_

#Text=Supplementary Information
#Text=Supplementary Information accompanies this paper at (10.1038/s41398-019-0399-4).
221-1	43798-43811	Supplementary	_
221-2	43812-43823	Information	_
221-3	43824-43837	Supplementary	_
221-4	43838-43849	Information	_
221-5	43850-43861	accompanies	_
221-6	43862-43866	this	_
221-7	43867-43872	paper	_
221-8	43873-43875	at	_
221-9	43876-43877	(	_
221-10	43877-43884	10.1038	_
221-11	43884-43885	/	_
221-12	43885-43891	s41398	_
221-13	43891-43892	-	_
221-14	43892-43895	019	_
221-15	43895-43896	-	_
221-16	43896-43900	0399	_
221-17	43900-43901	-	_
221-18	43901-43902	4	_
221-19	43902-43903	)	_
221-20	43903-43904	.	_

#Text=Conflict of interest
#Text=This research was funded by a Medical Research Council (MRC) grant (G0701497), and conducted within the Behavioural and Clinical Neuroscience Institute (BCNI), which is jointly funded by the MRC and Wellcome Trust.
222-1	43905-43913	Conflict	_
222-2	43914-43916	of	_
222-3	43917-43925	interest	_
222-4	43926-43930	This	_
222-5	43931-43939	research	_
222-6	43940-43943	was	_
222-7	43944-43950	funded	_
222-8	43951-43953	by	_
222-9	43954-43955	a	_
222-10	43956-43963	Medical	_
222-11	43964-43972	Research	_
222-12	43973-43980	Council	_
222-13	43981-43982	(	_
222-14	43982-43985	MRC	_
222-15	43985-43986	)	_
222-16	43987-43992	grant	_
222-17	43993-43994	(	_
222-18	43994-44002	G0701497	_
222-19	44002-44003	)	_
222-20	44003-44004	,	_
222-21	44005-44008	and	_
222-22	44009-44018	conducted	_
222-23	44019-44025	within	_
222-24	44026-44029	the	_
222-25	44030-44041	Behavioural	_
222-26	44042-44045	and	_
222-27	44046-44054	Clinical	_
222-28	44055-44067	Neuroscience	_
222-29	44068-44077	Institute	_
222-30	44078-44079	(	_
222-31	44079-44083	BCNI	_
222-32	44083-44084	)	_
222-33	44084-44085	,	_
222-34	44086-44091	which	_
222-35	44092-44094	is	_
222-36	44095-44102	jointly	_
222-37	44103-44109	funded	_
222-38	44110-44112	by	_
222-39	44113-44116	the	_
222-40	44117-44120	MRC	_
222-41	44121-44124	and	_
222-42	44125-44133	Wellcome	_
222-43	44134-44139	Trust	_
222-44	44139-44140	.	_

#Text=A.L.J. was supported by the Gates Cambridge Trust, D.G.S. by a studentship from the Cambridge Overseas Trust, and C.M. by the Wellcome Trust (105602/Z/14/Z) and the NIHR Cambridge Biomedical Research Centre.
223-1	44141-44146	A.L.J	_
223-2	44146-44147	.	_
223-3	44148-44151	was	_
223-4	44152-44161	supported	_
223-5	44162-44164	by	_
223-6	44165-44168	the	_
223-7	44169-44174	Gates	_
223-8	44175-44184	Cambridge	_
223-9	44185-44190	Trust	_
223-10	44190-44191	,	_
223-11	44192-44197	D.G.S	_
223-12	44197-44198	.	_
223-13	44199-44201	by	_
223-14	44202-44203	a	_
223-15	44204-44215	studentship	_
223-16	44216-44220	from	_
223-17	44221-44224	the	_
223-18	44225-44234	Cambridge	_
223-19	44235-44243	Overseas	_
223-20	44244-44249	Trust	_
223-21	44249-44250	,	_
223-22	44251-44254	and	_
223-23	44255-44258	C.M	_
223-24	44258-44259	.	_
223-25	44260-44262	by	_
223-26	44263-44266	the	_
223-27	44267-44275	Wellcome	_
223-28	44276-44281	Trust	_
223-29	44282-44283	(	_
223-30	44283-44289	105602	_
223-31	44289-44290	/	_
223-32	44290-44291	Z	_
223-33	44291-44292	/	_
223-34	44292-44294	14	_
223-35	44294-44295	/	_
223-36	44295-44296	Z	_
223-37	44296-44297	)	_
223-38	44298-44301	and	_
223-39	44302-44305	the	_
223-40	44306-44310	NIHR	_
223-41	44311-44320	Cambridge	_
223-42	44321-44331	Biomedical	_
223-43	44332-44340	Research	_
223-44	44341-44347	Centre	_
223-45	44347-44348	.	_

#Text=E.T.B. is employed part-time by GlaxoSmithKline and part-time by the University of Cambridge, and serves as the Head of Research and Development at the Cambridgeshire and Peterborough NHS Foundation Trust.
224-1	44349-44354	E.T.B	_
224-2	44354-44355	.	_
224-3	44356-44358	is	_
224-4	44359-44367	employed	_
224-5	44368-44377	part-time	_
224-6	44378-44380	by	_
224-7	44381-44396	GlaxoSmithKline	_
224-8	44397-44400	and	_
224-9	44401-44410	part-time	_
224-10	44411-44413	by	_
224-11	44414-44417	the	_
224-12	44418-44428	University	_
224-13	44429-44431	of	_
224-14	44432-44441	Cambridge	_
224-15	44441-44442	,	_
224-16	44443-44446	and	_
224-17	44447-44453	serves	_
224-18	44454-44456	as	_
224-19	44457-44460	the	_
224-20	44461-44465	Head	_
224-21	44466-44468	of	_
224-22	44469-44477	Research	_
224-23	44478-44481	and	_
224-24	44482-44493	Development	_
224-25	44494-44496	at	_
224-26	44497-44500	the	_
224-27	44501-44515	Cambridgeshire	_
224-28	44516-44519	and	_
224-29	44520-44532	Peterborough	_
224-30	44533-44536	NHS	_
224-31	44537-44547	Foundation	_
224-32	44548-44553	Trust	_
224-33	44553-44554	.	_

#Text=T.W.R. consults for Cambridge Cognition, Lundbeck, Otsuka, and Mundipharma.
225-1	44555-44560	T.W.R	_
225-2	44560-44561	.	_
225-3	44562-44570	consults	_
225-4	44571-44574	for	_
225-5	44575-44584	Cambridge	_
225-6	44585-44594	Cognition	_
225-7	44594-44595	,	_
225-8	44596-44604	Lundbeck	_
225-9	44604-44605	,	_
225-10	44606-44612	Otsuka	_
225-11	44612-44613	,	_
225-12	44614-44617	and	_
225-13	44618-44629	Mundipharma	_
225-14	44629-44630	.	_

#Text=He also holds a research grant from Shionogi.
226-1	44631-44633	He	_
226-2	44634-44638	also	_
226-3	44639-44644	holds	_
226-4	44645-44646	a	_
226-5	44647-44655	research	_
226-6	44656-44661	grant	_
226-7	44662-44666	from	_
226-8	44667-44675	Shionogi	_
226-9	44675-44676	.	_

#Text=The authors declare no additional conflict of interests.
227-1	44677-44680	The	_
227-2	44681-44688	authors	_
227-3	44689-44696	declare	_
227-4	44697-44699	no	_
227-5	44700-44710	additional	_
227-6	44711-44719	conflict	_
227-7	44720-44722	of	_
227-8	44723-44732	interests	_
227-9	44732-44733	.	_

#Text=References
#Text=Addiction is a brain disease, and it matters
#Text=Is there a common molecular pathway for addiction?
228-1	44734-44744	References	_
228-2	44745-44754	Addiction	_
228-3	44755-44757	is	_
228-4	44758-44759	a	_
228-5	44760-44765	brain	_
228-6	44766-44773	disease	_
228-7	44773-44774	,	_
228-8	44775-44778	and	_
228-9	44779-44781	it	_
228-10	44782-44789	matters	_
228-11	44790-44792	Is	_
228-12	44793-44798	there	_
228-13	44799-44800	a	_
228-14	44801-44807	common	_
228-15	44808-44817	molecular	_
228-16	44818-44825	pathway	_
228-17	44826-44829	for	_
228-18	44830-44839	addiction	_
228-19	44839-44840	?	_

#Text=The reward circuit: linking primate anatomy and human imaging
#Text=The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans
#Text=Dopamine in drug abuse and addiction: results from imaging studies and treatment implications
#Text=The debate over dopamine’s role in reward: the case for incentive salience
#Text=The mind of an addicted brain: neural sensitization of wanting versus liking
#Text=Familial transmission of substance use disorders
#Text=Genes and addictions
#Text=Genetic factors modulating the response to stimulant drugs in humans
#Text=Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence
#Text=Abnormal brain structure implicated in stimulant drug addiction
#Text=High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors
#Text=Reduced dopamine response to amphetamine in subjects at ultra-high risk for addiction
#Text=Blunted dopamine release as a biomarker for vulnerability for substance use disorders
#Text=Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors
#Text=Preliminary evidence for disrupted nucleus accumbens reactivity and connectivity to reward in binge drinkers
#Text=Determinants of early alcohol use in healthy adolescents: the differential contribution of neuroimaging and psychological factors
#Text=Prediction of alcohol drinking in adolescents: Personality-traits, behavior, brain responses, and genetic variations in the context of reward sensitivity
#Text=Neuropsychosocial profiles of current and future adolescent alcohol misusers
#Text=Beyond sensation seeking: a conceptual framework for individual differences in psychostimulant drug effects in healthy humans
#Text=Attitudinal factors protective against youth smoking: an integrative review
#Text=Reinforcement related behaviors and adolescent alcohol abuse: from localized brain structures to coordinated networks
#Text=Conditioned and sensitized responses to stimulant drugs in humans
#Text=Disruption of reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies
#Text=The endophenotype concept in psychiatry: etymology and strategic intentions
#Text=Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration
#Text=Familial risk factors favoring drug addiction onset
#Text=A twin study of the neuropsychological consequences of stimulant abuse
#Text=The enrichment study of the Minnesota twin family study: increasing the yield of twin families at high risk for externalizing psychopathology
#Text=Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction
#Text=Dopamine in drug abuse and addiction: results of imaging studies and treatment implications
#Text=The genetics of addictions: uncovering the genes
#Text=Dissociation of reward anticipation and outcome with event-related fMRI
#Text=Anticipatory affect: neural correlates and consequences for choice
#Text=First M., Spitzer R., Williams J.
229-1	44841-44844	The	_
229-2	44845-44851	reward	_
229-3	44852-44859	circuit	_
229-4	44859-44860	:	_
229-5	44861-44868	linking	_
229-6	44869-44876	primate	_
229-7	44877-44884	anatomy	_
229-8	44885-44888	and	_
229-9	44889-44894	human	_
229-10	44895-44902	imaging	_
229-11	44903-44906	The	_
229-12	44907-44921	neurocircuitry	_
229-13	44922-44924	of	_
229-14	44925-44932	illicit	_
229-15	44933-44948	psychostimulant	_
229-16	44949-44958	addiction	_
229-17	44958-44959	:	_
229-18	44960-44965	acute	_
229-19	44966-44969	and	_
229-20	44970-44977	chronic	_
229-21	44978-44985	effects	_
229-22	44986-44988	in	_
229-23	44989-44995	humans	_
229-24	44996-45004	Dopamine	_
229-25	45005-45007	in	_
229-26	45008-45012	drug	_
229-27	45013-45018	abuse	_
229-28	45019-45022	and	_
229-29	45023-45032	addiction	_
229-30	45032-45033	:	_
229-31	45034-45041	results	_
229-32	45042-45046	from	_
229-33	45047-45054	imaging	_
229-34	45055-45062	studies	_
229-35	45063-45066	and	_
229-36	45067-45076	treatment	_
229-37	45077-45089	implications	_
229-38	45090-45093	The	_
229-39	45094-45100	debate	_
229-40	45101-45105	over	_
229-41	45106-45114	dopamine	_
229-42	45114-45115	’	_
229-43	45115-45116	s	_
229-44	45117-45121	role	_
229-45	45122-45124	in	_
229-46	45125-45131	reward	_
229-47	45131-45132	:	_
229-48	45133-45136	the	_
229-49	45137-45141	case	_
229-50	45142-45145	for	_
229-51	45146-45155	incentive	_
229-52	45156-45164	salience	_
229-53	45165-45168	The	_
229-54	45169-45173	mind	_
229-55	45174-45176	of	_
229-56	45177-45179	an	_
229-57	45180-45188	addicted	_
229-58	45189-45194	brain	_
229-59	45194-45195	:	_
229-60	45196-45202	neural	_
229-61	45203-45216	sensitization	_
229-62	45217-45219	of	_
229-63	45220-45227	wanting	_
229-64	45228-45234	versus	_
229-65	45235-45241	liking	_
229-66	45242-45250	Familial	_
229-67	45251-45263	transmission	_
229-68	45264-45266	of	_
229-69	45267-45276	substance	_
229-70	45277-45280	use	_
229-71	45281-45290	disorders	_
229-72	45291-45296	Genes	_
229-73	45297-45300	and	_
229-74	45301-45311	addictions	_
229-75	45312-45319	Genetic	_
229-76	45320-45327	factors	_
229-77	45328-45338	modulating	_
229-78	45339-45342	the	_
229-79	45343-45351	response	_
229-80	45352-45354	to	_
229-81	45355-45364	stimulant	_
229-82	45365-45370	drugs	_
229-83	45371-45373	in	_
229-84	45374-45380	humans	_
229-85	45381-45390	Cognitive	_
229-86	45391-45402	dysfunction	_
229-87	45403-45406	and	_
229-88	45407-45424	anxious-impulsive	_
229-89	45425-45436	personality	_
229-90	45437-45443	traits	_
229-91	45444-45447	are	_
229-92	45448-45462	endophenotypes	_
229-93	45463-45466	for	_
229-94	45467-45471	drug	_
229-95	45472-45482	dependence	_
229-96	45483-45491	Abnormal	_
229-97	45492-45497	brain	_
229-98	45498-45507	structure	_
229-99	45508-45518	implicated	_
229-100	45519-45521	in	_
229-101	45522-45531	stimulant	_
229-102	45532-45536	drug	_
229-103	45537-45546	addiction	_
229-104	45547-45551	High	_
229-105	45552-45558	levels	_
229-106	45559-45561	of	_
229-107	45562-45570	dopamine	_
229-108	45571-45573	D2	_
229-109	45574-45583	receptors	_
229-110	45584-45586	in	_
229-111	45587-45597	unaffected	_
229-112	45598-45605	members	_
229-113	45606-45608	of	_
229-114	45609-45618	alcoholic	_
229-115	45619-45627	families	_
229-116	45627-45628	:	_
229-117	45629-45637	possible	_
229-118	45638-45648	protective	_
229-119	45649-45656	factors	_
229-120	45657-45664	Reduced	_
229-121	45665-45673	dopamine	_
229-122	45674-45682	response	_
229-123	45683-45685	to	_
229-124	45686-45697	amphetamine	_
229-125	45698-45700	in	_
229-126	45701-45709	subjects	_
229-127	45710-45712	at	_
229-128	45713-45723	ultra-high	_
229-129	45724-45728	risk	_
229-130	45729-45732	for	_
229-131	45733-45742	addiction	_
229-132	45743-45750	Blunted	_
229-133	45751-45759	dopamine	_
229-134	45760-45767	release	_
229-135	45768-45770	as	_
229-136	45771-45772	a	_
229-137	45773-45782	biomarker	_
229-138	45783-45786	for	_
229-139	45787-45800	vulnerability	_
229-140	45801-45804	for	_
229-141	45805-45814	substance	_
229-142	45815-45818	use	_
229-143	45819-45828	disorders	_
229-144	45829-45840	Individuals	_
229-145	45841-45847	family	_
229-146	45848-45855	history	_
229-147	45856-45864	positive	_
229-148	45865-45868	for	_
229-149	45869-45879	alcoholism	_
229-150	45880-45884	show	_
229-151	45885-45895	functional	_
229-152	45896-45904	magnetic	_
229-153	45905-45914	resonance	_
229-154	45915-45922	imaging	_
229-155	45923-45934	differences	_
229-156	45935-45937	in	_
229-157	45938-45944	reward	_
229-158	45945-45956	sensitivity	_
229-159	45957-45961	that	_
229-160	45962-45965	are	_
229-161	45966-45973	related	_
229-162	45974-45976	to	_
229-163	45977-45988	impulsivity	_
229-164	45989-45996	factors	_
229-165	45997-46008	Preliminary	_
229-166	46009-46017	evidence	_
229-167	46018-46021	for	_
229-168	46022-46031	disrupted	_
229-169	46032-46039	nucleus	_
229-170	46040-46049	accumbens	_
229-171	46050-46060	reactivity	_
229-172	46061-46064	and	_
229-173	46065-46077	connectivity	_
229-174	46078-46080	to	_
229-175	46081-46087	reward	_
229-176	46088-46090	in	_
229-177	46091-46096	binge	_
229-178	46097-46105	drinkers	_
229-179	46106-46118	Determinants	_
229-180	46119-46121	of	_
229-181	46122-46127	early	_
229-182	46128-46135	alcohol	_
229-183	46136-46139	use	_
229-184	46140-46142	in	_
229-185	46143-46150	healthy	_
229-186	46151-46162	adolescents	_
229-187	46162-46163	:	_
229-188	46164-46167	the	_
229-189	46168-46180	differential	_
229-190	46181-46193	contribution	_
229-191	46194-46196	of	_
229-192	46197-46209	neuroimaging	_
229-193	46210-46213	and	_
229-194	46214-46227	psychological	_
229-195	46228-46235	factors	_
229-196	46236-46246	Prediction	_
229-197	46247-46249	of	_
229-198	46250-46257	alcohol	_
229-199	46258-46266	drinking	_
229-200	46267-46269	in	_
229-201	46270-46281	adolescents	_
229-202	46281-46282	:	_
229-203	46283-46301	Personality-traits	_
229-204	46301-46302	,	_
229-205	46303-46311	behavior	_
229-206	46311-46312	,	_
229-207	46313-46318	brain	_
229-208	46319-46328	responses	_
229-209	46328-46329	,	_
229-210	46330-46333	and	_
229-211	46334-46341	genetic	_
229-212	46342-46352	variations	_
229-213	46353-46355	in	_
229-214	46356-46359	the	_
229-215	46360-46367	context	_
229-216	46368-46370	of	_
229-217	46371-46377	reward	_
229-218	46378-46389	sensitivity	_
229-219	46390-46407	Neuropsychosocial	_
229-220	46408-46416	profiles	_
229-221	46417-46419	of	_
229-222	46420-46427	current	_
229-223	46428-46431	and	_
229-224	46432-46438	future	_
229-225	46439-46449	adolescent	_
229-226	46450-46457	alcohol	_
229-227	46458-46466	misusers	_
229-228	46467-46473	Beyond	_
229-229	46474-46483	sensation	_
229-230	46484-46491	seeking	_
229-231	46491-46492	:	_
229-232	46493-46494	a	_
229-233	46495-46505	conceptual	_
229-234	46506-46515	framework	_
229-235	46516-46519	for	_
229-236	46520-46530	individual	_
229-237	46531-46542	differences	_
229-238	46543-46545	in	_
229-239	46546-46561	psychostimulant	_
229-240	46562-46566	drug	_
229-241	46567-46574	effects	_
229-242	46575-46577	in	_
229-243	46578-46585	healthy	_
229-244	46586-46592	humans	_
229-245	46593-46604	Attitudinal	_
229-246	46605-46612	factors	_
229-247	46613-46623	protective	_
229-248	46624-46631	against	_
229-249	46632-46637	youth	_
229-250	46638-46645	smoking	_
229-251	46645-46646	:	_
229-252	46647-46649	an	_
229-253	46650-46661	integrative	_
229-254	46662-46668	review	_
229-255	46669-46682	Reinforcement	_
229-256	46683-46690	related	_
229-257	46691-46700	behaviors	_
229-258	46701-46704	and	_
229-259	46705-46715	adolescent	_
229-260	46716-46723	alcohol	_
229-261	46724-46729	abuse	_
229-262	46729-46730	:	_
229-263	46731-46735	from	_
229-264	46736-46745	localized	_
229-265	46746-46751	brain	_
229-266	46752-46762	structures	_
229-267	46763-46765	to	_
229-268	46766-46777	coordinated	_
229-269	46778-46786	networks	_
229-270	46787-46798	Conditioned	_
229-271	46799-46802	and	_
229-272	46803-46813	sensitized	_
229-273	46814-46823	responses	_
229-274	46824-46826	to	_
229-275	46827-46836	stimulant	_
229-276	46837-46842	drugs	_
229-277	46843-46845	in	_
229-278	46846-46852	humans	_
229-279	46853-46863	Disruption	_
229-280	46864-46866	of	_
229-281	46867-46873	reward	_
229-282	46874-46884	processing	_
229-283	46885-46887	in	_
229-284	46888-46897	addiction	_
229-285	46897-46898	:	_
229-286	46899-46901	an	_
229-287	46902-46913	image-based	_
229-288	46914-46927	meta-analysis	_
229-289	46928-46930	of	_
229-290	46931-46941	functional	_
229-291	46942-46950	magnetic	_
229-292	46951-46960	resonance	_
229-293	46961-46968	imaging	_
229-294	46969-46976	studies	_
229-295	46977-46980	The	_
229-296	46981-46994	endophenotype	_
229-297	46995-47002	concept	_
229-298	47003-47005	in	_
229-299	47006-47016	psychiatry	_
229-300	47016-47017	:	_
229-301	47018-47027	etymology	_
229-302	47028-47031	and	_
229-303	47032-47041	strategic	_
229-304	47042-47052	intentions	_
229-305	47053-47059	Social	_
229-306	47060-47072	determinants	_
229-307	47073-47076	and	_
229-308	47077-47080	the	_
229-309	47081-47087	health	_
229-310	47088-47090	of	_
229-311	47091-47095	drug	_
229-312	47096-47101	users	_
229-313	47101-47102	:	_
229-314	47103-47116	socioeconomic	_
229-315	47117-47123	status	_
229-316	47123-47124	,	_
229-317	47125-47137	homelessness	_
229-318	47137-47138	,	_
229-319	47139-47142	and	_
229-320	47143-47156	incarceration	_
229-321	47157-47165	Familial	_
229-322	47166-47170	risk	_
229-323	47171-47178	factors	_
229-324	47179-47187	favoring	_
229-325	47188-47192	drug	_
229-326	47193-47202	addiction	_
229-327	47203-47208	onset	_
229-328	47209-47210	A	_
229-329	47211-47215	twin	_
229-330	47216-47221	study	_
229-331	47222-47224	of	_
229-332	47225-47228	the	_
229-333	47229-47247	neuropsychological	_
229-334	47248-47260	consequences	_
229-335	47261-47263	of	_
229-336	47264-47273	stimulant	_
229-337	47274-47279	abuse	_
229-338	47280-47283	The	_
229-339	47284-47294	enrichment	_
229-340	47295-47300	study	_
229-341	47301-47303	of	_
229-342	47304-47307	the	_
229-343	47308-47317	Minnesota	_
229-344	47318-47322	twin	_
229-345	47323-47329	family	_
229-346	47330-47335	study	_
229-347	47335-47336	:	_
229-348	47337-47347	increasing	_
229-349	47348-47351	the	_
229-350	47352-47357	yield	_
229-351	47358-47360	of	_
229-352	47361-47365	twin	_
229-353	47366-47374	families	_
229-354	47375-47377	at	_
229-355	47378-47382	high	_
229-356	47383-47387	risk	_
229-357	47388-47391	for	_
229-358	47392-47405	externalizing	_
229-359	47406-47421	psychopathology	_
229-360	47422-47429	Cocaine	_
229-361	47430-47434	cues	_
229-362	47435-47438	and	_
229-363	47439-47447	dopamine	_
229-364	47448-47450	in	_
229-365	47451-47457	dorsal	_
229-366	47458-47466	striatum	_
229-367	47466-47467	:	_
229-368	47468-47477	mechanism	_
229-369	47478-47480	of	_
229-370	47481-47488	craving	_
229-371	47489-47491	in	_
229-372	47492-47499	cocaine	_
229-373	47500-47509	addiction	_
229-374	47510-47518	Dopamine	_
229-375	47519-47521	in	_
229-376	47522-47526	drug	_
229-377	47527-47532	abuse	_
229-378	47533-47536	and	_
229-379	47537-47546	addiction	_
229-380	47546-47547	:	_
229-381	47548-47555	results	_
229-382	47556-47558	of	_
229-383	47559-47566	imaging	_
229-384	47567-47574	studies	_
229-385	47575-47578	and	_
229-386	47579-47588	treatment	_
229-387	47589-47601	implications	_
229-388	47602-47605	The	_
229-389	47606-47614	genetics	_
229-390	47615-47617	of	_
229-391	47618-47628	addictions	_
229-392	47628-47629	:	_
229-393	47630-47640	uncovering	_
229-394	47641-47644	the	_
229-395	47645-47650	genes	_
229-396	47651-47663	Dissociation	_
229-397	47664-47666	of	_
229-398	47667-47673	reward	_
229-399	47674-47686	anticipation	_
229-400	47687-47690	and	_
229-401	47691-47698	outcome	_
229-402	47699-47703	with	_
229-403	47704-47717	event-related	_
229-404	47718-47722	fMRI	_
229-405	47723-47735	Anticipatory	_
229-406	47736-47742	affect	_
229-407	47742-47743	:	_
229-408	47744-47750	neural	_
229-409	47751-47761	correlates	_
229-410	47762-47765	and	_
229-411	47766-47778	consequences	_
229-412	47779-47782	for	_
229-413	47783-47789	choice	_
229-414	47790-47795	First	_
229-415	47796-47797	M	_
229-416	47797-47798	.	_
229-417	47798-47799	,	_
229-418	47800-47807	Spitzer	_
229-419	47808-47809	R	_
229-420	47809-47810	.	_
229-421	47810-47811	,	_
229-422	47812-47820	Williams	_
229-423	47821-47822	J	_
229-424	47822-47823	.	_

#Text=Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Research (SCID-I/NP). 2002.
230-1	47824-47834	Structured	_
230-2	47835-47843	Clinical	_
230-3	47844-47853	Interview	_
230-4	47854-47857	for	_
230-5	47858-47867	DSM-IV-TR	_
230-6	47868-47872	Axis	_
230-7	47873-47874	I	_
230-8	47875-47884	Disorders	_
230-9	47884-47885	,	_
230-10	47886-47894	Research	_
230-11	47895-47902	Version	_
230-12	47902-47903	,	_
230-13	47904-47915	Non-Patient	_
230-14	47916-47924	Research	_
230-15	47925-47926	(	_
230-16	47926-47932	SCID-I	_
230-17	47932-47933	/	_
230-18	47933-47935	NP	_
230-19	47935-47936	)	_
230-20	47936-47937	.	_
230-21	47938-47942	2002	_
230-22	47942-47943	.	_

#Text=American Psychiaatric Association.
231-1	47944-47952	American	_
231-2	47953-47965	Psychiaatric	_
231-3	47966-47977	Association	_
231-4	47977-47978	.	_

#Text=Diagnostic and Statistical Manual of Mental Disorders. 2002.
232-1	47979-47989	Diagnostic	_
232-2	47990-47993	and	_
232-3	47994-48005	Statistical	_
232-4	48006-48012	Manual	_
232-5	48013-48015	of	_
232-6	48016-48022	Mental	_
232-7	48023-48032	Disorders	_
232-8	48032-48033	.	_
232-9	48034-48038	2002	_
232-10	48038-48039	.	_

#Text=Drug use and dependence in cocaine dependent subjects, community-based individuals, and their siblings
#Text=A longitudinal analysis of risk factors for child maltreatment: findings of a 17-year prospective study of officially recorded and self-reported child abuse and neglect
#Text=The relationship between parental substance abuse and child maltreatment: findings from the Ontario Health Supplement
#Text=Validity of the Childhood Trauma Questionnaire in an adolescent psychiatric population
#Text=Urinary elimination of cocaine metabolites in chronic cocaine users during cessation
#Text=Prefrontal hypoactivity associated with impaired inhibition in stimulant-dependent individuals but evidence for hyperactivation in their unaffected siblings
#Text=Distinctive personality traits and neural correlates associated with stimulant drug use versus familial risk of stimulant dependence
#Text=Enhanced orbitofrontal cortex function and lack of attentional bias to cocaine cues in recreational stimulant users
#Text=Take it or leave it: prefrontal control in recreational cocaine users
#Text=Cognitive control dysfunction and abnormal frontal cortex activation in stimulant drug users and their biological siblings
#Text=Drug addiction endophenotypes: impulsive versus sensation-seeking personality traits
#Text=FMRI visualization of brain activity during a monetary incentive delay task
#Text=Spatial smoothing systematically biases the localization of reward-related brain activity
#Text=Gene-environment interaction in patterns of adolescent drinking: regional residency moderates longitudinal influences on alcohol use
#Text=Learning-related human brain activations reflecting individual finances
#Text=Converging effects of cocaine addiction and sex on neural responses to monetary rewards
#Text=Misunderstanding analysis of covariance
#Text=Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications
#Text=From the ventral to the dorsal striatum: devolving views of their roles in drug addiction
#Text=Parallel organization of functionally segregated circuits linking basal ganglia and cortex
#Text=Functional neuroimaging of psychiatric disorders: exploring hidden behaviour
#Text=The relevance of behavioural measures for functional-imaging studies of cognition
#Text=Structural and behavioral correlates of abnormal encoding of money value in the sensorimotor striatum in cocaine addiction
#Text=Tentative evidence for striatal hyperactivity in adolescent cannabis-using boys: a cross-sectional multicenter fMRI study
#Text=Dopaminergic dysfunction in abstinent dexamphetamine users: results from a pharmacological fMRI study using a reward anticipation task and a methylphenidate challenge
#Text=Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users
#Text=Enhanced striatal responses during expectancy coding in alcohol dependence
#Text=Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity
#Text=Tolerance and sensitization to the behavioral effects of drugs
#Text=Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies
#Text=Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men
#Text=Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue
#Text=The expanding effects of cocaine: studies in a nonhuman primate model of cocaine self-administration
#Text=Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
#Text=Striatal sensitivity to reward deliveries and omissions in substance dependent patients
#Text=Mesolimbic recruitment by nondrug rewards in detoxified alcoholics: effort anticipation, reward anticipation, and reward delivery
#Text=An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence
#Text=THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction
#Text=Robust changes in reward circuitry during reward loss in current and former cocaine users during performance of a monetary incentive delay task
#Text=Anticipatory reward processing in addicted populations: a focus on the monetary incentive delay task
#Text=Neurofunctional reward processing changes in cocaine dependence during recovery
#Text=Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics
#Text=Prefrontal response and frontostriatal functional connectivity to monetary reward in abstinent alcohol-dependent young adults
#Text=Chronic effects of cannabis use on the human reward system: an fMRI study
#Text=Alterations of monetary reward and punishment processing in chronic cannabis users: an FMRI study
#Text=Neural effects of positive and negative incentives during marijuana withdrawal
#Text=Incentive-elicited striatal activation in adolescent children of alcoholics
#Text=Accumbens functional connectivity during reward mediates sensation-seeking and alcohol use in high-risk youth
#Text=No differences in ventral striatum responsivity between adolescents with a positive family history of alcoholism and controls
#Text=Functional connectivity of human striatum: a resting state FMRI study
#Text=Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans
#Text=Corticostriatal circuitry
#Text=Drug addiction: updating actions to habits to compulsions ten years on
#Text=Contrasting network and modular perspectives on inhibitory control
#Text=Ventral striatum connectivity during reward anticipation in adolescent smokers
#Text=Reward sensitivity and waiting impulsivity: shift towards reward valuation away from action control
#Text=Altered social and non-social decision-making in recreational and dependent cocaine users
#Text=Stable self-serving personality traits in recreational and dependent cocaine users
#Text=Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment
#Text=European Monitoring Centre for Drug Addiction.
233-1	48040-48044	Drug	_
233-2	48045-48048	use	_
233-3	48049-48052	and	_
233-4	48053-48063	dependence	_
233-5	48064-48066	in	_
233-6	48067-48074	cocaine	_
233-7	48075-48084	dependent	_
233-8	48085-48093	subjects	_
233-9	48093-48094	,	_
233-10	48095-48110	community-based	_
233-11	48111-48122	individuals	_
233-12	48122-48123	,	_
233-13	48124-48127	and	_
233-14	48128-48133	their	_
233-15	48134-48142	siblings	_
233-16	48143-48144	A	_
233-17	48145-48157	longitudinal	_
233-18	48158-48166	analysis	_
233-19	48167-48169	of	_
233-20	48170-48174	risk	_
233-21	48175-48182	factors	_
233-22	48183-48186	for	_
233-23	48187-48192	child	_
233-24	48193-48205	maltreatment	_
233-25	48205-48206	:	_
233-26	48207-48215	findings	_
233-27	48216-48218	of	_
233-28	48219-48220	a	_
233-29	48221-48223	17	_
233-30	48223-48224	-	_
233-31	48224-48228	year	_
233-32	48229-48240	prospective	_
233-33	48241-48246	study	_
233-34	48247-48249	of	_
233-35	48250-48260	officially	_
233-36	48261-48269	recorded	_
233-37	48270-48273	and	_
233-38	48274-48287	self-reported	_
233-39	48288-48293	child	_
233-40	48294-48299	abuse	_
233-41	48300-48303	and	_
233-42	48304-48311	neglect	_
233-43	48312-48315	The	_
233-44	48316-48328	relationship	_
233-45	48329-48336	between	_
233-46	48337-48345	parental	_
233-47	48346-48355	substance	_
233-48	48356-48361	abuse	_
233-49	48362-48365	and	_
233-50	48366-48371	child	_
233-51	48372-48384	maltreatment	_
233-52	48384-48385	:	_
233-53	48386-48394	findings	_
233-54	48395-48399	from	_
233-55	48400-48403	the	_
233-56	48404-48411	Ontario	_
233-57	48412-48418	Health	_
233-58	48419-48429	Supplement	_
233-59	48430-48438	Validity	_
233-60	48439-48441	of	_
233-61	48442-48445	the	_
233-62	48446-48455	Childhood	_
233-63	48456-48462	Trauma	_
233-64	48463-48476	Questionnaire	_
233-65	48477-48479	in	_
233-66	48480-48482	an	_
233-67	48483-48493	adolescent	_
233-68	48494-48505	psychiatric	_
233-69	48506-48516	population	_
233-70	48517-48524	Urinary	_
233-71	48525-48536	elimination	_
233-72	48537-48539	of	_
233-73	48540-48547	cocaine	_
233-74	48548-48559	metabolites	_
233-75	48560-48562	in	_
233-76	48563-48570	chronic	_
233-77	48571-48578	cocaine	_
233-78	48579-48584	users	_
233-79	48585-48591	during	_
233-80	48592-48601	cessation	_
233-81	48602-48612	Prefrontal	_
233-82	48613-48625	hypoactivity	_
233-83	48626-48636	associated	_
233-84	48637-48641	with	_
233-85	48642-48650	impaired	_
233-86	48651-48661	inhibition	_
233-87	48662-48664	in	_
233-88	48665-48684	stimulant-dependent	_
233-89	48685-48696	individuals	_
233-90	48697-48700	but	_
233-91	48701-48709	evidence	_
233-92	48710-48713	for	_
233-93	48714-48729	hyperactivation	_
233-94	48730-48732	in	_
233-95	48733-48738	their	_
233-96	48739-48749	unaffected	_
233-97	48750-48758	siblings	_
233-98	48759-48770	Distinctive	_
233-99	48771-48782	personality	_
233-100	48783-48789	traits	_
233-101	48790-48793	and	_
233-102	48794-48800	neural	_
233-103	48801-48811	correlates	_
233-104	48812-48822	associated	_
233-105	48823-48827	with	_
233-106	48828-48837	stimulant	_
233-107	48838-48842	drug	_
233-108	48843-48846	use	_
233-109	48847-48853	versus	_
233-110	48854-48862	familial	_
233-111	48863-48867	risk	_
233-112	48868-48870	of	_
233-113	48871-48880	stimulant	_
233-114	48881-48891	dependence	_
233-115	48892-48900	Enhanced	_
233-116	48901-48914	orbitofrontal	_
233-117	48915-48921	cortex	_
233-118	48922-48930	function	_
233-119	48931-48934	and	_
233-120	48935-48939	lack	_
233-121	48940-48942	of	_
233-122	48943-48954	attentional	_
233-123	48955-48959	bias	_
233-124	48960-48962	to	_
233-125	48963-48970	cocaine	_
233-126	48971-48975	cues	_
233-127	48976-48978	in	_
233-128	48979-48991	recreational	_
233-129	48992-49001	stimulant	_
233-130	49002-49007	users	_
233-131	49008-49012	Take	_
233-132	49013-49015	it	_
233-133	49016-49018	or	_
233-134	49019-49024	leave	_
233-135	49025-49027	it	_
233-136	49027-49028	:	_
233-137	49029-49039	prefrontal	_
233-138	49040-49047	control	_
233-139	49048-49050	in	_
233-140	49051-49063	recreational	_
233-141	49064-49071	cocaine	_
233-142	49072-49077	users	_
233-143	49078-49087	Cognitive	_
233-144	49088-49095	control	_
233-145	49096-49107	dysfunction	_
233-146	49108-49111	and	_
233-147	49112-49120	abnormal	_
233-148	49121-49128	frontal	_
233-149	49129-49135	cortex	_
233-150	49136-49146	activation	_
233-151	49147-49149	in	_
233-152	49150-49159	stimulant	_
233-153	49160-49164	drug	_
233-154	49165-49170	users	_
233-155	49171-49174	and	_
233-156	49175-49180	their	_
233-157	49181-49191	biological	_
233-158	49192-49200	siblings	_
233-159	49201-49205	Drug	_
233-160	49206-49215	addiction	_
233-161	49216-49230	endophenotypes	_
233-162	49230-49231	:	_
233-163	49232-49241	impulsive	_
233-164	49242-49248	versus	_
233-165	49249-49266	sensation-seeking	_
233-166	49267-49278	personality	_
233-167	49279-49285	traits	_
233-168	49286-49290	FMRI	_
233-169	49291-49304	visualization	_
233-170	49305-49307	of	_
233-171	49308-49313	brain	_
233-172	49314-49322	activity	_
233-173	49323-49329	during	_
233-174	49330-49331	a	_
233-175	49332-49340	monetary	_
233-176	49341-49350	incentive	_
233-177	49351-49356	delay	_
233-178	49357-49361	task	_
233-179	49362-49369	Spatial	_
233-180	49370-49379	smoothing	_
233-181	49380-49394	systematically	_
233-182	49395-49401	biases	_
233-183	49402-49405	the	_
233-184	49406-49418	localization	_
233-185	49419-49421	of	_
233-186	49422-49436	reward-related	_
233-187	49437-49442	brain	_
233-188	49443-49451	activity	_
233-189	49452-49468	Gene-environment	_
233-190	49469-49480	interaction	_
233-191	49481-49483	in	_
233-192	49484-49492	patterns	_
233-193	49493-49495	of	_
233-194	49496-49506	adolescent	_
233-195	49507-49515	drinking	_
233-196	49515-49516	:	_
233-197	49517-49525	regional	_
233-198	49526-49535	residency	_
233-199	49536-49545	moderates	_
233-200	49546-49558	longitudinal	_
233-201	49559-49569	influences	_
233-202	49570-49572	on	_
233-203	49573-49580	alcohol	_
233-204	49581-49584	use	_
233-205	49585-49601	Learning-related	_
233-206	49602-49607	human	_
233-207	49608-49613	brain	_
233-208	49614-49625	activations	_
233-209	49626-49636	reflecting	_
233-210	49637-49647	individual	_
233-211	49648-49656	finances	_
233-212	49657-49667	Converging	_
233-213	49668-49675	effects	_
233-214	49676-49678	of	_
233-215	49679-49686	cocaine	_
233-216	49687-49696	addiction	_
233-217	49697-49700	and	_
233-218	49701-49704	sex	_
233-219	49705-49707	on	_
233-220	49708-49714	neural	_
233-221	49715-49724	responses	_
233-222	49725-49727	to	_
233-223	49728-49736	monetary	_
233-224	49737-49744	rewards	_
233-225	49745-49761	Misunderstanding	_
233-226	49762-49770	analysis	_
233-227	49771-49773	of	_
233-228	49774-49784	covariance	_
233-229	49785-49792	Cluster	_
233-230	49793-49800	failure	_
233-231	49800-49801	:	_
233-232	49802-49805	Why	_
233-233	49806-49810	fMRI	_
233-234	49811-49821	inferences	_
233-235	49822-49825	for	_
233-236	49826-49833	spatial	_
233-237	49834-49840	extent	_
233-238	49841-49845	have	_
233-239	49846-49854	inflated	_
233-240	49855-49869	false-positive	_
233-241	49870-49875	rates	_
233-242	49876-49881	Basal	_
233-243	49882-49889	ganglia	_
233-244	49890-49900	functional	_
233-245	49901-49913	connectivity	_
233-246	49914-49919	based	_
233-247	49920-49922	on	_
233-248	49923-49924	a	_
233-249	49925-49938	meta-analysis	_
233-250	49939-49941	of	_
233-251	49942-49945	126	_
233-252	49946-49954	positron	_
233-253	49955-49963	emission	_
233-254	49964-49974	tomography	_
233-255	49975-49978	and	_
233-256	49979-49989	functional	_
233-257	49990-49998	magnetic	_
233-258	49999-50008	resonance	_
233-259	50009-50016	imaging	_
233-260	50017-50029	publications	_
233-261	50030-50034	From	_
233-262	50035-50038	the	_
233-263	50039-50046	ventral	_
233-264	50047-50049	to	_
233-265	50050-50053	the	_
233-266	50054-50060	dorsal	_
233-267	50061-50069	striatum	_
233-268	50069-50070	:	_
233-269	50071-50080	devolving	_
233-270	50081-50086	views	_
233-271	50087-50089	of	_
233-272	50090-50095	their	_
233-273	50096-50101	roles	_
233-274	50102-50104	in	_
233-275	50105-50109	drug	_
233-276	50110-50119	addiction	_
233-277	50120-50128	Parallel	_
233-278	50129-50141	organization	_
233-279	50142-50144	of	_
233-280	50145-50157	functionally	_
233-281	50158-50168	segregated	_
233-282	50169-50177	circuits	_
233-283	50178-50185	linking	_
233-284	50186-50191	basal	_
233-285	50192-50199	ganglia	_
233-286	50200-50203	and	_
233-287	50204-50210	cortex	_
233-288	50211-50221	Functional	_
233-289	50222-50234	neuroimaging	_
233-290	50235-50237	of	_
233-291	50238-50249	psychiatric	_
233-292	50250-50259	disorders	_
233-293	50259-50260	:	_
233-294	50261-50270	exploring	_
233-295	50271-50277	hidden	_
233-296	50278-50287	behaviour	_
233-297	50288-50291	The	_
233-298	50292-50301	relevance	_
233-299	50302-50304	of	_
233-300	50305-50316	behavioural	_
233-301	50317-50325	measures	_
233-302	50326-50329	for	_
233-303	50330-50348	functional-imaging	_
233-304	50349-50356	studies	_
233-305	50357-50359	of	_
233-306	50360-50369	cognition	_
233-307	50370-50380	Structural	_
233-308	50381-50384	and	_
233-309	50385-50395	behavioral	_
233-310	50396-50406	correlates	_
233-311	50407-50409	of	_
233-312	50410-50418	abnormal	_
233-313	50419-50427	encoding	_
233-314	50428-50430	of	_
233-315	50431-50436	money	_
233-316	50437-50442	value	_
233-317	50443-50445	in	_
233-318	50446-50449	the	_
233-319	50450-50462	sensorimotor	_
233-320	50463-50471	striatum	_
233-321	50472-50474	in	_
233-322	50475-50482	cocaine	_
233-323	50483-50492	addiction	_
233-324	50493-50502	Tentative	_
233-325	50503-50511	evidence	_
233-326	50512-50515	for	_
233-327	50516-50524	striatal	_
233-328	50525-50538	hyperactivity	_
233-329	50539-50541	in	_
233-330	50542-50552	adolescent	_
233-331	50553-50567	cannabis-using	_
233-332	50568-50572	boys	_
233-333	50572-50573	:	_
233-334	50574-50575	a	_
233-335	50576-50591	cross-sectional	_
233-336	50592-50603	multicenter	_
233-337	50604-50608	fMRI	_
233-338	50609-50614	study	_
233-339	50615-50627	Dopaminergic	_
233-340	50628-50639	dysfunction	_
233-341	50640-50642	in	_
233-342	50643-50652	abstinent	_
233-343	50653-50667	dexamphetamine	_
233-344	50668-50673	users	_
233-345	50673-50674	:	_
233-346	50675-50682	results	_
233-347	50683-50687	from	_
233-348	50688-50689	a	_
233-349	50690-50705	pharmacological	_
233-350	50706-50710	fMRI	_
233-351	50711-50716	study	_
233-352	50717-50722	using	_
233-353	50723-50724	a	_
233-354	50725-50731	reward	_
233-355	50732-50744	anticipation	_
233-356	50745-50749	task	_
233-357	50750-50753	and	_
233-358	50754-50755	a	_
233-359	50756-50771	methylphenidate	_
233-360	50772-50781	challenge	_
233-361	50782-50791	Increased	_
233-362	50792-50799	ventral	_
233-363	50800-50808	striatal	_
233-364	50809-50813	BOLD	_
233-365	50814-50822	activity	_
233-366	50823-50829	during	_
233-367	50830-50838	non-drug	_
233-368	50839-50845	reward	_
233-369	50846-50858	anticipation	_
233-370	50859-50861	in	_
233-371	50862-50870	cannabis	_
233-372	50871-50876	users	_
233-373	50877-50885	Enhanced	_
233-374	50886-50894	striatal	_
233-375	50895-50904	responses	_
233-376	50905-50911	during	_
233-377	50912-50922	expectancy	_
233-378	50923-50929	coding	_
233-379	50930-50932	in	_
233-380	50933-50940	alcohol	_
233-381	50941-50951	dependence	_
233-382	50952-50957	Acute	_
233-383	50958-50966	nicotine	_
233-384	50967-50981	differentially	_
233-385	50982-50989	impacts	_
233-386	50990-51002	anticipatory	_
233-387	51003-51010	valence	_
233-388	51010-51011	-	_
233-389	51012-51015	and	_
233-390	51016-51033	magnitude-related	_
233-391	51034-51042	striatal	_
233-392	51043-51051	activity	_
233-393	51052-51061	Tolerance	_
233-394	51062-51065	and	_
233-395	51066-51079	sensitization	_
233-396	51080-51082	to	_
233-397	51083-51086	the	_
233-398	51087-51097	behavioral	_
233-399	51098-51105	effects	_
233-400	51106-51108	of	_
233-401	51109-51114	drugs	_
233-402	51115-51126	Alterations	_
233-403	51127-51129	in	_
233-404	51130-51142	dopaminergic	_
233-405	51143-51146	and	_
233-406	51147-51160	glutamatergic	_
233-407	51161-51173	transmission	_
233-408	51174-51176	in	_
233-409	51177-51180	the	_
233-410	51181-51190	induction	_
233-411	51191-51194	and	_
233-412	51195-51205	expression	_
233-413	51206-51208	of	_
233-414	51209-51219	behavioral	_
233-415	51220-51233	sensitization	_
233-416	51233-51234	:	_
233-417	51235-51236	a	_
233-418	51237-51245	critical	_
233-419	51246-51252	review	_
233-420	51253-51255	of	_
233-421	51256-51267	preclinical	_
233-422	51268-51275	studies	_
233-423	51276-51284	Modeling	_
233-424	51285-51298	sensitization	_
233-425	51299-51301	to	_
233-426	51302-51312	stimulants	_
233-427	51313-51315	in	_
233-428	51316-51322	humans	_
233-429	51322-51323	:	_
233-430	51324-51326	an	_
233-431	51327-51328	[	_
233-432	51328-51331	11C	_
233-433	51331-51332	]	_
233-434	51332-51342	raclopride	_
233-435	51342-51343	/	_
233-436	51343-51351	positron	_
233-437	51352-51360	emission	_
233-438	51361-51371	tomography	_
233-439	51372-51377	study	_
233-440	51378-51380	in	_
233-441	51381-51388	healthy	_
233-442	51389-51392	men	_
233-443	51393-51401	Dopamine	_
233-444	51402-51409	release	_
233-445	51410-51412	in	_
233-446	51413-51416	the	_
233-447	51417-51423	dorsal	_
233-448	51424-51432	striatum	_
233-449	51433-51439	during	_
233-450	51440-51455	cocaine-seeking	_
233-451	51456-51464	behavior	_
233-452	51465-51470	under	_
233-453	51471-51474	the	_
233-454	51475-51482	control	_
233-455	51483-51485	of	_
233-456	51486-51487	a	_
233-457	51488-51503	drug-associated	_
233-458	51504-51507	cue	_
233-459	51508-51511	The	_
233-460	51512-51521	expanding	_
233-461	51522-51529	effects	_
233-462	51530-51532	of	_
233-463	51533-51540	cocaine	_
233-464	51540-51541	:	_
233-465	51542-51549	studies	_
233-466	51550-51552	in	_
233-467	51553-51554	a	_
233-468	51555-51563	nonhuman	_
233-469	51564-51571	primate	_
233-470	51572-51577	model	_
233-471	51578-51580	of	_
233-472	51581-51588	cocaine	_
233-473	51589-51608	self-administration	_
233-474	51609-51615	Neural	_
233-475	51616-51623	systems	_
233-476	51624-51626	of	_
233-477	51627-51640	reinforcement	_
233-478	51641-51644	for	_
233-479	51645-51649	drug	_
233-480	51650-51659	addiction	_
233-481	51659-51660	:	_
233-482	51661-51665	from	_
233-483	51666-51673	actions	_
233-484	51674-51676	to	_
233-485	51677-51683	habits	_
233-486	51684-51686	to	_
233-487	51687-51697	compulsion	_
233-488	51698-51706	Striatal	_
233-489	51707-51718	sensitivity	_
233-490	51719-51721	to	_
233-491	51722-51728	reward	_
233-492	51729-51739	deliveries	_
233-493	51740-51743	and	_
233-494	51744-51753	omissions	_
233-495	51754-51756	in	_
233-496	51757-51766	substance	_
233-497	51767-51776	dependent	_
233-498	51777-51785	patients	_
233-499	51786-51796	Mesolimbic	_
233-500	51797-51808	recruitment	_
233-501	51809-51811	by	_
233-502	51812-51819	nondrug	_
233-503	51820-51827	rewards	_
233-504	51828-51830	in	_
233-505	51831-51841	detoxified	_
233-506	51842-51852	alcoholics	_
233-507	51852-51853	:	_
233-508	51854-51860	effort	_
233-509	51861-51873	anticipation	_
233-510	51873-51874	,	_
233-511	51875-51881	reward	_
233-512	51882-51894	anticipation	_
233-513	51894-51895	,	_
233-514	51896-51899	and	_
233-515	51900-51906	reward	_
233-516	51907-51915	delivery	_
233-517	51916-51918	An	_
233-518	51919-51926	initial	_
233-519	51927-51932	study	_
233-520	51933-51935	of	_
233-521	51936-51942	neural	_
233-522	51943-51952	responses	_
233-523	51953-51955	to	_
233-524	51956-51964	monetary	_
233-525	51965-51975	incentives	_
233-526	51976-51978	as	_
233-527	51979-51986	related	_
233-528	51987-51989	to	_
233-529	51990-51999	treatment	_
233-530	52000-52007	outcome	_
233-531	52008-52010	in	_
233-532	52011-52018	cocaine	_
233-533	52019-52029	dependence	_
233-534	52030-52033	THC	_
233-535	52034-52041	reduces	_
233-536	52042-52045	the	_
233-537	52046-52058	anticipatory	_
233-538	52059-52066	nucleus	_
233-539	52067-52076	accumbens	_
233-540	52077-52085	response	_
233-541	52086-52088	to	_
233-542	52089-52095	reward	_
233-543	52096-52098	in	_
233-544	52099-52107	subjects	_
233-545	52108-52112	with	_
233-546	52113-52114	a	_
233-547	52115-52123	nicotine	_
233-548	52124-52133	addiction	_
233-549	52134-52140	Robust	_
233-550	52141-52148	changes	_
233-551	52149-52151	in	_
233-552	52152-52158	reward	_
233-553	52159-52168	circuitry	_
233-554	52169-52175	during	_
233-555	52176-52182	reward	_
233-556	52183-52187	loss	_
233-557	52188-52190	in	_
233-558	52191-52198	current	_
233-559	52199-52202	and	_
233-560	52203-52209	former	_
233-561	52210-52217	cocaine	_
233-562	52218-52223	users	_
233-563	52224-52230	during	_
233-564	52231-52242	performance	_
233-565	52243-52245	of	_
233-566	52246-52247	a	_
233-567	52248-52256	monetary	_
233-568	52257-52266	incentive	_
233-569	52267-52272	delay	_
233-570	52273-52277	task	_
233-571	52278-52290	Anticipatory	_
233-572	52291-52297	reward	_
233-573	52298-52308	processing	_
233-574	52309-52311	in	_
233-575	52312-52320	addicted	_
233-576	52321-52332	populations	_
233-577	52332-52333	:	_
233-578	52334-52335	a	_
233-579	52336-52341	focus	_
233-580	52342-52344	on	_
233-581	52345-52348	the	_
233-582	52349-52357	monetary	_
233-583	52358-52367	incentive	_
233-584	52368-52373	delay	_
233-585	52374-52378	task	_
233-586	52379-52394	Neurofunctional	_
233-587	52395-52401	reward	_
233-588	52402-52412	processing	_
233-589	52413-52420	changes	_
233-590	52421-52423	in	_
233-591	52424-52431	cocaine	_
233-592	52432-52442	dependence	_
233-593	52443-52449	during	_
233-594	52450-52458	recovery	_
233-595	52459-52466	Ventral	_
233-596	52467-52475	striatal	_
233-597	52476-52486	activation	_
233-598	52487-52493	during	_
233-599	52494-52500	reward	_
233-600	52501-52513	anticipation	_
233-601	52514-52524	correlates	_
233-602	52525-52529	with	_
233-603	52530-52541	impulsivity	_
233-604	52542-52544	in	_
233-605	52545-52555	alcoholics	_
233-606	52556-52566	Prefrontal	_
233-607	52567-52575	response	_
233-608	52576-52579	and	_
233-609	52580-52594	frontostriatal	_
233-610	52595-52605	functional	_
233-611	52606-52618	connectivity	_
233-612	52619-52621	to	_
233-613	52622-52630	monetary	_
233-614	52631-52637	reward	_
233-615	52638-52640	in	_
233-616	52641-52650	abstinent	_
233-617	52651-52668	alcohol-dependent	_
233-618	52669-52674	young	_
233-619	52675-52681	adults	_
233-620	52682-52689	Chronic	_
233-621	52690-52697	effects	_
233-622	52698-52700	of	_
233-623	52701-52709	cannabis	_
233-624	52710-52713	use	_
233-625	52714-52716	on	_
233-626	52717-52720	the	_
233-627	52721-52726	human	_
233-628	52727-52733	reward	_
233-629	52734-52740	system	_
233-630	52740-52741	:	_
233-631	52742-52744	an	_
233-632	52745-52749	fMRI	_
233-633	52750-52755	study	_
233-634	52756-52767	Alterations	_
233-635	52768-52770	of	_
233-636	52771-52779	monetary	_
233-637	52780-52786	reward	_
233-638	52787-52790	and	_
233-639	52791-52801	punishment	_
233-640	52802-52812	processing	_
233-641	52813-52815	in	_
233-642	52816-52823	chronic	_
233-643	52824-52832	cannabis	_
233-644	52833-52838	users	_
233-645	52838-52839	:	_
233-646	52840-52842	an	_
233-647	52843-52847	FMRI	_
233-648	52848-52853	study	_
233-649	52854-52860	Neural	_
233-650	52861-52868	effects	_
233-651	52869-52871	of	_
233-652	52872-52880	positive	_
233-653	52881-52884	and	_
233-654	52885-52893	negative	_
233-655	52894-52904	incentives	_
233-656	52905-52911	during	_
233-657	52912-52921	marijuana	_
233-658	52922-52932	withdrawal	_
233-659	52933-52951	Incentive-elicited	_
233-660	52952-52960	striatal	_
233-661	52961-52971	activation	_
233-662	52972-52974	in	_
233-663	52975-52985	adolescent	_
233-664	52986-52994	children	_
233-665	52995-52997	of	_
233-666	52998-53008	alcoholics	_
233-667	53009-53018	Accumbens	_
233-668	53019-53029	functional	_
233-669	53030-53042	connectivity	_
233-670	53043-53049	during	_
233-671	53050-53056	reward	_
233-672	53057-53065	mediates	_
233-673	53066-53083	sensation-seeking	_
233-674	53084-53087	and	_
233-675	53088-53095	alcohol	_
233-676	53096-53099	use	_
233-677	53100-53102	in	_
233-678	53103-53112	high-risk	_
233-679	53113-53118	youth	_
233-680	53119-53121	No	_
233-681	53122-53133	differences	_
233-682	53134-53136	in	_
233-683	53137-53144	ventral	_
233-684	53145-53153	striatum	_
233-685	53154-53166	responsivity	_
233-686	53167-53174	between	_
233-687	53175-53186	adolescents	_
233-688	53187-53191	with	_
233-689	53192-53193	a	_
233-690	53194-53202	positive	_
233-691	53203-53209	family	_
233-692	53210-53217	history	_
233-693	53218-53220	of	_
233-694	53221-53231	alcoholism	_
233-695	53232-53235	and	_
233-696	53236-53244	controls	_
233-697	53245-53255	Functional	_
233-698	53256-53268	connectivity	_
233-699	53269-53271	of	_
233-700	53272-53277	human	_
233-701	53278-53286	striatum	_
233-702	53286-53287	:	_
233-703	53288-53289	a	_
233-704	53290-53297	resting	_
233-705	53298-53303	state	_
233-706	53304-53308	FMRI	_
233-707	53309-53314	study	_
233-708	53315-53324	Diffusion	_
233-709	53325-53331	tensor	_
233-710	53332-53337	fiber	_
233-711	53338-53346	tracking	_
233-712	53347-53352	shows	_
233-713	53353-53361	distinct	_
233-714	53362-53377	corticostriatal	_
233-715	53378-53386	circuits	_
233-716	53387-53389	in	_
233-717	53390-53396	humans	_
233-718	53397-53412	Corticostriatal	_
233-719	53413-53422	circuitry	_
233-720	53423-53427	Drug	_
233-721	53428-53437	addiction	_
233-722	53437-53438	:	_
233-723	53439-53447	updating	_
233-724	53448-53455	actions	_
233-725	53456-53458	to	_
233-726	53459-53465	habits	_
233-727	53466-53468	to	_
233-728	53469-53480	compulsions	_
233-729	53481-53484	ten	_
233-730	53485-53490	years	_
233-731	53491-53493	on	_
233-732	53494-53505	Contrasting	_
233-733	53506-53513	network	_
233-734	53514-53517	and	_
233-735	53518-53525	modular	_
233-736	53526-53538	perspectives	_
233-737	53539-53541	on	_
233-738	53542-53552	inhibitory	_
233-739	53553-53560	control	_
233-740	53561-53568	Ventral	_
233-741	53569-53577	striatum	_
233-742	53578-53590	connectivity	_
233-743	53591-53597	during	_
233-744	53598-53604	reward	_
233-745	53605-53617	anticipation	_
233-746	53618-53620	in	_
233-747	53621-53631	adolescent	_
233-748	53632-53639	smokers	_
233-749	53640-53646	Reward	_
233-750	53647-53658	sensitivity	_
233-751	53659-53662	and	_
233-752	53663-53670	waiting	_
233-753	53671-53682	impulsivity	_
233-754	53682-53683	:	_
233-755	53684-53689	shift	_
233-756	53690-53697	towards	_
233-757	53698-53704	reward	_
233-758	53705-53714	valuation	_
233-759	53715-53719	away	_
233-760	53720-53724	from	_
233-761	53725-53731	action	_
233-762	53732-53739	control	_
233-763	53740-53747	Altered	_
233-764	53748-53754	social	_
233-765	53755-53758	and	_
233-766	53759-53769	non-social	_
233-767	53770-53785	decision-making	_
233-768	53786-53788	in	_
233-769	53789-53801	recreational	_
233-770	53802-53805	and	_
233-771	53806-53815	dependent	_
233-772	53816-53823	cocaine	_
233-773	53824-53829	users	_
233-774	53830-53836	Stable	_
233-775	53837-53849	self-serving	_
233-776	53850-53861	personality	_
233-777	53862-53868	traits	_
233-778	53869-53871	in	_
233-779	53872-53884	recreational	_
233-780	53885-53888	and	_
233-781	53889-53898	dependent	_
233-782	53899-53906	cocaine	_
233-783	53907-53912	users	_
233-784	53913-53925	Pretreatment	_
233-785	53926-53934	measures	_
233-786	53935-53937	of	_
233-787	53938-53943	brain	_
233-788	53944-53953	structure	_
233-789	53954-53957	and	_
233-790	53958-53975	reward-processing	_
233-791	53976-53981	brain	_
233-792	53982-53990	function	_
233-793	53991-53993	in	_
233-794	53994-54002	cannabis	_
233-795	54003-54013	dependence	_
233-796	54013-54014	:	_
233-797	54015-54017	an	_
233-798	54018-54029	exploratory	_
233-799	54030-54035	study	_
233-800	54036-54038	of	_
233-801	54039-54052	relationships	_
233-802	54053-54057	with	_
233-803	54058-54068	abstinence	_
233-804	54069-54075	during	_
233-805	54076-54086	behavioral	_
233-806	54087-54096	treatment	_
233-807	54097-54105	European	_
233-808	54106-54116	Monitoring	_
233-809	54117-54123	Centre	_
233-810	54124-54127	for	_
233-811	54128-54132	Drug	_
233-812	54133-54142	Addiction	_
233-813	54142-54143	.	_

#Text=Treatment for Cocaine Dependence: Reviewing Current Evidence. 2014.
234-1	54144-54153	Treatment	_
234-2	54154-54157	for	_
234-3	54158-54165	Cocaine	_
234-4	54166-54176	Dependence	_
234-5	54176-54177	:	_
234-6	54178-54187	Reviewing	_
234-7	54188-54195	Current	_
234-8	54196-54204	Evidence	_
234-9	54204-54205	.	_
234-10	54206-54210	2014	_
234-11	54210-54211	.	_
